The influence of P2Y12 antagonists on vascular NO signalling by Sagan, Ewelina Nina
  
 
 
 
The influence of P2Y12 antagonists  
on vascular NO signalling 
 
 
A Thesis submitted for the Degree of Doctor of Philosophy 
by 
Ewelina Nina Sagan 
M.Sc. Biotechnology, Technical University of Lodz, Poland 
 
Institute of Molecular and Experimental Medicine  
Wales Heart Research Institute 
Cardiff University 
UK 
January 2013
  
 
 
 
 
 
 
 
 
 
 
 
 
For to my fiancé Michał, who supported me along the way  
and encouraged to stay focused on my writing.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
Acknowledgements 
I am greatly indebted to my supervisor Dr. Philip James for his immense 
contribution to all aspects of my work on this thesis, as well as my everyday life at 
Wales Heart Research Institute (WHRI). I would like to thank him for the scientific 
and personal support he gave me during the past three years. I will truly miss his 
intellectually stimulating company and all discussions we had. 
I am also grateful to my second supervisor Prof. Julian Halcox, as well as Dr. 
Richard Anderson and Mr. Shantu Bundhoo for their clinical input to my research. 
Special thanks goes to Shantu, with whom I shared many of my scientific interests 
and working hours. Without his ideas and hard work completing this thesis would not 
have been possible. 
I would like to thank Dr. Keith Morris from University of Wales, Dr. Sheila 
Francis from University of Sheffield and Dr. William Ford from School of Pharmacy 
for their help and support to conduct some of my studies beyond WHRI.  
I also value the assistance and friendship of many of my colleagues from our 
research group: Ms. Jessica Dada, Mr. Phillip Freeman, Mr. Gareth Willis, Ms. Katie 
Connolly, Mr. Laurence Thornhill and from elsewhere: Ms. Maria Duda, Ms. Monika 
Seidel and Ms. Anna Uryga. Thank you all for making my PhD and stay in Cardiff 
such an amazing experience! 
Finally, I would like to thank my parents for loving and believing in me. 
 
 
  
First begin 
Taking in. 
Cargo stored, 
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Giving out. 
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Weary brain, 
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Never press; 
Nerve stress 
Always shows. 
Nature knows. 
Critics kind, 
Never mind! 
Critics flatter, 
No matter! 
Critics curse, 
None the worse. 
Critics blame, 
All the same! 
Do your best. 
Hang the rest! 
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Abstract 
 
 
P2Y12 antagonists are pharmacological agents used clinically in advanced 
stages of coronary artery disease in order to inhibit ADP-induced activation and 
aggregation of platelets and prevent deadly thrombotic events. Of the orally-
prescribed P2Y12 antagonists available clopidogrel is the most established, it exhibits 
an excellent safety track record and is a popular drug, and was accredited for years the 
second-best selling drug in the world.  However, since clopidogrel was introduced to 
the market in 1997 many pleiotropic effects have been noticed, which suggest other 
off-target yet beneficial effects in addition to its anti-platelet effects.  
 
The overall hypothesis being tested in this body of work was that P2Y12 
antagonists, clopidogrel in particular, have the positive influence on vascular NO 
signalling. 
 
A vascular model was set up using isolated rabbit aortae in which clopidogrel 
enhanced NO donor-induced vasorelaxation. Although the precise mechanism was not 
found, the effect was independent of P2Y12 receptors and possibly linked to decreased 
superoxide production and improved anti-oxidant/inflammatory status in vessels. This 
finding might be relevant for patients receiving concomitant therapy with organic 
nitrates and clopidogrel.  
 
In vitro studies revealed novel S-nitrosation properties of P2Y12 antagonists, 
surprisingly without the need for metabolism to their active form. Newly synthesized 
SNO derivatives of clopidogrel and prasugrel were more potent in inhibition of 
platelet aggregation and induction of vasodilation than their parental forms. Although 
the formation of drug-SNO species has to be confirmed in vivo, they have a potential 
to increase NO bioavailability in patients.  
 
Clopidogrel administration to coronary artery disease patients resulted in 
upregulated plasma levels of nitrite and cGMP after 2 h-intake of a loading dose, 
which were further increased after 3 days of a maintenance therapy. This effect was 
never shown before in man and most likely reflects improved endogenous NO 
production, but also providing additional protection from the effects of nitrite at the 
same time. 
 
Taken together, the results of this thesis clearly demonstrate the influence of 
clopidogrel on vascular response to NO as well as NO production, metabolism and 
bioavailability. It is important to identify these alternative pathways especially in the 
current era with alternative P2Y12 antagonists that overcome some of the limitations 
of clopidogrel but may not share all the beneficial properties. 
 
  
Commonly used abbreviations: 
 
2Cs   Copper (I) chloride/cysteine 
Ach   Acetylcholine 
ADP  Adenosine diphosphate 
AMP  Adenosine monophosphate 
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2+
   Calcium ion 
CAD   Coronary artery disease 
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cGMP   Cyclic guanosine 3’-5’monophosphate 
COX   Cyclooxygenase 
Cu
+  
Cuprous ion 
Cu
2+  
Cupric ion 
Cys  Cysteine 
DMSO  Dimethyl sulphoxide 
EC  Endothelial cells 
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EDTA  Ethelene diamine tetra acetic 
eNOS   Endothelial nitric oxide synthase 
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H
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NO2
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prp  platelet rich plasma 
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I. GENERAL INTRODUCTION 
 
1. Vascular endothelium 
 
The vascular endothelium forms the inner cellular lining of blood vessels in 
the entire vascular system, from the heart to the smallest capillary, with a surface area 
of 1-7 m
2
 and a cumulative weight of 1 kg in humans
1
. This enormous interface 
facilitates the contact between blood stream and tissues. However, the vascular 
endothelium is more than a simple, passive transporter; it is a highly dynamic and 
heterogeneous organ that possesses vital secretory, synthetic, metabolic, and 
immunologic functions. This versatile role of vascular endothelium is affected by its 
unique semi-permeable structure in addition to the presence of membrane-bound 
receptors for numerous molecules including proteins, lipid transporting particles, 
metabolites and hormones. The specific structure and multiple receptors allow 
vascular endothelium to interact with blood cells from the outside as well as smooth 
muscle cells from the inside in order to mediate the whole range of physiological 
pathways including the control of vasomotor tone, blood cell trafficking, haemostatic 
balance, permeability, proliferation, survival, and innate and adaptive immunity2 
(Figure 1.1). For the same reasons the vascular endothelium is involved in most if not 
all cardiovascular disease states, either as a primary determinant of pathophysiology 
or as a victim of associated damage.  
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Figure 1.1. Major functions of vascular endothelium. The endothelial cells (1) govern the transport between blood and tissues using the caveolae/vesicle 
system and the intracellular junctions; (2) regulate the vascular tone by secretion of vasoactive substances that relax or constrict SMCs; (3) inhibit coagulation 
of blood by (i) control of thrombin generation, which otherwise activates the coagulation cascade, (ii) production of NO and PGI2, which inhibit platelet 
activation, adhesion and aggregation and (iii) degradation, storage or physical separation of signals that activate (e.g. ADP) or facilitate the adhesion of 
platelets (vWf, collagen); (4) control the immunity and inflammation by facilitating the migration of leukocytes into the sites of vascular injury; (5) initiate 
new blood vessel formation (angiogenesis) which is essential for tissue growth, wound repair and cancer growth. Described in details in text. Adapted
3
. 
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1.1 Major functions of vascular endothelium 
 
1.1.1 Transport of plasma molecules 
 
The primary role of endothelium is to form a semi-permeable membrane that 
retain blood cells and plasma proteins within the circulating blood stream and at the 
same time allow the passage of small solutes such as glucose, adrenaline and drugs 
between tissue and blood. The vascular permeability is regulated at two main levels, 
depending on the inflammatory status of cells. In the absence of a pathological 
stimulus, endothelial cells tightly monitor the transport of plasma molecules by means 
of non-specific and receptor-mediated endocytosis (within endothelial cells) and 
transcytosis (across endothelial cells). Some molecules (insulin or lipoproteins) are 
endocytosed to be used by the cell itself, others (transferrin, albumin) are transcytosed 
to reach the underlying cells, whereas others undergo both routes (LDL)
2
. Under 
physiological conditions these processes require only the involvement of the 
caveolae/vesicle system, while the restrictive intracellular junctions stay impermeable 
to macromolecules (albumin, blood cells). However, upon the release of inflammatory 
mediators, the activation of vasodilatory pathways result in additional increased 
junctional permeability, allowing for example the passage of leukocytes and more 
intense transport of albumin
2, 4
.  
 
1.1.2 Maintenance of vascular tone 
 
Endothelial cells regulate vascular tone by releasing vasodilating factors 
including nitric oxide (NO), prostacyclin (PGI2), endothelium-derived 
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hyperpolarizing factor (EDHF) and others, as well as vasoconstrictors, including 
endothelin (ET1), angiotensin-II (Ang-II), platelet-activating factor (PAF) and others 
(Table 1). These vasoactive mediators not only regulate the tone and growth of the 
underlying smooth muscle cells, but also regulate the reactivity of circulating 
leukocytes, erythrocytes, and platelets, and govern vascular permeability. Their 
biological effects are regulated by the localization of specific receptors on vascular 
and/or blood cells, through their rapid metabolism or gene transcription.  
 
Agent Vascular effects Other effects 
NO Vasodilation                                    
Inhibition of SMC proliferation  
Inducement of angiogenesis 
Inhibition of platelet adhesion, activation 
and aggregation; promotion of platelet 
disaggregation                                     
Inhibition of leukocyte adhesion             
Regulation of inflammation and apoptosis     
PGI2 Vasodilation                                 
Inhibition of SMC proliferation  
Inducement of angiogenesis 
Inhibition of platelet adhesion, activation 
and aggregation; promotion of platelet 
disaggregation                                    
Inhibition of leukocyte adhesion             
Regulation of inflammation and apoptosis  
EDHF Vasodilation (esp. resistance vessels) - 
PAF Vasoconstriction Inducement of platelet activation and 
aggregation 
ET1
4
 Vasoconstriction (via ETA receptor), 
main action                                      
Vasodilation (via ETB receptor and by 
stimulation of NO, PGI2 release) 
Mitogenesis of SMC                           
Activation of angiotensin-converting 
enzyme (ACE) 
Ang-II
5
 Vasoconstriction (via AT1 receptor), 
main action                                       
Vasodilation (via AT2 receptor and by 
stimulation of NO release)                                      
Angiogenesis 
Increase of sympathetic nervous system 
activity                                             
Maintenance of fluid homeostasis   
Inducement of leukocyte adhesion 
 
Table 1. Principal vasoregulatory substances synthesized by endothelium, their effects 
on the vasculature and other processes. Vasoactive compounds not listed here, i.e. 
prostaglandins are discussed in text (see I. General Introduction, pages 41-43). Adapted
6
. 
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1.1.3 Blood coagulation 
 
A pivotal physiological function of the vascular endothelium is to maintain 
blood fluidity by providing an anti-coagulant surface and controlling the mechanisms 
that promote platelet activation, adhesion and result in blood clotting (Table 2). The 
anti-coagulant surface of endothelium is maintained thanks to the glycocalyx coating, 
a network of membrane-bound proteoglycans and glycoproteins integrated with 
endothelium- and plasma-derived soluble proteins
2, 6, 7
. Heparan sulfate (HS) 
proteoglycans represent 50–90% of the total amount of proteoglycans and they are 
bound to anti-thrombin III (A-THIII), which inhibits thrombin and its pro-coagulant 
actions
7
. Another soluble proteoglycan thrombomodulin (TM) that also binds 
thrombin, changes its substrate specificity from cleavage of fibrinogen and release of 
fibrin (mediator of blood clotting) to cleavage and activation of the anti-coagulant 
protein C
6
. 
Apart from providing the anti-coagulant surface, the endothelium also secretes 
NO and PGI2 into plasma, which inhibit platelet activation, adhesion and aggregation. 
Moreover, it converts the platelet activators such as ADP and ATP into the inert AMP 
through the action of ADPases and ATPases
3
. Importantly, endothelial cells also store 
the active ultra-large von Willebrand factor (vWf) in Weibel-Palade bodies and 
become a physical barrier between platelets and the basal lamina, preventing the 
activation and adhesion of platelets to the endothelial surface by means of a direct 
contact with vWf and collagen
3
. Therefore, resting endothelial cells display anti-
coagulant and anti-thrombotic properties. However, in the presence of thrombotic 
stimuli the endothelium becomes activated and cells change their status from being 
anti- to pro-coagulant (Table 2). This involves the induction of tissue factor (TF), 
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which accelerates the factor VII-dependent activation of factors X and IX, followed 
by an activation of other coagulation factors and a subsequent generation of thrombin, 
and fibrin, a prerequisite for the formation of a thrombus
8
 (Figure 1.2).  
 
Function 
Anti-coagulant, anti-
thrombotic 
Pro-coagulant, pro-
thrombotic 
Control of  thrombin 
generation and 
coagulation cascade 
TFPIs                                           
HS/A-THIII                                                  
TM/APC, protein S 
TF, FIX, X, XII               
Thrombin, fibrin 
Release of vasoactive 
agents 
NO, PGI2 TXA2, ET-1 
Degradation
a
/storage
b
/ 
separation
c
 of platelet 
agonists 
ADPase
a
 
Weibel-Pallade bodies
b
             
Integrity of endothelial 
membrane
c
 
ADP
a
 
vWF
b
                                 
Collagen
c
 
Activation/inhibition of 
the fibrynolytic system 
t-PA, u-PA PAI-1, PAI-2 
 
Table 2. Regulation of coagulation and thrombosis by vascular endothelium. 
a,b,c
corresponding factors. Only examples are resented. Abbreviations: APC (activated protein 
C), A-THIII (anti-thrombin III), HS (heparan sulphate proteoglycans), PAI (plasminogen 
activator inhibitor), TF (tissue factor), TFPIs (tissue factor pathway inhibitors), TM 
(thrombomodulin), t-PA (tissue-type plasminogen activator), u-PA (urokinase-type 
plasminogen activator), vWF (von Willebrand factor). Adapted
4, 6
. 
 
 
After the blood clot is formed, the endothelium is involved in the regulation of 
the fibrinolytic system, which converts the proenzyme plasminogen into active 
plasmin that degrades fibrin, ultimately leading to the digestion of the thrombus. The 
fibrynolytic system can be activated by tissue-type (t-PA) and urokinase-type (u-PA) 
plasminogen activators and inhibited by specific plasminogen activator inhibitors 
(PAI-1 and PAI-2) or α2-antiplasmin
6
. Therefore, endothelial cells can control the life-
span of a thrombus by increased or decreased secretion of t-PA and of PAI-1 from the 
vessel wall. 
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Figure 1.2. Coagulation cascade. Initial Phase – TF (Tissue factor) activates factor VII 
complex, which then triggers factor X, either directly or indirectly via factor IX, and 
transforms prothrombin into thrombin in small amounts. Amplification Phase - thrombin that 
has been formed, along with Ca
2+
 from the blood and APL (anionic phospholipids) derived 
from platelets, actively participates in a positive feedback process for the activation of factors 
XI, IX, VIII, and V, and, especially, to accelerate platelet activation. Propagation Phase - 
large quantities of activated factor X lead to the more conversion of prothrombin into 
thrombin and, through the action of thrombin, conversion of fibrinogen into fibrin. Adapted
8
. 
 
1.1.4 Immunity and inflammation 
 
Endothelial cells play a crucial part in the regulation of immunity and 
inflammation in the first instance by antigen presentation to T cells and recruitment of 
inflammatory cells to the inflamed sites and in the second instance by expression of 
adhesion molecules and release of vasoactive and chemotactic factors, which facilitate 
the adherence and migration of circulating cells into the affected area (Table 3).  
 
 
TF+VIIa 
Inital Phase Amplification Phase Propagation Phase 
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Mediator class Pro-inflammatory Anti-inflammatory 
Vasoactive agents Ang-II, ET1, PGI2, PGE2, TXA2 NO, PGI2, PGE2, PGJ2 
Complement C3a, C5a C1q receptor 
Adhesion molecules E-selectin, P-selectin, ICAM-1, 
VCAM-1 
αvβ3 integrin, TSP receptor, PS 
receptor 
Cytokines TNF-α, IL-1β, IL-6 TGF-β1, IL-10 
Chemokines IL-8, MCP-1, MIP-1α - 
Transcription factors NF-κB, STAT, NF-AT, AP-1 PPARγ 
Mechanical forces Stretch Shear stress 
 
 
Table 3. Mediators of pro- and anti-inflammatory responses in vascular cells. 
Abbreviations: AP-1 (activator protein-1), ICAM-1 (intercellular adhesion molecule-1), IL 
(interleukin), LT (leukotriene), MCP-1 (monocyte chemotactic protein-1), MIP-1α 
(macrophage inflammatory protein-1α), NF (nuclear factor), PG (prostaglandin), PPARγ 
(peroxisome proliferator-activated receptor γ), PS (phosphatidylserine), STAT (signal 
transducers and activators of transcription), TGF-β1 (transforming growth factor-β1), TNF 
(tumour-necrosis factor), TSP (thrombospondin), VCAM-1 (vascular cell adhesion molecule-
1). Only examples are presented. Adapted
9, 10
. 
 
Both leukocytes and platelets interact with damaged vessel surfaces through a 
multistep process including (i) the initial formation of reversible attachments, (ii) 
activation of the attached cells, (iii) development of stronger, irreversible adhesions 
and (iv) recruitment of other circulating cells
11
 (Figure 1.3). The activation and 
aggregation of platelets result in the formation of a thrombus (see I. General 
Introduction, pages 51-54) while the adhesion of leukocytes promotes their movement 
to the inflammatory sites, which then leads to heat, redness, swelling, pain and loss of 
function (the five signs of inflammation)
10
. In fact, there is a clear relationship 
between inflammation and thrombosis. For example, the pro-coagulant thrombin is 
capable of stimulating multiple inflammatory pathways, and equally, activated 
inflammatory cells produce many molecules such as TF, thrombin, IL-6, IL-8, and 
monocyte chemotactic protein MCP-1 which are capable of activating coagulation
5, 12
. 
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Additionally, platelet activation leads to pro-thrombotic and pro-inflammatory 
responses via release of secondary mediators (ADP, TXA2 and thrombin) from dense 
granules and inflammatory mediators (e.g. IL-1, TGF-β, TNF-α, RANTES) from 
alpha granules
13
. 
 
 
Figure 1.3. Sequential steps in leukocyte recruitment showing leukocyte margination, 
rolling, firm adhesion and transmigration. At first leukocytes are attracted to endothelium 
by inflammatory mediators (chemokines, cytokines) released from tissue macrophages. Then, 
the reversible binding of selectins (P-, E-, L-selectins) expressed on leukocytes and 
endothelium facilitate rolling and reversible capturing of leukocytes. This leads to the 
activation of integrins and subsequent binding to their adhesion molecules (VCAM-1 and 
ICAM-1) on endothelium. Under the influence of additional chemokines, leukocytes become 
strongly attached and flattened until they start their migration to the sites of injury. Adapted
14
 
 
Finally after the injurious stimulus is removed, the endothelium promotes the 
suppression of (i) pro-inflammatory gene expression, (ii) leukocyte movement and 
activation, (iii) thrombus formation, followed by clearance of inflammatory cells by 
apoptosis and phagocytosis; all in order to restore normal tissue structure and 
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function. Hence, the controlled pro-inflammatory response to the vascular injury and 
infection, followed by the adequate anti-inflammatory responses and resolution of 
inflammation are crucial for the maintenance of the vascular homeostasis. Prolonged 
inflammation causes endothelial dysfunction associated with the pathogenesis of 
many cardiovascular diseases. 
 
1.1.5 Angiogenesis 
 
Endothelial cells possess a remarkable ability to divide rapidly in response to 
hypoxia and inflammation and as such, they play a pivotal role in angiogenesis (the 
growth of blood vessels). Angiogenesis is as important in the embryo for the 
development of the vascular system and organ growth as in the adult for wound 
healing and repair. In the adult, the vessel growth starts from the recruitment of 
endothelial progenitor cells (EPCs) from the bone marrow to sites of 
neovascularisation
15
. EPCs are incorporated into nascent vessels or stimulate new 
vessel growth by releasing pro-angiogenic factors. This process is known as 
vasculogenesis. Angiogenesis itself refers to endothelial budding and sprouting in 
response to angiogenic factors, which loosen their inter-endothelial junctions (e.g. 
Ang-2) and break down the surrounding ECM (e.g. plasminogen activators, matrix 
metalloproteinases), liberating matrix-bound angiogenic growth factors (e.g. FGF-2, 
VEGF, IGF-1, TGF-β, TNF-α)15. After the new vessel sprout is formed out of naked 
endothelial cells, it becomes stabilised by recruitment of SMCs and pericites, 
deposition of ECM and tightening of cell junctions in the process named 
arteriogenesis
15
.  
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The abnormal or excessive stimulus for angiogenesis contributes to the 
pathogenesis of many malignant, inflammatory, infectious and immune disorders 
including cancer, atherosclerosis, asthma, diabetes, cirrhosis, AIDS and many 
others
15
.  
 
1.2 Endothelial dysfunction in cardiovascular diseases 
 
Endothelial cells perform several functions required to maintain vascular 
homeostasis. They are capable of producing a variety of molecules: vasodilators and 
vasoconstrictors, procoagulants and anticoagulants, oxidants and anti-oxidants, 
inflammatory and anti-inflammatory mediators, angiogenic and anti-angiogenic 
factors in order to balance all needs of the vascular system (Figure 1.4)
5
. However, 
when endothelial cells are injured, they loose the capacity to maintain homeostasis, 
which leads to the so called “endothelial dysfunction” and development of vascular 
disease
5. This is not to be confused with the term “endothelial activation/stimulation”, 
which usually refers to the changed status of endothelial cells from anti-coagulant or 
anti-inflammatory to pro-coagulant or pro-inflammatory in response to local infection. 
The symptoms of both endothelial activation and dysfunction are often similar in 
terms of the thrombus formation or the enhancement of leukocyte recruitment but the 
outcomes are different; the first is beneficial and associated with host defense while 
the other is pathological and linked to vascular diseases
16
. 
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Figure 1.4. Equilibrium between the differing functions in vascular endothelium. The 
left side of the balance represents features of resting endothelial cells, which dominate in 
healthy endothelium. On the right side, there are main characteristics of activated endothelial 
cells which are engaged in response to the local infection. Adapted
5
 
 
Endothelial dysfunction has been implicated in the pathophysiology of diverse 
cardiovascular diseases including all stages of atherosclerosis, thrombosis, 
hypertension, coronary artery disease (CAD), peripheral artery disease (PAD), 
diabetes, obesity, chronic heart and renal failure
17
. It has been not only associated 
with common cardiovascular risk factors but also correlated with disease progression 
and used as a prognostic tool for prospective cardiovascular events. Furthermore 
therapies known to reduce cardiovascular risk improve endothelial function while 
failure of the endothelium to respond is associated with higher risk
18, 19
.   
  
1.2.1 Reactive oxygen species and oxidative stress 
 
Reactive oxygen species (ROS) are partially reduced and highly reactive O2 
metabolites such as superoxide (O2
•-
) and O2
•-
-derived hydroxyl radicals (
.
OH), 
hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-
). They are created during 
mitochondrial oxidative phosphorylation and other electron transfer reactions in all 
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aerobic organisms and serve as signalling molecules in the regulation of signal 
transduction, gene expression and pathogen defense responses
20, 21
. In the vascular 
endothelium NADPH oxidases are considered a main source of O2
•-
, although other 
enzymes such as cytochrome P450 (CYP450), xanthine oxidoreductase (XO), 
mitochondrial complex I and III, uncoupled eNOS, cyclooxygenase (COX), and 
lipooxygenase (LOX) also contribute.  
Oxidative stress is defined as an imbalance between the production of ROS 
and their removal by naturally occurring anti-oxidant defenses of cells including 
enzymatic activity of catalase and superoxide dismutases (SODs), as well as direct 
actions of anti-oxidants like glutathione, vitamin E, β-carotene, ascorbate, urate and 
many others
22
. Increased cellular production of O2
•-
 and H2O2 can facilitate formation 
of the more toxic and reactive ·OH in the presence of divalent metal ions such as iron 
(Fenton reaction) or copper
23
. As ·OH has a very short half-life and high reactivity, it 
can rapidly damage any surrounding macromolecules, including: (i) amino acids, 
potentially leading to protein inactivation/denaturation; (ii) carbohydrates, causing 
degradation; (iii) lipids, by interaction with polyunsaturated fatty acids of membrane 
phospholipids, leading to lipid peroxidation; and (iv) nucleic acids, resulting in 
possible mutations
20
. ONOO
-
 reacts directly with sulphur-containing amino acids 
(cysteine and methionine), as well as those with an aromatic structure (e.g. tryptophan 
and tyrosine)
24
. Prolonged exposure to oxidative stress induces cell proliferation, 
hypertrophy, apoptosis and inflammation through activation of redox-sensitive 
transcriptional factors (e.g. NF-κB, AP-1) and leads to further damage.23, 25 (Figure 
1.5).  
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Figure 1.5. Main mechanisms contributing to ROS-related endothelial dysfunction and 
complications in cardiovascular diseases. Adapted
25
. 
 
Oxidative stress has been identified as a key determinant of endothelial 
dysfunction associated with cardiovascular disease
17, 19, 22, 25
. It has been linked, 
among others to 1) loss of NO bioavailability at various levels (see I. General 
Introduction, pages 15-18), 2) increased amounts of oxidized LDL-cholesterol 
molecules (LDL-ox), which change the phenotype of macrophages into foam cells 
and contribute to artherosclerotic plaque formation, 3) accumulation of advanced 
glycation end-products (AGEs), which contribute to diabetic vasculopathy, 4) 
activation and aggregation of platelets causing thrombus formation, 5) increased 
activation of Ang-II implicated in hypertension and chronic renal failure. Clinical 
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interventions to reverse oxidative stress and concomitant endothelial dysfunction are 
based in majority on lifestyle modification including exercise and diet change, as well 
as pharmacological therapy using anti-oxidant or lipid-lowering agents (e.g. statins), 
blockade of platelet activation and aggregation (e.g. aspirin) and inhibition of Ang-II 
(e.g. ACE inhibitors)
19
.  
 
1.2.2 NO bioavailability 
 
NO is synthesized endogenously mainly from L-arginine in a complex 
reaction catalyzed by different members of the same family of enzymes called NO 
synthases (NOS). All NOS are heme- and flavin-containing enzymes that use 
NADPH, BH4 and O2 to convert L-arginine to L-cirtulline with concomitant release of 
NO
26
. NO is involved in fundamental processes of the cardiovascular system, such as 
vasodilation, neurotransmission, inflammation, thrombus formation and angiogenesis 
(see I. General Introduction, pages 22-24). Endothelial NOS (eNOS) is the main 
source of vascular NO and becomes uncoupled in the limited concentrations of 
essential co-factors (FAD, FMN, NADPH and BH4) or the substrate L-arginine as 
demonstrated in diabetes, hypercholesterolaemia and other vascular diseases
26
. 
Uncoupling of eNOS switches off its oxygenase function producing NO and activates 
its reductase function producing O2
•-
 and H2O2, which aggravates oxidative stress and 
endothelial dysfunction by lowering synthesis of NO and increasing production of 
ROS at the same time
26
. Oxidative stress also results in reduction of BH4 and 
accumulation of asymmetric dimethylarginine (ADMA), a competitive inhibitor of 
eNOS, which has been identified as an independent risk factor and possible marker in 
patients with CAD
27
. eNOS gene expression and enzymatic activity may also be 
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negatively affected by altered eNOS phosporylation mediated by the phosphatidyl-
inositol-3-kinase(PI3K)/ Akt pathway, dimerization, and intracellular localization to 
caveolae
25, 26
. 
Physiological levels of NO can also be dramatically reduced by its reaction 
with O2
•-
, which leads to the formation of ONOO
-
. ONOO
-
 is a major mediator of the 
pathological effects associated with NO, particularly under conditions of severe 
oxidative stress and advanced disease (e.g. highly developed atherosclerosis or 
diabetes, sepsis), when the production of both O2
•-
 and NO are augmented
26
. ONOO
-
 
like other reactive oxygen/nitrogen species (ROS/RNS) mediate the deleterious 
oxidation and nitration of proteins, lipids, or DNA and contribute substantially to 
oxidative stress and endothelial dysfunction
26
 (Figure 1.6).  
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Figure 1.6. Cellular targets of NO and associated nitrogen oxides. The most sensitive 
target of NO is sGC, followed by cytochrome c oxidase (CcOx) and non-heme iron (NHI; at 
the top). Reaction of NO with ROS changes target susceptibility (at the bottom). Under 
conditions of increased free radical production, NO forms oxidation products that react with 
proteins, lipids, DNA, and FeS centers predominantly over the targets shown at the top. 
Adapted
24
 
 
Reduced NO availability as a result of decreased synthesis (by uncoupled or 
reduced eNOS regulation) or increased degradation (by reaction with O2
•-
) is a 
hallmark of endothelium dysfunction
17, 25
. While some of the available therapies 
aimed at increasing NO bioavailability involve restoring the oxygenase function of 
eNOS by replenishing limited BH4 factor and/or L-arginine, others focus on reducing 
the oxidative stress caused by O2
•-
 and ONOO
-
, which alters NO production, amount 
and function of its downstream receivers
28
. For example, high concentrations of 
vitamin C have been shown to restore NO-dependent responses in ApoE-deficient 
mice and in CAD patients due to its anti-oxidant properties to reduce oxidation of 
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BH4
28
. Moreover, inhibition of upregulated vascular enzymes generating O2
•-
 such as 
CYP450 improved endothelium-dependent NO-mediated vasodilation in CAD 
patients. Interestingly, a number of clinical trials have not confirmed the protective 
effects of vitamin E on atherosclerosis progression or major cardiovascular events
29
. 
The apparent lack of clinical usefulness of some anti-oxidant therapies is not clear. It 
has been suggested that because anti-oxidants, including vitamins, react with O2
•-
 one 
billion times slower than NO, a reaction of O2
•-
 with NO is thermodynamically 
preferred
29
. There are also studies indicating that vitamins do not penetrate into the 
vascular wall sufficiently, hence they may reach therapeutic levels in the plasma but 
not in tissues. Therefore, not ROS but the enzymes contributing to their upregulation 
have become more interesting targets for reducing oxidative stress and improving NO 
bioavailability. 
 
1.3 Measurement of endothelial function 
 
Assessment of endothelial function is a useful diagnostic and prognostic tool 
in the setting of cardiovascular risk. Since the endothelium carries out a great variety 
of functions, including control of vasomotor tone, coagulation of blood and 
inflammation, a number of biochemical markers have been used as indicators of 
endothelial dysfunction, such as selectins, ILs, ICAM-1, VCAM-1, C-reactive protein 
(CRP), TNF-α, interferon γ (IFN-γ), MCP-1, vWf, t-PA, PAI-1, microparticles, 
circulating endothelial cells etc. (Table 4).   
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Markers Effects 
Oxidative stress: TAC of plasma, PGF2α, 
ADMA, oxLDL, lipid peroxides, protein 
modifications (3-NT, 8-OHdG) 
Inactivates NO, damages lipids, proteins and 
DNA, upregulates inflammatory and 
coagulation responses 
NO pathway: ADMA, impaired FMD or 
vascular response to acetylcholine, low levels 
of NO metabolites 
Limits NO bioavailability 
Circulating endothelial cells Marker for endothelial injury 
Microparticles Vesicles formed by cell membranes after 
endothelial activation 
Angiogenic growth factors: VEGF, PlGF Induce permeability, migration and 
angiogenesis 
Cytokines: ILs, TNFα, MCP-1 Stimulate more ROS production and 
upregulation of inflammatory genes 
Inflammation markers: vWF, E-selectin, 
VCAM-1, ICAM-1 
Reflect extent of endothelial cell activation 
and damage 
Platelet activation and aggregation: P-
selectin, TXA2/TXB2 
Cause thrombus formation at injured sites 
Fibrynolytic pathway: PAI-1, tPA Associated with endothelial injury 
 
Table 4. Biomarkers reflecting endothelial dysfunction (injury). Only examples are 
presented. Abbreviations are explained in text. Adapted
23, 30, 31
 
 
1.3.1 Oxidative stress 
 
In terms of measuring oxidative stress, methods range from direct detection of 
ROS species with various electrodes, to stabilization of ROS using spin traps, or their 
effect on fluorescent probes, through measurement of oxidation (oxLDL, 8-OHdG, 
lipid peroxides) or nitrosation [(3-nitrotyrosine (3-NT)] end-products, and 
downstream markers of oxidation activity (ADMA, PGF2α, AGEs). ROS are 
extremely unstable and reactive molecules, which make the specific quantification of 
certain species (O2
·-
, ·OH, H2O2, ONOO
-
) in biological systems a real challenge. 
Furthermore, because different ROS have distinct half-lives, diffusion rates and rates 
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of reaction with other molecules, one factor controlling the outcome of ROS may be 
their site of production. Therefore, an observation of upregulated ROS is indicative 
only and should be accompanied by other measures, including relevant source 
enzymes (e.g NADPH, XO, uncoupled eNOS) and effectors of the oxidative signal. 
An alternative measure of oxidative stress, which can be used in plasma, is to 
record the plasma total anti-oxidant capacity (TAC), also known as oxygen radical 
absorbance capacity (ORAC)
32, 33
. This method instead of measuring amount or 
outcome of ROS, provides information on how efficient different anti-oxidant 
defenses of various components of blood are in providing protection against ROS 
attack. Although TAC/ORAC is only the net effect of many different compounds and 
systemic interactions, it gives more biologically relevant information than that 
obtained from measuring individual anti-oxidants. It should be noted that results from 
TAC/ORAC can be interpreted in different ways depending on the time and level of 
oxidative stress. For example, the in vivo increase of oxidative stress in plasma could 
be due to a temporal imbalance of anti-oxidant responses, thus will be reflected as a 
reduction in TAC. However, a prolonged exposure to oxidative stress may lead to the 
chronic adaptation and upregulation of anti-oxidant defenses in vivo, which will be 
reflected by an increased TAC in this setting. 
 
1.3.2 NO bioavailability 
 
NO bioavailability can be determined by measuring the vasomotor response to 
physiological or pharmacological stimuli. Quantitative coronary angiography after 
intra-arterial infusion of acetylcholine is a widely used, although a quite invasive 
approach in vivo. Non-invasive measurements of flow-mediated dilation (FMD) of the 
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brachial artery by imaging with high-resolution ultrasound are more promising 
methods for wide application in humans. These also exhibit certain limitations due to 
significant methodological variation among operators and differences in baseline 
diameters/values of various individuals. In vitro, endothelial function may be assessed 
on isolated vessels, where isometric tension is recorded on a myograph for their 
responses to endogenous or exogenous NO donors.  
Laboratory methods to determine NO bioavailability are based on the actual 
quantification of NO. Free NO is extremely difficult to measure due to its unstable 
nature and high reactivity with other molecules. There have been several 
methodologies developed using NO electrodes, NO spin traps [in conjunction with 
electron paramagnetic resonance (EPR)], or NO fluorescent probes allowing the 
capture and measurement of NO in real time or accumulated over time. However, all 
these techniques suffer from insufficient specificity of detection [e.g. 
diaminofluorescein (DAF fluorescent probe)] or inadequate sensitivity, which become 
particularly problematic in complex biological samples such as plasma where actual 
levels are typically around the detection limit. Another approach is to measure more 
stable metabolites of NO namely nitrite, nitrate and S-nitosothiols (RSNO). These are 
the primary oxidation metabolites of NO. However care must be taken in interpreting 
results since these are no longer perceived as being unnecessary bi-products of NO 
but have been shown to be potential ‘stores’ of NO that can circulate and can be re-
cycled to exhibit biological function under certain conditions (see I. General 
Introduction, pages 25-28). NO metabolites can be measured using Griess reagent, 
HPLC or ozone-based chemiluminescence (OBC). While the Griess method has very 
poor sensitivity and HPLC involves laborious procedures, OBC is currently the most 
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specific and sensitive method to measure NO release from different NO metabolites 
with minimum processing of the samples required
34
.  
 
2. Nitric Oxide in the vasculature 
 
NO is produced by a variety of mammalian cells, including endothelium, 
macrophages, neurons, cardiomyocytes, platelets, and fibroblasts. NO produced by 
the endothelium modulates vasomotor tone, inhibits platelet adhesion and 
aggregation, inhibits smooth muscle cell proliferation and governs vascular 
permeability. NO can also exhibit distinctly different and even opposing redox 
functions depending on the amount and microenvironmental conditions in which it is 
produced. Under physiological conditions at low concentrations of O2
•-
, NO mediates 
anti-oxidant, anti-apoptotic and protective effects; it defends cells from oxidative 
stress by scavenging O2
•-
, inhibits expression of adhesion molecules (VCAM-1, 
ICAM-1) and selectins (P-selectin, E-selectin), and inactivates Bad and caspase-9
26
. 
Conversely, excessive NO production in the presence of oxidative stress contributes 
and augments ROS-mediated tissue damage and lipid peroxidation by production of 
highly reactive ONOO
-
 and direct inhibition of mitochondrial respiratory chain 
enzymes
26
  (Figure 1.8). 
 
2.1 NOS as a cellular source of NO 
 
Different NOS isoforms: neuronal NOS (nNOS/NOS1), endothelial NOS 
(eNOS, NOS3) and inducible NOS (iNOS/NOS2) were named after the tissue in 
which they were first purified and cloned however, since then, they have been 
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identified elsewhere (Table 5). Both nNOS and eNOS are expressed constitutively, 
exhibit low basal activity and are stimulated by the increase in intracellular Ca
2+
 
concentration and Ca
2+
/calmodulin binding
26
. eNOS is highly expressed in endothelial 
cells and is a major source of plasma NO, generating NO in response to shear stress 
and other physiological stimuli. Furthermore, it has been shown that activity of eNOS 
can be regulated not only by Ca
2+
 levels, but also by numerous transcriptional and 
translational events affecting its mRNA stability, intracellular translocation and 
phosphorylation
26
. iNOS, on the other hand, is tightly bound to Ca
2+
/calmodulin 
complex and does not depend on intracellular Ca
2+
 concentration. It is primarily 
expressed in response to immunological stimuli, is mainly regulated at the 
expressional level and generates large amounts of NO (100-1000-fold more NO than 
eNOS)
26
. The high amounts of NO produced by iNOS can have beneficial anti-
microbial, anti-atherogenic and anti-apoptotic actions. However, aberrant iNOS 
induction has been associated with numerous human diseases such as asthma, 
arthritis, neurodegenerative diseases, tumor development or septic shock. 
Furthermore, a certain pattern of increased iNOS accompanied by reduced eNOS has 
been reported in atherosclerosis as well as response to ischaemia, 
hypercholesterolaemia and ROS
26
. 
In addition to the classical NOS-dependent production, NO can also be 
released from S-nitrosothiols and/or via reduction of nitrate and nitrite back to NO by 
mechanisms, which have not been fully elucidated (see I. General Introduction, pages 
25-28). 
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NOS Distribution Regulation Main functions 
nNOS/ 
NOS1
35, 
36
 
Neurons    
Skeletal muscle    
Epithelial cells 
Endothelial 
cells  
Cardiomyocytes 
Agonists of NMDA receptors 
Ca
2+
/calmodulin             
mRNA↑              
Phosphorylation 
Neuroprotection and 
neurotransmission in NANC 
nerves (nNOS
-/-
 -pain↓, 
memory↓)                   
Regulation of cardiac function 
(nNOS
-/-
, nNOS┴ -cardiac 
contractlity↑)                                 
Peristalsis (nNOS
-/-
-gastric 
dilation and stasis) 
iNOS/ 
NOS2
26, 
35, 37
 
Most cell types 
in response to 
inflammation 
Pulmonary 
epithelial cells 
Endotoxin and cytokines (IL-
1, IL-2, TNF-α, IFN-γ)  
mRNA↑↑↑ (mostly 
transcriptionally regulated) 
Regulation of immune response 
to pathogens (iNOS
-/-
-leukocyte 
recruitment↑ in endotoxic 
shock)                    
Angiogenesis (iNOS
-/-
-tumors↑) 
eNOS/ 
NOS3
26, 
35
 
Endothelial 
cells 
Cardiomyocytes 
Neurons, 
astrocytes 
Platelets  
Epithelial cells           
Skeletal muscle 
Receptor-dependent agonists 
(thrombin, ADP, BK, 
substance P, His, Ach, 
VEGF)           
Ca
2+
/calmodulin             
mRNA↑ (shear stress, 
VEGF, chronic exercise, 
TGFβ, statins, oestrogens)                    
mRNA↓ (TNF-α, LPS) 
Phosporylation          
Intracellular trafficking 
(meristoylation and 
palmitoylation, interaction 
with caveolin-1 and -3, 
hsp90, CHIP etc.) 
Vascular smooth muscle 
relaxation (eNOS┴, eNOS
-/-
-
blood pressure↑)          
Inhibition of platelet 
aggregation (eNOS┴-bleeding 
time↓)                         
Regulation of vascular perme-
ability (eNOS
-/-
, eNOS┴ -
leukocyte recruitment↑)                     
Inhibition of vascular SMC 
proliferation (eNOS
-/-
-
hyperplasia↑)         
Angiogenesis (eNOS
-/-
-wound 
healing↓)                              
Cardiac contractility (Ca
2+
 -
spark frequency) 
 
Table 5. Summary of NOS characteristics including their tissue distribution, regulation 
and main functions. The different roles of particular NOS isoforms are well documented in 
the literature and selected examples are listed in brackets. For a more in-depth view, the 
reader is directed to the citations. It should be noted that some NOS inhibitors may block 
more than one isoform and that gene knockout therapy may potentially upregulate the 
compensatory pathways, which altogether may confound some of the findings. Symbols: ┴ -
isoform specific inhibition, -/- -knockout mice, ↑ - enhanced, ↓ -reduced. 
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2.2 Inorganic nitrate and nitrite as alternative sources of NO 
 
Nitrite (NO2
-
) and nitrate (NO3
-
) are the primary oxidation products of NO. 
Nitrate in the diet contributes ~70% of nitrate levels in plasma in humans. At normal 
O2 levels, NO produced from eNOS and other sources is oxidized to NO2
-
 and then to 
NO3
-
 through a series of reactions and various NO metabolites intermediates 
(equations below). 
 
2 2
2 2 3
2 3 2 2
2 2 2 3
2 2
2 2
2 2
NO O NO
NO NO N O
N O H O NO H
NO H O NO NO H
 
  
 
 
  
   
                                                                                                  
 
However, under low O2 conditions NO2
-
 can be reduced back to NO thanks to 
enhanced activity of ‘nitrite reductases’, which act as oxygen sensors38, 39. These 
enzymes include among others deoxyhaemoglobin, xanthine oxidoreductase (XO), 
aldehyde oxidase (AO), eNOS, cytochrome P450 and the mitochondrial transport 
chain. The ability of NO2
-
 to serve as an alternative source of NO in ischemic/hypoxic 
conditions has been appreciated in human physiology relatively recently. NO2
-
 
administration has been shown to vasodilate hypoxic tissue regions
40-42
, reduce blood 
pressure
43
 and provide cytoprotection in ischaemia/reperfusion injury
40, 44-46
.  
Lately, NO3
-
 has been discovered to be another alternative source of NO via 
reduction to NO2
-
 by nitrate reductase-containing bacteria residing in human saliva
47
. 
When nitrate rich food (green leafy vegetables, beetroot) is ingested, NO3
-
 is reduced 
to NO2
-
 over a few hours via the entero-salivary circulation, which is reflected by an 
increase in plasma levels of both metabolites
48-50
. Dietary supplementation of NO3
-
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and the subsequent increase in NO2
-
 has been shown to provide vasodilation and 
reduction in blood pressure
48, 50, 51
, inhibition of platelet aggregation
50, 51
, protection 
against ischaemia/reperfusion injury
50
 and reduction of oxygen cost in exercise
52-54
.  
Therefore, both NO2
-
 and NO3
-
 have a great potential in therapeutic treatment 
of cardiovascular diseases associated with endothelial dysfunction, reduced NO 
bioavailability and regional ischaemia as well as an improvement of exercise 
performance
50, 55, 56
. Current therapy of CAD, angina and heart failure involves 
application of organic nitrates and is limited to short-term treatment due to nitrate 
tolerance, increased oxidative stress and endothelial dysfunction, which occurs in 
chronic use
57
. Additionally, the efficacy of NO donors including organic nitrates 
depends on a healthy endothelium which is usually disturbed in cardiovascular 
diseases, which suggests that therapy with NO2
-
 and/or NO3
-
 might be a better 
alternative
46
. 
 
Figure 1.7. Proposed NO3
-
-NO2
-
-NO pathway. Adapted
58
. 
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Although nitrite and dietary nitrate has demonstrated to have a range of 
beneficial vascular effects, there are still certain issues that remain to be explained and 
investigated. First of all, the interindividual variability in baseline plasma nitrite and 
nitrate seem to have an impact on the level of augmentation of these metabolites in 
plasma and the magnitude of vascular changes in response to the dietary nitrate. For 
example, dietary nitrate did not enhance running performance in elite cross-country 
skiers although earlier studies have reported improved exercise performance in 
healthy adults
59
. The elite athletes had lower baseline nitrite than normal individuals 
and the nitrite augmentation after dietary nitrate ingestion was also respectively 
smaller. In another study, dietary nitrate reduced blood pressure in males, which had 
lower baseline nitrite concentration but had no influence on females with higher 
baseline plasma concentrations
51
. Although these observations need confirmation, 
they suggest that the efficiency of NO3
-
 and/or NO2
-
 treatment may depend on initial 
plasma levels of these metabolites. 
Another issue of concern are effects of nitrite beyond its reduction to NO, 
which may influence the vasculature and contribute to the observed NO-like effects. 
Alternative pathways of nitrite activity include the formation of nitrosothiols and 
nitrated fatty acids, as well as direct vasodilation via COX-mediated pathways
42, 46, 55, 
60
. Although the majority of nitrite vascular effects are thought to be mediated by NO, 
the exact mechanism is not well defined. The difficulty in identifying a specific 
signalling pathway perhaps comes from a rapid redistribution of NO2
-
 within different 
compartments of blood and tissues. For example, a low-dose infusion of nitrite has 
been shown to induce a prolonged vasodilator effect in the pulmonary vasculature 
even after plasma NO2
-
 levels returned back to baseline
40
. 
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The long-term effects of dietary nitrate supplementation have to be 
investigated in man in order to elucidate the implied interaction with other nutrients 
(e.g. polyphenols) and possible cancerogenic effect
55
.  
 
2.3 S-nitrosothiols as alternative sources and effectors of NO 
 
S-nitrosothiols (RSNOs) are derivatives and storage forms of NO, where a 
nitrosonium moiety (NO
+
) is covalently bound to the sulfhydryl group (SH) of 
proteins or low-molecular-mass thiols. NO
+
 is a by-product of NO metabolism in 
blood (equation 1 below) and can also be formed from nitrite in acidic pH (equation 2 
below). NO
+
 reacts with SH groups forming RSNO (equation 3 below). 
 
2 2 2 4
2 2 3
2 3 2
2 2
2 2
NO O NO N O
NO NO N O
N O H NO H O
 
 

 
                                                                                   (1) 
2 2
2NO H NO H O
                                                                         (2) 
RSH NO RSNO H
                                                                                         (3) 
 
RSNOs possess many of the biological activities of NO itself such as 
relaxation of smooth muscle, inhibition of platelet aggregation or regulation of 
cellular redox, apoptotic and inflammatory responses
61-64
. RSNOs execute these 
functions via two main mechanisms: 1) they can act as special NO donors providing 
protection and storage of the NO
+
 group, which can be transferred to other RSNOs 
(transnitrosation) and released only when cleaved ; 2) they can induce post-
translational modifications of cysteine residues on proteins (S-nitrosylation) and 
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therefore, contribute to the regulation of their function and signal transduction
65-67
. 
RSNOs are stable in acidic or alkaline conditions but can be cleaved very efficiently 
by transition metals (e.g. Cu, Hg), and even ascorbate. This property of RSNOs is 
used for their detection by 2 C’s (mixture of CuCl and Cys) or HgCl2 reagents (see 
III. General Methods, page 88). 
The in vivo reduction mechanism of RSNOs back to NO (denitrosylation) is 
still the matter of some debate
65
, although in SNO-proteins S-nitrosoglutathione 
reductase (GSNOR) and thioredoxin (Trx) were reported to play an important role
68
; 
GSNOR is not only required for physiological denitrosylation of GSNO but also 
governs S-nitrosylation of other proteins by influencing the cellular equilibrium 
between protein S-nitrosothiols and GSNO.  
Over 100 proteins have been identified to be S-nitrosated in  human and other 
mammal pathophysiologies, including those affecting NO bioavailability and 
function
68, 69
. For example, it has been shown that S-nitrosylation activates ariginase 
and inhibits eNOS and eNOS regulating proteins (i.e. HSP90), as well as inhibits the 
main target for NO, sGC, which taken together has detrimental effects on NO 
production and signalling. On the other hand, inhibitory S-nitrosylation of NADPH 
and PDE5 help to preserve NO bioavailability by inhibiting production of O2
•-
 and 
increase levels of one of the main NO second messengers, cGMP
68
. Furthermore S-
nitrosylation of caspase3, N-ethylmaleimide-sensitive factor (NSF) and NF-κB were 
taken to explain the anti-apoptotic, anti-thrombotic and anti-inflammatory properties 
of NO
68
. Despite these recent discoveries, it is not yet clear how RSNOs and NO 
work in concert with each other and whether S-nitrosylation of proteins only reflects 
NO activity or on its own is truly a crucial mechanism in cell signalling. Nevertheless, 
some of the exogenous RSNOs compounds (CysNO, GSNO, SNAC) have been used 
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as endothelial-independent NO donors in animal and human model systems (see I. 
General Introduction, pages 49-51).  
It is important to distinguish between S-nitrosation and other thiol 
modifications, including S-glutathiolation and S-oxidation as different cysteine thiol 
adducts are regulated by different mechanisms depending on their microenvironments 
and the availability of reducing agents
70
. Interestingly, all thiol-mediated 
modifications of proteins are mediated by ROS/RNS and correlate with various stages 
of oxidative stress (Figure 1.8). Hence, not only S-nitrosation but also S-
glutathiolation and S-oxidation have been implicated in both redox signalling and 
oxidative damage
70
. 
 
 
Figure 1.8. Influence of ROS/RNS on post-translational oxidative modification of thiols 
in pathophysiology. Adapted
70
. 
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3. Smooth muscle contraction and relaxation 
 
The middle layer of arteries, arterioles, venules and veins is composed mainly 
of vascular smooth muscle cells (SMC). SMC are wrapped around vessels so that 
their contractile tension (tone) regulates the vessel diameter
1
. 
 
3.1 The regulation of myosin light chain 
 
The contractile state of smooth muscle is regulated by phosphorylation and 
activity of the myosin light chain (MLC)
71
. Phosphorylation of MLC is mediated by 
MLC kinase (MLCK) and leads to the stimulation of the myosin ATPase activity and 
smooth muscle contraction. MLC phosphatase (MLCP) reverses this process by 
catalyzing the dephosphorylation of MLC. The balance between MLC kinase and 
phosphatase activities is a critical determinant in the contractile status of smooth 
muscle and it can be affected by (i) Ca
2+
, including the changing levels of intracellular 
calcium [Ca
2+
]i and Ca
2+
 sensitization, (ii) second messengers: cAMP, cGMP, inositol 
1,4,5-trisphosphate (IP3), diacylglycerol (DAG) and/or protein kinases (i.e. PKA, 
PKG, PKC, rhoA kinase). 
Upon elevation of [Ca
2+
]i and increased formation of Ca
2+
/Camodulin complex 
(Ca/CaM), MLCK binds Ca/CaM and is activated, which ultimately results in smooth 
muscle contraction. When [Ca
2+
]i is lowered, the MLCK is less active, thereby 
favouring smooth muscle relaxation. Additionally, Ca/CaM regulates activities of 
other enzymes such as Ca
2+
-dependent kinases, which influences the vasomotor tone 
by stimulation of the downstream signalling pathways or eNOS in endothelium, 
which catalyse production of NO and mediates endothelium-dependent relaxation.  
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Second messengers such as cAMP and cGMP change the MLC kinase/MLC 
phosphatase balance by activation of their relative kinases: PKA/PKG, which elicit 
multiple phosphorylations of cellular proteins that result in lowering of [Ca
2+
]i (see I. 
General Introduction, pages 43-45).  Furthermore, the vascular tone can be regulated 
through Ca
2+
-sensitization, due to the inhibition of MLC phosphatase by rhoA kinase 
and PKC. Thanks to the phenomenon of Ca
2+
-sensitization, the contraction of SMC is 
well maintained despite the substantial fall in [Ca
2+
]i, when Ca
2+
 is pumped back into 
sarcoplasmic reticulum (SR). Some protein kinases such as PKG can activate MLC 
phosphatase directly via inhibition of the inactivating RhoA pathway, ultimately 
resulting in dephosphorylation of the vasoconstricting MLC and relaxation of smooth 
muscle
1, 72
. 
 
3.2 Modulation of intracellular calcium (ion channels) 
 
The process of smooth muscle contraction and relaxation is modulated by the 
intracellular level of calcium [Ca
2+
]i, and the sensitivity of contractile proteins to 
[Ca
2+
]i in response to various stimuli. When calcium signalling is stimulated in a cell, 
Ca
2+
 enters the cytoplasm from one of two general sources: (i) it is released from 
intracellular stores, mainly from sarcoplasmic reticulum (SR) or (ii) it enters a cell 
from the extracellular space.  
In the vascular smooth muscle cell membrane, Ca
2+
 influx is regulated by L-
type voltage-operated Ca
2+
 channels (VOCC), receptor-operated Ca
2+
 channels 
(ROCC), and store-operated Ca
2+
 channels (SOCC)
73-75
. 
VOCC act as main Ca
2+
 channels in the vascular smooth muscle cell 
membrane and like other voltage-gated channels respond to changes in the membrane 
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potential. The resting membrane potential in artery ranges from -50 mV to -60 mV 
and is regulated by various members of K
+
 channels. This negative membrane 
potential allows VOCC to be slightly open and provides sufficient Ca
2+ 
influx that 
sustains the basal tone of the vessel. The opening of VOCC increases significantly 
with a depolarization (more positive potentials caused by inhibition and closure of K
+ 
channels), leading to Ca
2+
 influx and contraction. Conversely, a hyperpolarization 
(more negative potentials caused by activation and opening of K
+ 
channels) closes 
VOCC, decreases the [Ca
2+
]i, and causes relaxation.  
ROCC mediate signals without the necessity of a change in membrane 
potential. They are non-selective cation channels typically activated by inositol lipid 
signalling, which is initiated by the activation of G protein-coupled phospholipase C 
(PLC). PLC catalyzes the cleavage of phosphatidylinositol 4,5-biphosphate (PIP2) to 
form two second messengers IP3 and DAG. IP3 diffuses away from the membrane and 
binds to specific IP3 receptors (IP3R) on SR to allow Ca
2+
 release from the 
intracellular stores. Apart from IP3R, ryanodine receptors (RyR) also mediate Ca
2+
 
release from SR
1
. DAG remains in the plasma membrane where it activates PKC, 
which contributes to Ca
2+
-sensitization.  
SOCC mediates store-operated Ca
2+
 entry and thus plays a critical role to refill 
Ca
2+
 in SR and to maintain Ca
2+
 homeostasis. The molecular identity of SOCC and 
the mechanism linking SR depletion to the SOC channels are not clear. However it is 
believed that SOCC are composed of transient receptor potential (TRP) proteins and 
their activation can be independent of IP3 production
75-77
.  
Ca
2+
 efflux to the extracellular space is regulated by other families of proteins: 
the plasma membrane Ca
2+
 ATPase (PMCA) and the Na
+
/Ca
2+
 exchanger (NCX)
78, 79
. 
The NCX is a large-capacity, low-affinity carrier, which is mostly found in excitable 
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cells, where it ejects the bulk amounts of Ca
2+
. The PMCA is a lower capacity system 
and has a high affinity for Ca
2+
 even at the very low [Ca
2+
]i, thereby maintaining Ca
2+
 
at its normally very low levels in resting cells. Uptake into the SR is mediated by the 
sarco- and endoplasmic reticulum Ca
2+
 ATPase family (SERCA)
80
. 
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Figure 1.9. Principal ion channels (green), ion pumps (blue) and exchangers (orange) in the cellular membrane and sarcoplasmic 
reticulum (SR) of vascular cells. K
+
 channels generate while Cl
-
 and Ca
2+
 channels modulate the negative membrane potentials. VOCC and 
ROCC mediate contraction by transmitting extracellular Ca
2+
 into the cell and IP3R and RyR channels contribute to high levels of [Ca
2+
]i by 
emptying SR stores of Ca
2+
. Na
+
-H
+
 exchanger fight intracellular acidosis during sustained contraction. The Ca
2+
 ATPase (PMCA) and the 
Na
+
/Ca
2+
 exchanger mediate relaxation by transmitting [Ca
2+
]i outside the cell. SERCA pumps refill SR stores with Ca
2+
. Na
+
-K
+
-ATPase 
pumps and HCO3-Cl
-
 exchangers maintain the respective high intracellular K
+
 and Cl
-
 concentrations. Adapted
1
. 
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As discussed above, ion channels provide the major source of [Ca
2+
]i that 
activates contractile proteins in SMC. On the contrary, the rise in [Ca
2+
]i in EC 
stimulates the synthesis and release of vasoactive substances: NO, PGI2 and 
endothelium-derived hyperpolarization factor (EDHF) which all induce endothelium-
dependent vasorelaxation via various mechanisms (see I. General Introduction, pages 
43-48). As in SMC, EC express K
+
 channels, which contribute to the determination 
and regulation of endothelial membrane potential whereas they generally (in conduit 
arteries) lack voltage-gated Ca
2+
 channels
81
. Therefore, a major mode of Ca
2+
 entry to 
these cells is mediated by various types of ROCC and SOCC while Ca
2+
 efflux is 
based on the activity of PMCA and to lesser extent on NCX. Intracellular stores of 
Ca
2+
 in endothelial SR are emptied by IP3R and RyR and refilled by SERCA
81
.  
 
3.3 Signalling via G-protein-coupled receptors 
 
G proteins are signal transducers, attached to the cell surface plasma 
membrane, that connect receptors to effectors and thus to intracellular signalling 
pathways. GPCRs are seven-transmembrane receptors which communicate signals 
from a large number of (i) biogenic amines: noradrenaline, dopamine, 5-
hydroxytryptamine (5-HT), histamine, acetylcholine; (ii) amino acid and ions: 
glutamate, calcium, gamma-aminobutyric acid (GABA); (iii) lipids: lysophosphatidic 
acid (LPA), sphingosine-1-phosphate (S1P), prostaglandins, leukotrienes; (iv) 
peptides and proteins: chemokines, angiotensin, thrombin, endothelin, bradykinin and 
(v) others: light, odorants, nucleotides
82, 83
.  
 In the G protein’s unactivated state, the G protein is bound to GDP and exists 
as a heterotrimer consisting of α, β, and γ subunits. Upon receptor activation, the G 
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protein exchanges GDP for GTP, causing the dissociation of the GTP-bound α and βγ 
subunits and triggering diverse signalling cascades. On the basis of sequence and 
signalling similarity, the Gα subunits have been divided into four families (Gαs, Gαi/o, 
Gαq/11, Gα12/13) and this classification has served to define both receptor and effector 
coupling
82
 (Table 6). 
Main signal transduction pathways involving GPCRs include the cAMP signal 
pathway and the IP3 signal pathway. Typically Gαs stimulates adenylyl cyclase and 
increases levels of cAMP, whereas Gαi/o inhibits adenylyl cyclase and lowers cAMP 
levels. Members of the Gαq/11 family bind to and activate PLC, which cleaves PIP2 
into DAG and IP3. Besides the regulation of these classical second-messenger 
generating systems, Gβγ subunits and Gα subunits such as Gα12/13 and Gαq/11 can also 
control activities of other intracellular signal-transducing molecules, including small 
GTP-binding proteins of the Ras and Rho families and members of the mitogen-
activated protein kinases (MAPK) including extracellular signal-regulated kinase 
(ERK), c-jun N-terminal kinase (JNK), p38 and ERK5
82, 84
. These proteins regulate 
various cellular activities, such as cell growth, differentiation and survival. 
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G protein Receptors (examples) Main signalling pathway 
Gαs Β-adrenergic                       
Dopamine D1, D5              
Adenosine A2                      
Serotonin 5-HT4, 6, 7          
Glucagon receptors 
AC↑→cAMP↑ 
 
Gαi/o α2-adrenergic                   
Muscarinic M2, M4              
Adenosine A1, A3               
Serotonin 5-HT1, 5            
Purinergic P2Y12, P2Y13, P2Y14 
AC↓→cAMP↓ 
Gαq/11 α1-adrenergic                    
Muscarinic M1, M3, M5     
Serotonin 5-HT2                
Purinergic P2Y1, P2Y2, P2Y4, P2Y6   
PAR4                                             
TP 
PLC↑→IP3↑, DAG↑ 
Gα12/13 PAR1                                             
TP 
Rho↑→MAPK↑ 
 
Table 6. A recent classification of G-protein-coupled receptors (GPCR) based on the 
homology of Gα subunits. Adapted85.  
  
The final cellular response after the activation of particular GPCR depends on 
the specificity of agonist and the distribution of receptors. Some ligands with a broad 
specificity are able to activate more than one G protein. For example, epinephrine, a 
nonselective agonist of all adrenergic receptors, signals through (i) the β-adrenergic 
receptor coupled to Gαs, causing an increased heart rate, (ii) the α1-adrenergic 
receptor to Gαq/11, leading to vasoconstriction and (iii) the α2-adrenergic receptor to 
Gαi/o, opening K
+
 channels
86
. Despite the broad specificity of some agonists, their 
overall effect also depends on the tissue distribution of their receptors. For example, 
the activation of endothelial cell Gαi/o–coupled M3 muscarinic receptors by 
acetylcholine results in a release of endothelium-derived relaxing factors, which relax 
vascular smooth muscle pre-contracted with norepinephrine. Removal of the 
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endothelium eliminates the relaxant effect and reveals contraction caused by direct 
action of acetylcholine on vascular smooth muscle mediated primarily by M3-
muscarinic receptors coupled to Gαq/11-proteins
87
.  
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Figure 1.10. GPCR-mediated vasoconstriction of SMCs. The central part leading to constricting MLC lies in the raise of [Ca
2+
]i, which by binding to Cam 
(Ca-Cam), activates MLCK. Depending on which GPCR is activated by agonist, [Ca
2+
]i can by increased by multiple mechanisms. In red- stimulation of Gαi/o 
subunit leads to the inhibition of AC/cAMP/PKA pathway, which evokes a rise in [Ca
2+
]i. In green- activation of Gαq/11 triggers PLC/PIP2/IP3 cascade and 
release of stored Ca
2+ 
in SR. Additionally, closing K
+
 channels causes the membrane depolarization and opening of VOCC, which transmit the extracellular 
Ca
2+
 into cells. In purple- the sustained constriction is maintained by phosphorylation=inhibition of MLCP by PKC and/or RhoK (Ca
2+
 sensitisation). 
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3.4 Prostaglandins and vascular tone 
 
Prostaglandins (PGs) are a major product of the arachidonic acid (AA) cascade 
generated by cyclooxygenase (COX) enzymes. AA is a plasma fatty acid derived 
from the cleavage of dietary linoleic and linolenic acids by phospholipase 2 (PLA2). 
In endothelial cells, PLA2 activation is a Ca
2+
- dependent step. COX enzymes utilize 
AA to catalyze the formation of short-lived intermediates prostaglandin G2 and 
prostaglandin H2, which are then transformed to different prostaglandins: (i) PGD2, 
PGE2 and PGF2α via PG isomerases, (ii) PGI2 via PGI2 synthase (PGIS) or (iii) TXA2 
via TXA2 synthase (TXS)
88
. COX enzymes are present in two isoforms: COX-1 and 
COX-2 and they prefentially co-localise with particular isomerases/synthases to 
determine the final PG produced (Figure 1.11). Therefore, COX-1 usually couples 
with TXS, PGF isomerases and the cytosolic PGE2 isomerase while COX-2 typically 
links to PGIS and the microsomal PGE isomerase
88
. Conventionally, COX-1 is 
regarded as a constitutive enzyme with house-keeping functions, whereas COX-2 is 
considered the inducible form with a particular role in inflammation. Indeed, it has 
been shown that COX-1 is constitutively expressed in endothelial and smooth muscle 
cells in vitro, while the expression of COX-2 is increased by growth factors, cytokines 
and LPS
89
. However, it is now apparent that COX-2 is the dominant source of PGI2 
produced even under physiological conditions and that both COX isoforms are 
upregulated in foam cells and in SMC in atherosclerotic plaque
89
.              
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Figure 1.11. COX pathway. COX enzymes metabolize arachidonic acid (AA) to PGI2, 
PGD2, PGE2, PGF2α and TXA2 via tissue specific isomerases. Adapted
89
. 
 
While PGI2 is a main vasodilator (see I. General Introduction, page 45), TXA2 
is a major vasoconstrictor of the COX pathway, acting via the TP receptor and the 
classical Gαq/11-dependent signalling (see I. General Introduction, pages 36-41). TXA2 
is mostly known as a main metabolite of COX-1 activity in platelets, stimulating 
activation of new platelets and increasing platelet aggregation (see I. General 
Introduction, pages 51-54). However, it has been shown that either COX isoform may 
generate TXA2 and TXS mRNA can also be found in tissues other than platelets
88
. 
Other prominent eicosanoids such as PGE2, PGD2 and PGF2α may also 
contribute to a lesser extent to the regulation of vascular tone
88
. PGE2, like PGI2 is a 
dominant product of COX-2 under physiological conditions in vivo. PGE2 may act via 
four receptor subtypes: Gq-coupled EP1 and EP3, causing increase of [Ca
2+
]i in SMC 
and vasoconstriction and/or Gs-coupled EP2 and EP4, leading to decrease of [Ca
2+
]i in 
SMC and vasodilatation (see I. General Introduction, pages 36-41). The contrasting 
biological effects of these receptors come from their varied tissue distribution, as well 
as different concentrations of PGE2. PGD2 is produced largely by activated mast cells 
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and causes vasodilatation while PGF2α is a vasoconstrictor and its enhanced formation 
has been associated with oxidative stress and cardiovascular diseases (see I. General 
Introduction, page 19). 
 
3.5 Endothelium-dependent vasorelaxation 
 
Vascular smooth muscle relaxation (vasorelaxation, vasodilation) is caused by 
either removal/inhibition of the contractile stimulus or by direct action of an agonist 
that enhances the relaxation mechanism. Depending on the origin of this agonist, the 
relaxation of SMC is dependent or independent on the endothelium. Regardless of the 
stimulus, decreased [Ca
2+
]i in SMC and increased MLC phosphatase activity is a pre-
requisite for vasorelaxation (see I. General Introduction, page 31-32).  
Endothelium-dependent vasorelaxation is mediated primarily by three 
different mediators: NO, PGI2 and EDHF released by endothelium which then 
diffuses to smooth muscle. 
 
3.5.1 NO and vascular tone 
 
The main receptor for NO is an enzyme sGC, which catalyses the conversion 
of guanosine triphosphate (GTP) to the second messanger cGMP. NO-induced 
activation of sGC depends on the presence of a reduced Fe
2+
 haem moiety and results 
in a 200-fold increase of the activity of sGC
90
. Accumulation of cGMP leads 
primarily to the activation of the cGMP-dependent protein kinase I (PKGI), and also 
cGMP-gated channels, cyclic nucleotide phosphodiesterases (PDEs) and cGMP-
dependent protein kinase II (PKGII)
90
. Many targets of PKGI activity have been 
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identified including: (i) activation of K
+
 channels, (ii) inhibition of L-type Ca
2+
 
channels, (iii) activation of the Ca
2+
 Mg
2+
 ATPase and (iv) the Na
+
/Ca
2+
 exchanger, 
(v) activation of SERCA, (vi) inhibition of the sarcoplasmic reticulum IP3 receptor or 
the PLC-dependent formation of IP3 and (vii) activation of the MLC phosphatase
90
. 
Generally speaking, the activation of NO/sGC/cGMP/PKG pathway in vascular cells 
initiates a cascade of phosphorylation reactions, which result in lowering the 
intracellular levels of Ca
2+
 and ultimately, in the relaxation of the smooth muscle 
cells. The level of cellular cGMP is determined largely by the balance between its 
synthesis by sGC and breakdown by PDEs, although the cGMP-gated channels may 
also play a role by exporting cGMP from some cells
90
.  
It should be acknowledged that NO may contribute independently of sGC and 
PKG to lower cytosolic Ca
2+
 levels via (i) direct S-nitrosation and thus activation of 
K
+
 channels; (ii) reaction with superoxide (O2
·-
) with the formation of peroxynitrite 
(ONOO
-
), which can bind to glutathione (GSH) and activate SERCA and (iii) direct 
inhibition of CYP450 which can produce 20-HETE, an inhibitor of large conductance 
Ca
2+
-dependent K
+
 channel (BKCa)
91
. Interestingly, cGMP-independent events 
contribute proportionately more to the overall vasorelaxation induced when 
comparing the effect of NO donors to that of endogenous NO
92
. Moreover, there is a 
differential involvement of cGMP-dependent and -independent vasodilation between 
various NO donors. For NO donors belonging to RSNO group, cGMP-independent 
effects might be explained by the particular metabolism of RSNO involving 
transnitrosation and S-nitrosylation of proteins
93
 (see I. General Introduction, pages 
28-30). For other NO donors, which generate NO spontaneously a possible 
explanation for the discrepancies between endogenous and exogenous NO, is that the 
site of NO generation has an influence on the proportion of vasorelaxation mediated 
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by cGMP-independent mechanisms. In other words, NO generated within the tissue 
has more ready access to sGC whereas NO delivered from outside the cell may more 
easily access non-sGC sites of action.   
 
 
Figure 1.12. Cellular responses to NO and NO donors including cGMP-dependent and 
cGMP-independent mechanisms. Adapted
92
. 
 
3.5.2 PGI2 and vascular tone 
 
Vasorelaxation induced by PGI2, the main vascular product of COX-2 activity, 
is determined by specific vascular smooth muscle cell receptors known as the 
isoprostenoid (IP) receptors. The IP receptor is a seven transmembrane receptor which 
couples primarily to Gs to activate AC and increase cAMP levels
88
. Accumulation of 
cAMP leads mainly to the activation of the cAMP-dependent protein kinases I and II 
(PKAI and PKAII) together with the GTP-exchange protein EPAC, the cAMP-gated 
ion channels and PDEs
90
. PKA phosphorylates many target proteins, including (i) K
+
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channels, (ii) L-type Ca
2+
 channels, (iii) SERCA2, (iv) RyR, (v) MLCK and (vi) 
eNOS which lead eventually to the lowering of cytosolic Ca
2+
 levels and relaxation of 
SMC
94-96
.  
 
3.5.3 Crosstalk between NO and PGI2 pathways and vascular tone 
 
Some of the phosphorylation substrates of PKA are shared with PKG, making 
a link between the PGI2/AC/cAMP/PKA and NO/sGC/cGMP/PKG systems. In fact, 
there are many well documented examples of cross-activation between these two 
signalling pathways, not only on the level of i) activated protein kinases, but also ii) 
between cAMP and cGMP catalytic sites of PDEs, or even iii) the expression and 
activity of COX and NOS enzymes themselves
90, 97, 98
.  
It has been shown that cGMP and cAMP compete for catalytic sites of certain 
PDEs, which are able to hydrolyze both cyclic nucleotides. For example, cAMP-
dependent PDE 3 (PDE3), which normally accelerates the degradation of cAMP, can 
be inhibited by the modest elevation of cGMP
90
. In this way, cGMP can enhance the 
cAMP signalling. However, the much higher levels of cGMP can bind to the allosteric 
site and thus, act as an activator of another cAMP-dependent PDE i.e. PDE2 reducing 
the cAMP signalling
90
. On the other hand, the elevation of cAMP is unlikely to affect 
more cGMP-specific PDEs like PDE5, PDE6 or PDE9
90
. 
In recent years it has been suggested that NO and PGs may regulate their own 
biosynthesis and NOS/COX activity. NO proved to increase COX activity by different 
means, for example by (i) reaction with the superoxide, which otherwise inactivates 
COX, (ii) S-nitrosylation and activation of COX and iii) the regulation of NF-κB, 
which is a potent inducer of COX-2
12, 97, 99-102
. In addition, the potential role of an 
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iron-heme center of COX enzyme was also indicated
97, 102
. It is known that COX 
contains an iron-heme center at the active site and that NO interacts with iron 
containing enzymes leading to either a stimulation (in the case of sGC) or inhibition 
(e.g. aconitase) of the enzymatic activity.  
In terms of vasodilation, the majority of studies reveal the compensatory role 
of NO towards the inhibited COX activity
103, 104
. For example, it was shown that in 
vivo, inhibition of COX using non steroidal anti-inflammatory drugs (NSAIDs) is 
without effect on basal blood pressure in healthy mice suggesting that NO 
compensates for the loss of vasodilatory PGs. However, when L-NAME was present 
together with NSAIDs, a significant enhancement of blood pressure and 
phenylephrine-induced constriction were found
103
 (Figure 1.13). Similarly, aortic 
rings from COX2
-/-
 mice constricted significantly more than WT mice when NO 
generation was blocked
103
.  
Accordingly, there are studies using eNOS
-/-
 mice, showing that COX-2-
derived PGs compensate for loss of NO in regulation of coronary hemodynamics and 
flow-induced dilatation in vivo. Furthermore, although L-NAME was shown to 
increase blood pressure in WT mice, when L-NAME was co-administered with 
NSAIDs, the resulting blood pressure elevation was much higher and more 
prolonged
103
.  
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Figure 1.13. Crosstalk between NO and prostacyclin. Healthy large vessels maintain tone 
predominantly using NO. If NO is depleted, COX-2–derived prostanoids (e.g. PGI) 
compensate. Then, inhibition of COX-2 leads to constriction because PGI synthesis is 
blocked and may predispose to cardiovascular side effects. Repletion with NO prevents the 
increase in tone mediated by COX-2 blockade. Adapted
103
. 
 
3.5.4 EDHF and vascular tone 
 
The precise nature of the EDHF has not been defined, but is broadly 
considered as a substance or a change in membrane potential generated by EC and 
transmitted to SMC via myoendothelial gap junctions
105
. Spreading to the smooth 
muscle cell, EDHF leads to the hyperpolarization of the membrane, and as a 
consequence, to the relaxation of SMC without the increase of intracellular 
concentration of cyclic nucleotides – cGMP or cAMP, which is characteristic of the 
classical vasodilators
106
. Hence, in vitro EDHF-dependent relaxation of vessels is 
defined as the residual relaxation in the presence of inhibitors for NO and PGI2. 
However, this raises the question of whether EDHF exists when NO is present or 
whether it is purely a compensatory mechanism. The most popular candidates for 
EDHF include epoxyeicosatrienoic acids (EETs), potassium ions (K
+
), and hydrogen 
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peroxide (H2O2). Although there is still a lot of controversy around the nature of 
EDHF, there is a common agreement that it is associated with the activation of two 
populations of endothelial Ca
2+
- dependent potassium channels: the small-
conductance KCa (SKCa) and the intermediate-conductance KCa (IKCa) potassium 
channels
107
. Endothelium-dependent hyperpolarization is more significant in the 
regulation of the vascular tone of small, resistance vessels (<300 μm), thereby playing 
a particularly important role in the microcirculation
108
. 
EDHF has been shown to accrue greater significance in terms of overall 
vasodilation as the size of the blood vessels decreases. In this sense it is inversely 
related to NO production by NOS. Thus in smaller vessels, EDHF is thought to be the 
main vasodilator, a factor that might be particularly important in diabetes with the 
associated pathologies of neuropathy and retinopathy. 
 
3.6 Endothelium-independent vasorelaxation (NO donors) 
 
Endothelium-independent vasorelaxation is mostly triggered by stimulation of 
Gαs-dependent activation of the AC/cAMP/PKA pathway by an agonist (i.e. 
adenosine, histamine, adrenaline) or by delivery of exogenous NO with NO donors. 
Different NO donors have often different profiles of action depending on the 
mechanism of NO generation and delivery
65
 (Table 7). 
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Class Examples Mechanism of NO generation 
Organic nitrate GTN 
ISDN 
Tissue activation 
Metal nitrosyl sodium nitroprusside Tissue activation 
Syndonimine SIN-1 Spontaneous generation of NO 
NONOate amines DEA/NO 
DETA/NO 
MAHMA/NO 
Sper/NO 
Spontaneous generation of NO 
S-nitrosothiols CysNO 
GSNO 
SNAC 
SNAP 
CapSNO 
NO generation is catalysed by Cu
+
 
ions but S-nitrosothiols can also act 
via other mechanisms (see I. General 
Introduction, pages 28-30) 
 
Table 7. Classification of different NO donors. Abbreviations: CapSNO (S-
nitrosocaptopril), CysNO (S-nitrosocysteine ), DEA/NO (2-(N,N-diethylamino)diazen-1-ium-
1,2-diolate), DETA/NO (Z-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-
1,2-diolate), GSNO (S-nitroso-glutathione), GTN (glyceryl trinitrate), ISDN (isorbide 
dinitrate), MAHMA/NO (Z-1-N-methyl-N-[6-(N-methylammoniohexyl) amino]diazen-1-ium-
1,2-diolate), SIN-1 (3-morpholino-sydnonimine), SNAC (S-nitroso-N-acetylcysteine), SNAP 
(S-nitroso-N-acetyl-DL-penicillamine), Sper/NO (Z-1-{N-[3-aminopropyl]-N-{4-{3-
aminopropylammonio)butyl]-amino} diazen-1-ium-1,2-diolate). Adapted
92
. 
 
The use of some NO donors has shown certain limitations or undesired side 
effects. For example, organic nitrates were successfully used in prevention and 
treatment of angina pectoris until it was discovered that patients develop tolerance to 
long-acting nitrates due to progressive decrease in availability of reduced thiol groups 
and/or increased vascular superoxide production. Another tissue-activated-NO donor 
sodium nitroprusside used in the treatment of hypertensive emergencies was 
associated with an accumulation of cyanide in the body. In turn, the liberation of NO 
from syndonimine was accompanied by concomitant release of superoxide. 
Furthermore, despite the fact that NONOate amines are very efficient in generation of 
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NO, they are also very short-lived NO donors and for that reason not always suitable 
in clinical practice. Probably the most promising class of NO donors with some 
additional therapeutic potential are S-nitrosothiols (RSNO)
109
. RSNOs mediate many 
of their biological activities of NO not only by donating a NO group but also by 
nitrosation and S-nitrosylation of proteins (ion channels, receptors, enzymes), thus 
bypassing the generation of free NO (see I. General Introduction, pages 28-30). Some 
RSNOs have been successfully used in clinical practice
110
, including i) SNAC for 
prevention of contrast-induced nephropathy, treatment of paracetamol poisoning, and 
thinning of respiratory secretions; ii) CapSNO for the treatment of hypertension and 
heart failure and iii) SNAP for the treatment of rheumatoid arthritis. RSNO are less 
subject to neutralization of the NO moiety, and can therefore be considered capable of 
remote NO delivery. This was first demonstrated with arterial infusion of GSNO to 
result in downstream vasodilation.  
 
4. Anti-platelet therapy 
 
4.1 Pathophysiology of atherothrombosis 
 
 Platelets are anuclear blood cells that circulate in a human’s cardiovascular 
system mostly in quiescent form thanks to i) the anti-coagulant and anti-thrombotic 
surface of endothelium, ii) secretion of NO by endothelium and platelets and PGI2 by 
endothelium, iii) degradation, storage or separation of platelet agonists in endothelial 
Weibel-Pallade bodies and in platelet storage granules and iv) inhibition of the 
fibrynolytic system (see I. General Introduction, pages 5-7). During acute coronary 
syndromes (ACS) and percutaneous coronary interventions (PCI) vascular 
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endothelium is activated or damaged due to atherosclerotic plaque rupture or surgical 
procedures exposing the subendothelial matrix. This leads to release of pro-
thrombotic factors and localized platelet activation and adhesion. Initial contact of 
platelets with vascular endothelium is mediated by primary agonists: vWf and 
collagen, which interact with their respective GPCR and stimulate the extracellular 
release of secondary agonists: ADP, TXA2 and thrombin into the blood
111
. These 
secondary mediators cause platelets to change shape, stick to each other and secrete 
the contents of their storage granules. Platelet activation triggers a conformational 
change in glycoprotein IIb/IIIa (GBIIb/IIIa) receptors (integrin αIIbβ3), which 
increases their affinity for fibrinogen and vWF, causing platelet aggregation and 
thrombus formation
112
 (Figure 1.14). Importantly, the activation of GBIIb/IIIa 
promotes coagulation and fibrynolytic pathways leading to thrombus stabilization and 
subsequent platelet fibrin clot formation (see I. General Introduction, pages 5-7).  
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Figure 1.14. Stages in thrombus and plug formation. At a site of vascular injury, thrombus 
formation is initiated by the exposure of collagen and vWf in the vessel wall situated in 
extracellular matrix (ECM). Rolling platelets are activated and adhere to the collagen matrix 
by interaction between GPIb-IX-V receptor with vWf and GPVI with collagen. The secretion 
of ADP, TXA2 and thrombin from platelet storage granules serves to amplify ongoing platelet 
activation. These events switch on intracellular signalling leading to inside-out activation of 
resting β-integrins recruiting circulating platelets in developing platelet aggregates. 
Fibrinogen and vWf bound to activated integrins contribute to thrombus stabilisation and 
fibrin clot formation. Adapted
111
 
 
The thrombus may resolve locally and is an essential part of vascular 
homeostasis or alternatively it may embolize (migrate) to a distal part of the body and 
can often be the cause of severe ischemic events such as myocardial infarction (MI), 
ischemic stroke (IS), transient ischemic attack (TIA), pulmonary embolism, acute 
ischemia of limb and vascular death. That is why atherothrombosis is a common 
consequence and the ultimate cause of death in numerous cardiovascular diseases 
(CVD), including peripheral artery disease (PAD), coronary artery disease (CAD), 
atrial fibrylation, atheroslerosis, hypercoagulability, periprocedular vascular injury 
etc. In order to improve outcomes of CVD patients numerous anti-platelet and anti-
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thrombotic therapies directed at modulating the key components of platelet activation 
and aggregation and thrombus generation (including blood coagulation) have been 
developed
113
. 
 
4.2 Targets for anti-platelet therapies 
 
Current anti-platelet therapies target primarily COX-1 and platelet surface 
receptors such as TXA2, P2Y12, GBIIb/IIIa receptors and proteinase-activated 
receptor 1 (PAR1)
4
 (Figure 1.15).  
 
 
Figure 1.15. Main targets of anti-platelet therapies. Platelet aggregation can be inhibited 
by drugs blocking 1) COX-1 activity and TXA2 formation (e.g. aspirin), 2) the action of 
soluble agonists (e.g. TXA2, P2Y12, PAR1 antagonists) or the binding of fibrinogen and other 
ligands to GPIIb/IIIa receptors. Adapted
4
 
 
 
TXA2 is generated from its precursor arachidonic acid (AA) through the 
activation of COX-1 pathway (see I. General Introduction, page 41). The release of 
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TXA2 from platelets causes amplification of their activation via TXA2/prostaglandin 
H2 (PGH2) receptor (TP) coupled to Gq and G12/13 (see I. General Introduction, pages 
36-41)
111
. TXA2 actions can be inhibited at the level of COX-1 or through direct 
inhibition of TP receptors. TP receptors are also expressed in other cell types such as 
smooth muscle cells, macrophages, and monocytes
114
. 
ADP controls platelet activation via two platelet receptors P2Y1 (Gq coupled) 
and P2Y12 (Gi coupled; see I. General Introduction, pages 36-41)
111
. P2Y1 receptors 
mediate changes in platelet shape, calcium mobilization and initiation of reversible 
aggregation whereas P2Y12 receptors amplify aggregation by inhibition of AC and 
decrease in cAMP. Although sustained aggregation requires activation of both 
receptors, the P2Y12 receptor is considered a better target because of its less uniform 
distribution in other tissues and a dominant role in platelet aggregation
115
. P2Y12 
receptors are primarily present in platelets and only minor expression has been found 
in endothelial cells, brain, glial cells and smooth muscle cells
116
. In turn, P2Y1 
receptors are ubiquitously expressed in many tissues including heart, blood vessels, 
smooth muscle cells, neural tissue, testis, prostate, ovary, and platelets
114
. 
Thrombin acts predominantly via protease-activated receptors 1 and 4 (PAR1 
and PAR4), which couple to Gq, G12/13 and in some cases also to Gi (see I. General 
Introduction, pages 36-41)
111
. Early traces of thrombin generated during the initiation 
phase of coagulation by tissue factor (TF) cleave a portion of PARs, which activates 
them and triggers multiple signal transduction pathways that modulate thrombosis, 
coagulation and inflammation. PARs are widely distributed in the vascular system and 
occur on platelets, endothelial cells, leukocytes and vascular smooth muscle cells
115
. 
PAR1 is more potent when activated than PAR4, and thus PAR1 is the preferred 
target for developing therapies
115
. 
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Experimental anti-platelet therapies target other platelet receptors including 
integrins αIIbβ3 and α2β1, P-selectin, prostaglandin E2 (EP3), 5-hydroxytryptamine 
2A (5HT2A) receptors as well as intracellular proteins such as PDEs and 
phosphoinositide 3-kinase (PI3K) and endothelial products i.e. NO
113
.  
 
4.3 Dual anti-platelet therapy 
 
Because platelet activation is determined by numerous signalling pathways, a 
multidrug treatment has been proposed to provide higher efficacy than individual 
therapies in the prevention of atherothrombotic complications
117
. Aspirin is the first 
anti-platelet agent to be evaluated and remains the main component of a dual anti-
platelet therapy. Aspirin is known to irreversibly acetylate Ser529 of COX-1 
inhibiting the platelet TXA2 production for the lifespan of platelets, although other 
COX-1 independent actions have also been recognized
113
. In high risk patients, 
aspirin reduces the risk of vascular death by ~15 % and non-fatal vascular events by 
~30 % as shown by meta-analysis of over 100 randomized trials
113
. However, 10-20 
% of aspirin–treated patients have recurrent vascular events in 5 years after their 
incident event
115
. Furthermore, aspirin therapy is associated with upper-GI toxicity 
and hemorrhage and ~5 % people are intolerant to the drug
118
. Altogether, it 
stimulated for the development of better anti-platelet drugs.   
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4.3.1 P2Y12 antagonists 
 
P2Y12 antagonists are very attractive agents for inhibition of platelet activation 
and aggregation because they block the ADP-related amplification of platelet 
activation including not only aggregation but also further procoagulant response and 
secretion from alpha- and dense- granules
119
. Unlike GPIIb/IIIa antagonists, they do 
not provide a complete blockage of platelet aggregation leading to intolerable 
bleeding. Initial P2Y12 antagonists that have been discovered belong to the group of 
thienopyridines and were named sequentially ticlopidine, clopidogrel and prasugrel. 
Thienopyridines require a hepatic metabolism to generate active metabolites, which 
bind irreversibly to the active site of the P2Y12 receptor for the lifetime of platelet
120
. 
Due to certain limitations of these drugs, a new generation of P2Y12 inhibitors has 
been developed including ticagrelor, cangrelor and elinogrel, which interact reversibly 
with the allosteric site of the P2Y12 receptor
121
. Since cangrelor and elinogrel require 
intravenous administration, their use is restricted to hospitalized patients and they are 
not discussed here. This thesis focuses on the main lines of anti-platelet therapy 
administered to the out-patient population. 
 
4.3.1.1 Ticlopidine 
 
Ticlopidine alone or in combination with aspirin was shown to be beneficial 
and superior to oral anticoagulants in preventing stent thrombosis (Innovative 
Stratification of Arrhythmic Risk-ISAR, Stent Anticoagulation Restenosis Study-
STARS)
115
, more effective than aspirin or placebo in the secondary prevention of 
stroke (Ticlopidine Aspirin Stroke Study-TASS, Canadian American Ticlopidine 
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Study-CATS)
115
 and more effective than placebo in patients with mixed 
atherothrombosis (Swedish Ticlopidine Multicentre Study-STIMS)
115
. However, 
ticlopidine also has been associated with unfavorable side effects such as neutropenia, 
bone marrow aplasia and thrombotic thrombocytopenic purpura and therefore largely 
replaced by clopidogrel, which offered better safety profiles (Clopidogrel Aspirin 
Stent International Cooperative Study-CLASSICS, Ticlid or Plavix Post-Stents-
TOPPS)
115, 122, 123
. 
 
4.3.1.2 Clopidogrel 
 
In the Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events 
(CARPIE) study clopidogrel monotherapy was modestly more effective than aspirin 
in reduction of the composite end point of MI, IS or vascular death with most of the 
benefit observed in patients with PAD
117, 124
. Since that trial, a number of studies have 
evaluated the efficacy and safety of dual anti-platelet therapy with clopidogrel and 
aspirin in several settings including in patients with ACS (Clopidogrel as Adjunctive 
Reperfusion Therapy-Thrombosis in Myocardial Infarction-CLARITY-TIMI
125
, 
Clopidogrel and Metoprolol in Myocardial Infarction Trial-COMMIT
126
, Clopidogrel 
in Unstable Angina to Prevent Recurrent Events-CURE
127
), undergoing PCI 
(Clopidogrel for the Reduction of Events During Observation-CREDO
128
, PCI-
CLARITY
129
, PCI-CURE
130
) and those with stroke (Management of 
Atherothrombosis with Clopidogrel in High-Risk Patients-MATCH
131
) and mixed 
atherothrombotic disorders (Clopidogrel for High Atherothrombotic Risk and 
Ischemic Stabilization-CHARISMA
132
). In general a clear benefit of clopidogrel in 
combination with aspirin was observed in a wide range of patients with ACS and 
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across the spectrum of patients undergoing coronary stenting as a secondary 
prevention strategy. However, current data do not support dual anti-platelet therapy 
with clopidogrel in the primary prevention or treatment of cerebrovascular disease
117
. 
Major clinical trials of clopidogrel are summerised in Table 8. 
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Trial Clopidogrel 
therapy (n) 
Comperator   
therapy (n) 
 
End points Findings 
ACS  
CLARITY-
TIMI
a,125
 
300 mg LD, 75 mg 
MD (1752) for 30 
days 
Placebo (1739) Composite of occluded infarct 
artery on angiography, or death or 
recurrent MI before angiography 
36 % reduction in primary outcome with clopidogrel 
and 20 % reduction in CV death, MI or ischemia that 
required urgent revascularization, no increase in 
TIMI major or total bleeding. 
COMMIT
a,126
 75 mg MD for 4 
weeks (22961) 
Placebo (22891) First: composite of death, 
reinfarction or IS; second: death 
from any cause during scheduled 
treatment period 
Improved outcomes with clopidogrel (first: RRR=     
9 %; second: RRR=7%), no increase in bleeding. 
CURE
a,127
 300 mg LD, 75 mg 
MD for 3-13 
months (6259) 
Placebo (6303) First: composite of vascular death, 
nonfatal MI or IS; second: 
composite of first primary outcome 
or refractory ischemia 
Clopidogrel more effective than placebo in reducing 
both outcome measures (first: RR=0.8; second: 
RR=0.86) but increased bleeding. 
DISPERSE-2
a,133
 300 mg LD, 75 mg 
MD for 12 weeks 
(327) 
90 (334) or 180 (323) 
mg/bid ticagrelor 
MD 
The Kaplan-Meier rate of major or 
minor bleeding through 4 weeks 
No difference in major bleeding but an increase in 
minor bleeding at the higher dose of ticagrelor. 
PLATO
a,134
 300-600 mg LD, 75 
mg MD for 12 
months (9333) 
180 mg ticagrelor 
LD, 90 mg/bid MD 
ticagrelor (9291) 
First: composite of vascular death, 
MI or IS; second: composite of first 
primary outcome and/or death from 
any cause, ischemia, TIA, or other 
arterial thrombotic event. 
Improved outcomes with ticagrelor (first: HR=0.84; 
second: HR=0.84-0.88) but higher rate of non-
CABG-related major bleeding according to study and 
TIMI criteria and higher incidence of dyspnea and 
ventricular pauses in the first week. 
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PCI and/or stent 
CREDO
a,128
 300 mg LD pre-
PCI, 75 mg MD to 
day 28; 75 mg MD 
day 29–12 months 
(1053) 
Placebo 3–24 h pre-
PCI , 75 mg MD 
clopidogrel to day 
28; placebo day 29–
12 months (1063) 
First: 1-year composite of death, 
MI, IS; second: 28-day composite 
of death, MI, urgent 
revascularization 
Improved primary outcome with clopidogrel 
(RRR=26.9 %). Clopidogrel pretreatment did not 
improve the secondary point. No significant increase 
in major bleeding. 
PCI-
CLARITY
a,129
 
300 mg LD, 75 mg 
MD (933) 
Placebo (930) Composite of vascular death, 
recurrent MI, IS (measured from 
PCI to 30 days after randomization) 
Improved outcomes with clopidogrel (OR 0.54); no 
significant increase in TIMI major or minor bleeds. 
PCI-CURE
a,130
 300 mg LD, 75 mg 
MD (1313) 
Placebo (1345) Composite of vascular death, MI or 
urgent revascularization, within 30 
days of PCI 
Clopidogrel more effective than placebo (31 % 
reduction in cardiovascular death or MI); no 
difference in major bleeding. 
TRITON-
TIMI
a,98
 
300 mg LD, 75 mg 
MD (6795) for 15 
months 
60 mg prasugrel LD, 
10 mg MD prasugrel 
(6813) 
Composite of vascular death, MI, 
IS 
Prasugrel more effective than clopidogrel (HR=0.81) 
but associated with increased major and fatal 
bleedings. 
CLASSICS
a,123
 300 mg LD, 75 
MD (345), or 75 
mg MD (335) 
250 mg/bid 
ticlopidine (340) 
Major bleeds, neutropenia, 
thrombocytopenia, drug 
discontinuation for noncardiac 
event 
Clopidogrel had superior safety and tolerability to 
ticlopidine. 
TOPPS
a,122
 300 mg LD, 75 mg 
MD (494) 
500 mg LD 
ticlopidine, 250 mg 
bid ticlopidine (522) 
Failure to complete 2 weeks of 
treatment 
Clopidogrel was better tolerated than Ticlopidine. 
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Other CVD (mixed atherothrombotis, stroke) 
CHARISMA and 
posthoc 
analysis
a,132
 
75 mg MD for 28 
moths (7802; 
posthoc: 4735) 
 
Placebo (7801; 
posthoc: 4743) 
First: composite of first occurrence 
of MI, IS or vascular death; second: 
composite of first primary outcome 
or hospitalization for unstable 
angina, TIA, or revascularization 
procedure 
Clopidogrel caused no significant reduction in 
primary outcome in patients with clinically evident 
CVD (CAD, PAD, CBVD) or multiple risk factors 
and significant reduction of the rates of the secondary 
end point (RR=0.92). Significant increase in 
moderate but not severe bleeding according to Gusto 
definition. Posthoc analysis revealed 17 % reduction 
in primary outcome with clopidogrel in patients with 
documented prior MI, IS or symptomatic PAD; non-
significant increase in moderate or severe bleeding. 
MATCH
131
 75 mg MD (3797) 75 mg clopidogrel 
and 75 mg aspirin 
(3802) 
Composite of MI, IS, vascular 
death or rehospitalization for acute 
ischemic events 
No significant reduction in primary outcome; more 
common major and life-threatening bleedings with 
dual therapy in patients with recent IS or TIA. 
CARPIE
124
 75 mg MD for 
median of 1.9 year 
(9599) 
325 mg aspirin 
(9586) 
Composite of first occurrence of 
MI, IS or vascular death 
Improved outcomes with clopidogrel (RRR=8.7 %) 
in patients with symptomatic atherosclerotic disease; 
in PAD patients (RRR=23.8%); no difference in rate 
of bleeding disorder but greater rate of GI bleeding 
with aspirin. 
 
Table 8. Key trials of clopidogrel therapy in comparison to placebo/aspirin/other P2Y12 antagonists (>500 patients). 
a
Both treatment arms received 
aspirin. Abbreviations (except for trial acronyms): ACS (acute coronary syndrome), bid (twice daily), CABG (coronary artery bypass graft), CAD (coronary 
artery disease), CBVD (cerebrovascular disease), CVD (cardiovascular disease), HR (hazard ratio), IS (ischemic stroke), LD (loading dose), MD (maintenance 
dose), MI (myocardial infarction), n (number of patients), OR (odds ratio), PAD (peripheral vascular disease), PCI (percutaneous coronary intervention), RR 
(relative risk), RRR (relative risk reduction), TIA (transient ischemic attack), TIMI (thrombosis in myocardial infarction). 
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Despite the beneficial actions of clopidogrel, its clinical utility is compromised 
by a delayed onset and offset of platelet inhibition and variable responses including 
nonresponsiveness to the drug occurring in up to 30% of patients. Introduction of 600 
mg loading dose shortened the delay in onset of action in comparison to 300 mg 
loading dose from 4-6 h to 2-4 h after administration
135
. A delayed offset of 
clopidogrel action is caused by the irreversible nature of its anti-platelet effects and 
increases a bleeding risk in patients who require an urgent surgery within 5 days of 
stopping treatment
127
. However, inhibition of platelets’s aggregation for their lifespan 
has advantages for patients who miss one or more doses of the drug.  
A heterogenous patients’ response to clopidogrel treatment is primarily 
explained in terms of the inter-individual variability in active metabolite generation. 
Because clopidogrel is metabolized in a 2-step process dependent on the CYP450 
liver enzymes
136
, genetic polymorphisms affecting these enzymes (e.g. in 
CYP2C19
137, 138
) and coadministration of drugs metabolized by them (e.g. lipophilic 
statins
139
 and proton pump inhibitors (PPIs)
140
) have shown to limit the formation of 
the clopidogrel active metabolite. However, there is no consistent clinical evidence 
confirming an adverse interaction between PPIs and clopidogrel affecting patient 
outcomes
141, 142
. Furthermore other mechanisms have been proposed to contribute 
such as the individual variability in absorption of clopidogrel and baseline platelet 
reactivity, inadequate dosing and cigarette smoking
115
. Nonresponsiveness to 
clopidogrel has been partially overcome by replacing 300 mg with 600 mg loading 
dose but is still common in ~20 % population
143
. These limitations of clopidogrel 
therapy led to development of new P2Y12 antagonists. 
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4.3.1.3 Prasugrel 
 
The third generation-thienopyridine, prasugrel, requires a single step 
activation and is not influenced by functional variability of CYP450 enzymes
144
. 
Thanks to more efficient metabolism than clopidogrel, prasugrel treatment was 
associated with more consistent, faster and potent inhibition of platelet aggregation
144
. 
In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel (TRITON-TIMI) prasugrel was more efficient than 
clopidogrel in treatment of patients with ACS undergoing PCI but was associated with 
a higher occurrence of life-threatening and fatal bleeding
98
. Results of this trial 
supported a concept that a superior P2Y12 antagonist improves the efficacy of dual 
anti-platelet therapy in ACS patients treated with PCI at expense of increased 
bleeding and therefore its use should be limited to treatment of high-risk groups. This 
led to investigation of alternative non-competitive and reversible inhibitors of P2Y12 
receptors such as ticagrelor, which would maintain receptors fully functional upon 
dissociation of drug and hopefully prevent excess bleeding.  
 
4.3.1.4 Ticagrelor 
 
Ticagrelor does not belong to thienopyridine family. It does not require 
metabolic activation for its anti-platelet activity but it does have an active metabolite, 
which is equally potent in inhibition of P2Y12 receptors as the parental drug. 
Ticagrelor works through affecting the allosteric site of the P2Y12 receptor, thus 
preventing ADP-induced signalling in platelets, rather than the actual binding of ADP 
to the receptor as influenced by the thienopyridines. This interaction is reversible and 
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has a half-life of 7-12 h, which imposes twice-daily dosing in order to maintain the 
inhibitory effect
145
.  
Ticagrelor provided a greater and faster inhibition of platelet aggregation both 
at post loading and at steady state than clopidogrel in ACS patients (Dose 
Confirmation Study Assessing Anti-Platelet Effects of AZD6140 versus Clopidogrel 
in NSTEMI 2-DISPERSE-2
133
, ONSET/OFFSET
79
). Furthermore the 
pharmacokinetics of ticagrelor were unaffected by prior clopidogrel dosing (Response 
to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching 
Therapies-RESPOND
146
). In the PLATelet inhibition and patient Outcomes (PLATO) 
trial, high risk patients with ACS had a 16 % lower rate of the composite end point 
(vascular death, MI and IS) than those receiving clopidogrel
134
.  Interestingly, a 
reduction in the rate of death from any cause was observed with ticagrelor despite 
only a moderate decrease in the risk of MI. This led to a speculation that beneficial 
effects of ticagrelor might be partially attributed to its off-target effects including an 
inhibition of adenosine uptake by erythrocytes in vitro. Increased adenosine plasma 
concentration caused by ticagrelor among other effects could potentially prevent 
sudden cardiac death, reduce infarct size or inhibit tumor growth
147
. The higher 
incidence of dyspnea and more frequent early ventricular pauses with ticagrelor 
reported in the PLATO study seem to support the adenosine-like effects of the drug. 
Importantly, there was no difference in the rate of overall major bleeding comparing 
ticagrelor with clopidogrel therapy, although the rate of non-procedure-related 
bleeding was increased with ticagrelor.   
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 Clopidogrel Ticagrelor 
Administration 600 mg LD, 75 mg 
MD daily 
180 mg LD, 90 mg 
MD twice daily 
Mechanism of action Prodrug, irreversible Active drug, reversible 
Max. inhibition of    
platelet aggregation 
40-60 85-95 
Onset of action 2-4 h (600 mg) 2-4 h 
Offset of action 5-7 days 3-5 days 
Half-life ~11 days 7-12 h 
Time to steady state 3-7 days 2-3 days 
Pharmacologic  
interactions 
Proton-pump 
inhibitors, calcium 
channel blockers 
CYP3A4/5 inhibitors: 
rifampicin, 
ketoconazol, diltiazem 
 
Table 9. Main pharmacologic characteristics of clopidogrel and ticagrelor. Adapted
145
. 
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II. THESIS AIMS: 
 
The overall objective of this body of work is to investigate off-target effects of 
thienopyridine and non-thienopyridine anti-platelet agents on vascular homeostasis. 
Specifically, these studies shall aim to: 
 
1. Study direct influences of parental forms of clopidogrel (pro-clopidogrel) on 
the responsiveness of rabbit aortae to nitric oxide (NO). In addition, the 
potential anti-oxidant and anti-inlammatory effects of pro-clopidogrel on 
vessels will be examined using electron paramagnetic resonance (EPR) and 
real time quantitative PCR (RT qPCR). 
 
2. Investigate the ability of thienopyridines and ticagrelor to make biologically 
active nitrosothiols in vitro. The properties of newly synthesized SNO 
derivatives will be tested in terms of inhibition of platelet aggregation, 
relaxation of rabbit aortae and transnitrosation reactions. 
 
3. Determine the influence of a loading dose and maintenance therapy with 
clopidogrel on plasma markers of NO production, metabolism and 
bioavailability in coronary artery disease (CAD) patients. The relationship 
between vascular, oxidative and platelet-derived effects of clopidogrel will be 
also examined. 
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III. GENERAL METHODS 
 
1. Animal sacrifice 
 
Male New Zealand White rabbits (2-2.5 kg) were terminally anesthetized by 
intravenous injection of sodium phenobarbitone (120 mg/kg; Merial Ltd.). The 
descending aorta was then excised and immersed in chilled Krebs buffer (containing 
109.2 mM NaCl, 2.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4
.
7 H2O, 25.0 mM 
NaHCO3, 11.0 mM D (+) Glucose, 1.5 mM CaCl2
.
2H2O, pH 7.4). The aorta was 
cleaned of adventitial tissue and cut into 2-mm-wide ring segments.  
P2Y12
-/- 
male mice and their genetically matched wild-type strain P2Y12
+/+ 
(20-
25 g) on a C57BL/6 background were kindly provided by Sheila Francis (The 
University of Sheffield). Genotyping of P2Y12 mice was performed elsewhere using 
polymerase chain reaction (PCR)
148
. Mice were sacrified by cervical dislocation and 
their descending aortas were excised and treated as above.  
All procedures were carried out according to UK Schedule 1 legislation under 
guidelines issued by Cardiff University. 
 
2. Isometric tension studies 
 
Rabbit aortic rings were mounted in a 8-channel tissue organ bath system 
(custom built) and isometric tension was recorded on a PowerLab 8/SP data 
acquisition system (ADInstruments). Mouse aortic rings were mounted in a 4-channel 
multi myograph system (DMT-610M) with in-built Powerlab data acquisition system 
(ADInstruments). Vessel segments (rabbit and mouse) were equilibrated for 30 min in 
                  
 
III. GENERAL METHODS  
-69- 
 
Krebs buffer at 37 °C and continuously bubbled with 5 % CO2 and 95 % O2. They 
were then gradually stretched to a resting tension of 2 g (rabbits) or 4 mN (mouse), 
which was maintained throughout the experiment. Arterial integrity was assessed first 
by constriction of vessels with phenylephrine (PE; 1 μM), followed by stimulation 
with acetylcholine (Ach; 10 μM). This was repeated two more times in order to 
achieve the maximal responses of each of the studied vessels.  
 
2.1 Measurement of vascular responses to PE, Ach and NO donors 
 
In the rabbit vessel preparation, cumulative dose response curves were initially 
performed for PE (1 nM-10 µM). PE (1 µM) produced 70-85 % of maximal response 
and this dose was then used to pre-constrict vessels for subsequent vasodilation 
experiments as it provided a greater range over which relaxation/contriction responses 
could be measured. Cumulative dose response curves to Ach (1 nM-10 µM), S-
nitrosoglutathione (GSNO, 1 nM-10 μM; Enzo Life Sciences), MAHMA NONOate 
(NOC9, 100 pM-1 μM; Enzo Life Sciences) or isosorbide dinitrate (ISDN, 0.42 nM-
4.24 µM; Heath Hospital) were performed on aortic rings following pre-constriction 
with PE. NOC9 was used in comparison to GSNO as it releases NO very quickly 
(t1/2=2.5 min) in neutral pH and does not depend on prior tissue metabolism. ISDN 
was used as the most commonly used NO donor in the clinical setting.  
In the mouse vessel preparation, cumulative dose responses to PE (1 nM-1 
µM) had to be performed before each experiment in order to achieve a stable 
constriction. Cumulative dose response curves to Ach and GSNO were performed, as 
for rabbit vessels.  
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Concentration-response curves to agonists were fitted using a standard 
sigmoid dose-response curve (Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)))) 
with a Hill Slope of 1.0 and no constraints. Doses producing 50 % response 
[log10(EC50)] were determined. Additionally, EC50Ratio (EC50R) was computed in 
chosen samples to report the change of EC50 in relation to corresponding controls 
(Figure 2.1). 
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Figure 2.1. Evaluation of aortic rings response to cumulative doses of agonists. When 
different relaxants were tested, vessels were firstly pre-constricted with PE and the 
[log10(EC50)] of agonists was calculated as a percentage relative to PE-induced constriction. 
When a constriction response to PE was tested, the highest effective PE concentration 
reflected 100 % response.  
 
2.2 Measurement of relaxant responses to thienopyridine-SNO (Th-SNO) 
 
In the rabbit vessel preparation, aortic rings were pre-constricted with 1 µM 
PE and a single dose of thienopyridine, thienopyridine-SNO (Th-SNO) mixture or 
nitrite was added. Drug preparation is described in detail in IV. Results (page 145). 
Briefly, 10 mM thienopyridine tablet solutions were mixed with varied concentrations 
of nitrite (1-10 mM) in order to make SNO derivatives. Parallel biochemical analysis 
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by Cu
+
/Cys (2Cs) ozone based chemiluminescence (OBC) revealed that only ~1 % of 
Th-SNO mixture contains Th-SNO. Therefore, in order to account for un-reacted 
reagents, the corresponding thienopyridine and nitrite solutions used for the reaction 
were also checked separately for vasodilatory capacity.  
The maximal relaxation (Rmax) of Th-SNO mixture was calculated as a 
percentage relative to PE-induced constriction. Nitrite-induced vasodilation was 
determined over the same time and subtracted from Rmax of Th-SNO mixture in 
order to control for un-reacted nitrite and report Th-SNO-induced vasorelaxation 
accurately (Figure 2.2). Native thienopyridine solutions did not induce significant 
relaxation of pre-constricted rings. 
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Figure 2.2 Evaluation of relaxation of pre-constricted aortic rings to single doses of Th-
SNO. Rmax of Th-SNO mixtures in time (T) were corrected by unreacted nitrite by 
subtraction of nitrite-induced relaxation over the same time (T). 
 
3. Electron paramagnetic resonance (EPR) 
 
Electron paramagnetic resonance (EPR) spectroscopy is the only technique 
capable of direct detection and identification of free radicals. The method is not 
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sensitive enough to detect short-lived species such as superoxide anion radical (O2
•-
) 
directly in biological samples, but spin trapping is used to stabilize radicals by 
creating longer-lived radical adduct species. The spin traps 5,5-dimethyl-1-pyrroline-
Noxide (DMPO), and 5-(diethoxyphosphoryl)-5-methyl-1- pyrroline-N-oxide 
(DEPMPO) are widely used for detection of O2
•-
, although DEPMPO has been 
preferred due to higher sensitivity, specificity and stability
129, 149, 150
. 
 
 
Figure 2.3. Structure of DEPMPO and its superoxide adduct DEPMPO-OOH. 
Adapted
151
 
 
Vascular superoxide formation was determined by spin trapping of O2
•-
 
released from rabbit aortic rings incubated in Krebs buffer with 100 mM DEPMPO 
(Axxora Uk Ltd.). Typically, 2 aortic rings were kept for 5 min in 100 µl buffer in one 
well of a 96-well plate. Samples containing DEPMPO- O2
•-
 adducts were loaded into 
a 0.8-1.1 mm i.d. glass capillary (Fisher Scientific UK), sealed with Crytoseal and 
placed into a quartz tube holder and into the cavity of a Bruker e-scan EPR 
spectrophotometer operating at 9.5 GHz. Typically 21 s scans were taken for up to 10 
min (typical recording conditions were: scan range 150 G, modulation amplitude 1.01 
G, microwave power 15.21 mW). Standards of superoxide were made for reference 
by mixing 0.3 mM hypoxanthine and 0.08 U/mg of xanthine oxidase (Figure 2.4). 
Potassium superoxide (KO2) was also used as a positive control (Figure 2.5). 
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Figure 2.4. Two step enzymatic process of hypoxanthine generation of O2
•-
 catalysed by 
xanthine oxidase. Adapted
152
 
 
EPR spectra were smoothed using polynomial fitting (2nd order) with adjacent 
averaging. The area under curve (AUC) of all component peaks of the EPR spectrum 
was analysed individually using GraphPad Prism and log10(AUC) was used to report 
the relative amounts of superoxide.  
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Figure 2.5. Representative trace of DEPMPO-O2
•-
 spin adducts of potassium superoxide. 
EPR spectra was smoothed using polynomial fitting (2nd order) with adjacent averaging. The 
presence of the characteristic 1:2:2:1 splitting of the DEPMPO-O2
•-
 adducts is visible.  
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4. Real time quantitative PCR (RT qPCR) 
 
4.1 Primer design 
 
Primers were designed using Primer3 and BLAST tools so as to be specific to 
the PCR templates and to be separated by at least one intron on the corresponding 
genomic DNA. The amplicon size was planned to be between 50 and 250 bp. The list 
of sense and antisense primers for rabbit mRNA are presented in Table 10. 
 
 
mRNA Sequence (5’ – 3’) Conc. (nM) 
COX-2 Sense CGATGACTGCCCAACGCCCA 
Antisense GGCGCAGTTTATGCTGTCTGTCCA 
230 
230 
GAPDH Sense CGCGTCCCCGAGACACGATG 
Antisense TGGTGACCAGGCGCCCAATG 
460 
460 
HPRT-1 Sense CGCAGCCCCAGCGTTGTGAT 
Antisense CCCTTGAGCACACAGAGGGC 
920 
920 
IL-1 β Sense TGCAGGCTCCAGGATGCACA 
Antisense TGAGGCCCAAGGCCACAGGT 
690 
690 
IL-6 Sense AAGACGGATGCTTCCCGCCG 
Antisense GCAACGGCTGGCTTGAGGGT 
690 
690 
iNOS Sense CAGAGCAGTACAAGCTCAC 
Antisense GGATCTCAGCCTCATGGTG 
690 
690 
TNF-α Sense GCCACCACGCTCTTCTGCCT 
Antisense GAGCTGGCCCTCCACTTGCG 
690 
690 
VCAM-1 Sense TGAGGAGCGAGGGGACCACG 
Antisense TCCAACCTCCAAAGGGCCACTCA 
460 
460 
 
Table 10. List of sense and antisense rabbit primers used in RT-qPCR. 
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4.2 Primer optimization 
 
In order to find the optimal concentrations of primers, 15 combinations of 
varying concentrations (230-920 nM) of the sense and antisense primers were 
checked. Primer combinations with the lowest threshold cycle values (Ct) and the 
highest fluorescence signal (ΔRn) were chosen (Figure 2.6) to give the most sensitive 
and reproducible assays. 
VCAM-1
18.0 18.2 18.4 18.6 18.8 19.0
2.5
3.0
3.5
4.0
4.5
5.0
ct

 R
n
 
Figure 2.6. Primer optimization. In red – chosen combination of primers. 
 
4.3 Extraction of RNA 
 
Extraction of RNA from rabbit aortic rings was performed using Trizol 
reagent, following modified Chomczynski method, which performs well with 50-100 
mg of tissue (one rabbit ring weighs approximately 70-80 mg).  
 
4.3.1 Vessel homogenization 
 
Each rabbit aortic ring was transferred from -80 °C into 500 µl Trizol, which 
is a mixture of phenol and guanidine isothiocyanate, and were homogenized using an 
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Ultra Turrax T25 homogenizer until completely disrupted. After 5 min incubation at 
room temperature, which permits the complete dissociation of nucleoprotein 
complexes, lysates were centrifuged at 12000 x g for 10 min at 4 °C to remove 
insoluble material.  
 
4.3.2 Removal of DNA and proteins 
 
100 µl chloroform was added to the supernatants, containing rabbit RNA, 
which then was shaken vigorously by hand for 15 s, incubated for 3 min at room 
temperature and centrifuged 12000 x g for 15 min at 4 °C. This allowed separation of  
the mixture into: i) a lower red phase, containing protein and lipid; ii) a white 
interphase, containing DNA and iii) a colourless upper phase, containing RNA.  
 
4.3.3 RNA precipitation 
 
After removal of DNA and proteins, RNA was carefully transferred to fresh 
tubes, and equal amounts of 70-75 % ethanol were added and vortexed to precipitate 
RNA. The RNA precipitate was usually not visible by naked eye.  
 
4.3.4 RNA wash and re-dissolving 
 
In order to improve the quality of extracted rabbit RNA, further steps were 
performed on columns provided by PureLink RNA mini kit (Invitrogen) as per the  
manufacturer’s protocol. RNA precipitate was retained on columns and washed 
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several times with buffers, helping to remove solvents used for RNA extraction. 
Finally, RNA was eluted from columns using 30 µl RNase-free water.  
 
4.3.5 Quantity and quality assessment of RNA 
 
The concentration and quality of isolated RNA were measured using the 
NanoDrop Spectrophotometer 1000. RNA has its absorption maximum at 260 nm and 
the absorbance ratios at 260/280 nm and 260/230 nm were used to assess its purity. 
Both ratios should be approximately 2.0-2.1. The RNA extraction method described 
here gave 70-180 ng/µl rabbit RNA. 260/280 ratio was 1.8-2.1, confirming samples 
were free of DNA impurities. The 260/230 ratio was more variable (0.3-2.1), and 
where the reading was below 1.0, this was taken to reflect there was a considerable 
contamination with protein or solvents, and the RNA preparation was further purified. 
Around 10 % samples required this purification step.  
 
4.3.6 Purification of RNA 
 
In order to purify RNA from protein and/or solvent impurities and improve 
260/230 ratio, 3 µl of 3 M sodium acetate and 60 µl of 100 % ethanol were added to 
30 µl RNA, vortexed and kept on ice for 15 min at -80 °C. After thawing, the mixture 
was centrifuged 12000 x g for 10 min at 4 °C, supernatant removed and 150 µl of 70 
% ethanol cooled to -20 °C was added. Then the mixture was vortexed, centrifuged 
12000 x g for 2 min at 4 °C and the RNA pellet was dried in the air. Finally, RNA 
precipitate was re-dissolved in RNase-free water and measured once again on the 
NanoDrop. 
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4.4 cDNA conversion and RT qPCR conditions 
 
500 ng of total RNA was reverse transcribed with random primers into cDNA 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) under 
the following conditions: 10 min at 25 °C, 120 min at 37 °C, 5 s at 85 °C and then 
stored at 4 °C for further analysis.  
The cDNA was diluted 20-fold prior to PCR amplifications, which were 
performed in a total volume of 10 μl using Fast SYBR® Green Master mix (Applied 
Biosystems). Negative controls were included, in order to check the possible 
contamination of cDNAs or assay reagents by genomic DNA. For this purpose, 
instead of cDNA, either mRNA or water was added to the reagent mix. 
All PCR amplifications were performed in triplicate under the following 
conditions: 2 min at 95 °C, followed by a total of 35 cycles (10 s at 95 °C, 10 s at 60 
°C and 26 s at 72 °C) and the melting curve analysis. Fluorescence was measured 
through the slow heating phase and Ct-values (intersections of the threshold with 
amplification plots) obtained by the LightCycler analysis software were collected for 
the analysis (see below).  
 
4.5 Method of calculation 
 
The relative expression of a target gene in relation to a reference (house-
keeping) gene was calculated for each sample and normalized against a calibrator on 
the basis of ΔΔCt method
153
. This method accounts for sample to sample variations 
caused by differences in the initial quality and quantity of the nucleic acid and 
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provides a constant calibrator point between PCR runs. The calibrator was prepared 
from untreated, fresh tissues. 
Results were expressed as the target/reference ratio of each sample normalized 
by the target/reference ratio of the calibrator (equation below). PCR efficiency (E) 
differences were corrected to 1.95 in order to achieve exact results. Ct values were 
determined automatically by the sequence detection system (SDS) software (Figure 
2.7). 
 
t
t
ΔC (calibrator-sample)
target
ΔC (calibrator-sample)
ref
(E )
Ratio(R)=
(E )
             
 
 
Figure 2.7. Calculation of Ct values by SDS software. The threshold is set above the 
baseline and within the exponential growth phase of the amplification curve. The intersection 
of the threshold with the amplification plot defines the Ct in real-time PCR assays. 
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Figure 2.8. Typical amplification plots of target (e.g. VCAM-1) and reference (GAPDH) 
genes in the sample and the calibrator. 
 
 
4.5.1 Choice of house-keeping gene 
 
Relative RNA levels from test samples were calculated normalized against one 
or two reference housekeeping genes GAPDH and HPRT-1 (Figure 2.9). Because 
results coming from either analysis were very similar, all experimental samples were 
subsequently normalized only against GAPDH.  
1 
2 
3 
4 
1-calibrator (VCAM-1) 
2-sample (VCAM-1) 
3-calibrator (GAPDH) 
4-sample (GAPDH) 
 
                  
 
III. GENERAL METHODS  
-81- 
 
TNF-
1 2 3 4 5 6
0
1
2
3
4
HPRT-1
GAPDH and HPRT-1
GAPDH
samples
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
Figure 2.9. Comparison of results calculated against one or two house-keeping genes. 
 
4.5.2 Melting curve analysis 
 
The specificity of the amplified product (amplicon) was verified after each 
experiment by the analysis of the melting curve. When a particular RT qPCR reaction 
was heated slowly, only one peak at the characteristic melting temperature should be 
revealed (Figure 2.10). Melting temperature is dependent on the guanine/cytosine 
(GC)-content and the size of amplicon. Primer-dimers and other nonspecific products 
or impurities would cause additional peaks. 
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Figure 2.10. Typical melting curve plots of GAPDH measured after one experiment. 
 
5. Nitric oxide analysis (NOA) using ozone-based chemiluminescence (OBC) 
 
NO metabolites: nitrite, nitrate and RSNO were measured using ozone-based 
chemiluminescence (NO analyzer, NOA280i, Sievers) as has been described 
previously
34, 154
. Typically, NO was cleaved from the species of interest by the use of 
specific cleavage reagents, it was then carried by inert N2 gas through the NaOH trap 
to the NOA, where it reacted with ozone (equation below). Energy released from this 
reaction in a form of a photon (hv) was amplified in a photo-multiplier tube (PMT) 
and was recorded as a potential difference (mV, Figure 2.11).  
 
* *
3 2 2 2 2
NO O NO O NO O hv                                                                         
Data was acquired as a series of peaks by the NOAnalysis Software (Liquid) 
and each peak was analyzed in terms of area under curve (AUC) using the Liquid 
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analysis or Origin software. The amount of NO metabolites was determined from 
relevant standard curves performed on a daily basis. 
 
 
Figure 2.11. NO analysis (NOA) using ozone-based chemiluminescence (OBC). A 
vacuum pump draws ozone and sample into the chemiluminescence reaction chamber. In the 
reaction chamber, NO previously released from the sample and neutralized reacts with ozone. 
The emitted energy is detected and amplified by PMT, which is measured and displayed on 
the computer as a potential difference between PMT’s plates (mV). Adapted154. 
 
5.1 Measurement of NO metabolites in plasma 
 
Platelet poor plasma (ppp) for NO metabolite analysis was isolated from 
K3EDTA vacutainer bottles by centrifugation immediately after blood collection 
(1500 g, 10 min, 4 °C), then snap frozen in liquid nitrogen and stored at -80 °C. 
Frozen samples were used for the analysis within six months after collection. It has 
been shown previously that levels of plasma nitrite and protein-bound NO remain 
unchanged up to 6 months
34
. After that time plasma RSNO and nitrite are gradually 
oxidized to nitrate. 
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Immediately prior to NO analysis, plasma samples were thawed for 3 min in a 
water bath at 37 °C. 
 
5.1.1 Plasma nitrite and S-nitrosothiols 
 
NO was cleaved from plasma nitrite (equation 1 below) and S-nitrosothiols 
(RSNO; equations 2 below) by tri-iodide reagent containing 28.5 mM I2, 66.9 mM KI 
and 0.78 M glacial acetic acid. The NOA setup for plasma nitrite and RSNO 
measurement in conjunction with the tri-iodide reagent is shown in Figure 2.12. The 
intra- and inter-assay coefficients of variation (CV) were 7 % and 17 %, respectively 
(See Shawmendra Bundhoo MD 2011). 
 
2 2 2
2 2 2 2 2HNO I H NO I H O
                                                                     (1) 
2 3
3
2 2
2 3 2
2 2 2 2 2
I I I
I RSNO I RS SR NO
NO I H NO I H O
 
  
  
 
    
    
                                                                        (2) 
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Figure 2.12. NOA setup for plasma nitrite and/or RSNO measurement. 200 µl sample (+ 
few drops of Antifoam
TM
) is injected through the rubber septum (1) into a specially 
constructed purge vessel with 5 ml tri-iodide reagent (2). The temperature of the reagent is 
maintained at 50 °C by a beaker of water (3) kept on a hot plate (4) linked to IKATRON® 
ETS-D4 fuzzy (5). Released NO is carried in an inert N2 gas stream controlled by a flowmeter 
(6; flow: 200 cm
2
/min) to a round-bottom flask with 1 M NaOH (7). NaOH protects NOA 
from damage by hot acid vapour and ensures that N-oxide contaminants are not converted to 
NO (no false positives). Neutralized NO vapour is directed to NO analyser (8). 
 
A standard curve was constructed using water and different concentrations of 
sodium nitrite 62.5 nM, 125 nM, 250 nM, 500 nM and 1000 nM (Figure 2.13). 
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Figure 2.13. Analysis of standard curve for plasma nitrite and RSNO measurement. 
Typical signals of water and 62.5 nM, 125 nM, 250 nM, 500 nM and 1000 nM sodium nitrite 
are shown (left). The corresponding AUC of detected peaks (corrected by AUC of water) 
were used to calculate the slope coefficient of the standard curve (right). 
 
In order to distinguish between nitrite and RSNO, the same sample was run 
before and after a pre-treatment with 5 % acidified sulphanilamide (290 mM),
which binds nitrite ions and allows the selective measurement of the residual 
plasma RSNO (Figure 2.14).  
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Figure 2.14. Typical plasma nitrite and RSNO signals before (left) and after (right) the 
adjacent smoothing. Plasma nitrite peaks were well defined and the corresponding AUC was 
determined using in-built Liquid analysis. Plasma RSNO peaks were smaller and less clear 
and therefore the Origin 7 software was used for the appropriate smoothing and calculation of 
AUC.
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5.1.2 Plasma nitrate 
 
NO was cleaved from plasma nitrate by vanadium chloride (equation below) 
reagent containing 49.9 mM VCl3 and 0.8 M HCl. The reagent was filtered through a 
0.22 µm filter before use, revealing a turquoise blue colour. The NOA setup for 
plasma nitrate measurement in conjunction with VCl3 reagent is shown in Figure 2.15. 
The intra- and inter-assay coefficients of variation (CV) were 4 % and 14 %, 
respectively (See Shawmendra Bundhoo MD 2011). 
 
3 3 5 2
2 4 2 2VCl HCl NO VCl H O NO
                                                                
 
 
Figure 2.15. NOA setup for plasma nitrate measurement. 20 µl sample is injected through 
the rubber septum (1) into a 2-neck round bottom flask with 30 ml vanadium chloride reagent 
(2). The temperature of the reagent is maintained at 85 °C by a beaker of water (3) kept on a 
hot plate (4) linked to IKATRON® ETS-D4 fuzzy (5). Released NO is carried in an inert N2 
gas stream controlled by a flowmeter (6; flow: 200 cm
2
/min) and directed through a 
condenser (7) to a round-bottom flask with 1 M NaOH (8). The water flow in the condenser 
was unconventional (*). The condenser and NaOH protects NOA from damage by very hot 
acid vapour. Neutralized NO vapour is directed to NOA analyser (9). 
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A standard curve was constructed using water and different concentrations of 
sodium nitrate 6.25 µM, 12.5 µM, 25 µM, 50 µM and 100 µM (Figure 2.16). In 
addition to nitrate ions, VCl3 reagent also reduces both NO2
- 
and RSNO to NO, thus 
providing a “total” plasma measure of nitrate+nitrite+RSNO. Therefore, the amount 
of nitrite and RSNO obtained by tri-iodide analysis was subtracted from that observed 
with VCl3 reagent in order to reflect an accurate nitrate value. 
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Figure 2.16. Analysis of standard curve for plasma nitrate measurement. Typical signals 
of 6.25 µM, 12.5 µM, 25 µM, 50 µM and 100 µM sodium nitrate are shown (left). The 
corresponding AUC of detected peaks (corrected by AUC of water) were used to calculate the 
slope coefficient of the standard curve (right). 
 
5.2 Measurement of RSNO in Th-SNO preparations 
 
The RSNO was cleaved from thienopyridine-SNO (Th-SNO) preparations 
(equations below) by 2 C’s reagent containing 0.1 mM CuCl and 0.97 mM cysteine. 
Despite the reagent, the NOA setup was the same as that used for tri-iodide (Figure 
2.12). The intra- and inter-assay coefficients of variation (CV) were 7 % and 18 %, 
respectively (See Shawmendra Bundhoo MD 2011). 
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A standard curve was constructed using water and different concentrations of 
nitroso-N-acetylcysteine (NACSNO) 250 nM, 500 nM, 1000 nM, 2000 nM and 4000 
nM. NACSNO was prepared fresh by mixing 1 M acidified N-acetylcysteine (NAC) 
and 1.1 M sodium nitrite in the dark. Before NOA analysis, the precise concentration 
of NACSNO was measured by UV spectrophotometer (Figure 2.17).  
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Figure 2.17. Spectrophotometric detection of NAC-SNO. The maximal absorbance of 
NACSNO at 334 nm was used to calculate the amount of NACSNO. For example, the 
absorbance 2.073 is equivalent to 0.57 M of NAC-SNO after dilution correction 
(2.073/727*200=0.57). 
 
It has been shown that the neutrality of 2 C’s reagent ensures that other 
metabolites such as nitrites and nitrates remain undetected in biological samples, 
providing specificity. However, considering the high concentrations of reagents used 
to make Th-SNO, the above method was validated for our purposes (see IV. Results, 
page 149-151).  
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6. ELISA 
 
All ELISAs were performed using commercially available kits. The 
absorbance was measured on the FLUOstar OPTIMA (BMG Labtech) or Multiscan 
EX (LABsystems) depending on the filter required. 
 
6.1 Rabbit aortic rings 
 
6.1.1 Vessel homogenization 
 
Previously frozen vessel segments were weighed and/or cut into smaller pieces 
and homogenized with 1.4 mm stainless blend beads (Next Advance, SSB14B) using 
BBX24- Bullet Blender®. Typically, 4 rabbit aortic rings were mixed with 150 μl 
homogenization buffer and 100 mg beads and homogenised for 10 min at speed 10. 
Homogenization buffer contained 100 μM IBMX. In a few cases the homogenisation 
was not efficient, samples were additionally homogenised using a glass homogeniser. 
Tissue homogenates were centrifuged  at 12000 x g for 15 min at 4 °C  to remove the 
cellular debris and tissue supernatants were stored at -20 °C. 
The different samples were standardized to total protein content measured by 
Bradford protein assay (cGMP) or by the weights of the aortic rings (cAMP).  
 
6.1.2 Bradford protein assay 
 
The total protein prior to cGMP measurement in rabbit aortic rings was 
quantified by the Pierce Coomassie® Protein Assay Reagent (23200) using a 
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modified Bradford Coomassie® Dye-protein binding colorimetric method. When 
Coomassie® Dye binds protein in an acidic medium, an immediate shift in absorption 
maximum occurs from 465 nm to 595 nm with a concomitant colour change from 
brown to blue.  
Tissue supernatants and BSA standards (25-2000 μg/ml) were loaded on a 96-
well plate (Greiner Bio-one, 655101) in duplicate followed by addition of 
Coomassie® Reagent, 10 min incubation on a bench top and readout at 595 nm. BSA 
standards were prepared in 0.9 % NaCl in homogenisation buffer.  
The above method resulted in 800-1400 μg/ml total protein from 4 rabbit 
aortic rings.  
 
6.1.3 cGMP 
 
cGMP was quantified using cGMP Direct Immunoassay Kit (Abcam
®
, 
ab65356) according to the manufacturer instructions. A standard curve was 
constructed by plotting the mean absorbance for each standard on the y axis against 
the pmol cGMP/50 µl on the x axis and the best fit curve was adjusted using 
GraphPad® software (Figure 2.18). 
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Figure 2.18. Standard curve of cGMP (tissue samples). 
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6.1.4 cAMP 
 
cAMP was quantified using cAMP Enzyme Immunoassay Kit (R&D systems; 
KGE002B) according to the manufacturer instructions. OD was determined at 450 nm 
and 550 nm for correction of optical imperfections in the plate. Readings at 550 nm 
were subtracted from the readings at 450 nm as recommended by the manufacturer. A 
standard curve was constructed by plotting the mean absorbance for each standard on 
a linear y axis against the concentration on a logarithmic x axis and the best fit curve 
was adjusted using GraphPad® software (Figure 2.19).  
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.0
0.5
1.0
1.5
2.0
cAMP standards
Interpolated values
log10(cAMP)
O
D
 
Figure 2.19. Standard curve of cAMP. 
 
 
6.2 Plasma samples 
 
Platelet poor plasma (ppp) was prepared in the same way as for NO 
metabolites measurement (see III. General Methods, page 83). 
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6.2.1 cGMP 
 
cGMP was quantified using cGMP Enzyme Immunoassay Kit (R&D systems; 
KGE003) according to the manufacturer’s instructions. Ppp was diluted 20x in assay 
buffer. It was essential to incubate immunological complexes on a horizontal orbital 
microplate shaker (0.12’’ orbit) set at 500±50 rpm, otherwise the signal amplitude 
was very low (Figure 2.20). 
OD was determined at 450 nm and 550 nm for correction of optical 
imperfections in the plate. Readings at 550 nm were subtracted from the readings at 
450 nm as recommended by the manufacturer. A standard curve was constructed by 
plotting the mean absorbance for each standard on a linear y axis against the 
concentration on a logarithmic x axis and the best fit curve was adjusted using 
GraphPad® software.  
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Figure 2.20. Standard curve of cGMP (plasma samples). Inappropriate mixing (A) versus 
appropriate mixing (B). 
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6.2.2 Soluble P-selectin 
 
Soluble P-selectin (sP-selectin) was quantified using a sP-selectin Enzyme 
Immunoassay Kit (R&D systems; BBE6) according to the manufacturer’s instructions. Ppp 
was diluted 15x in assay buffer. OD was determined at 450 nm and 650 nm for correction of 
optical imperfections in the plate. Readings at 650 nm were subtracted from the readings at 
450 nm as recommended by the manufacturer. A standard curve was constructed by plotting 
the mean absorbance for each standard on the y axis against the concentration on the x axis 
and the best fit curve was adjusted using GraphPad® software (Figure 2.21).  
 
0 10 20 30 40 50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Interpolated values
P-selectin standards
sP-selectin (ng/ml)
O
D
 
Figure 2.21. Standard curve of sP-selectin. 
 
6.2.3 3-Nitrotyrosine 
 
3-Nitrotyrosine (3-NT) was quantified using a 3-NT Enzyme Immunoassay Kit 
(Hycult® biotech; HK501-02) according to the manufacturer’s instructions. Ppp was diluted 
5x in assay buffer. OD was determined at 450 nm and 550 nm for correction of optical 
imperfections in the plate. Readings at 550 nm were subtracted from the readings at 450 nm 
as recommended by the manufacturer. A standard curve was constructed by plotting the mean 
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absorbance for each standard on a linear y axis against the concentration on a logarithmic x 
axis and the best fit curve was adjusted using GraphPad® software (Figure 2.22).  
We experienced difficulties in measuring 3-NT in 8 plasma samples. Although 5x 
dilution of plasma was optimal for most samples, some had very high OD, which was outside 
the standard curve. In turn, when higher plasma dilution was used, other samples had too low 
OD and could not be interpolated. Overall, a greater range of readings was obtained in 
comparison to other ELISA assays. 
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Figure 2.22. Standard curve of 3-Nitrotyrosine (3-NT). Some interpolated values were bigger than 
the highest 3-NT standard. However, increasing the plasma dilution up to 10x resulted in the OD 
lower than the lowest 3-NT standard in other samples. 
 
7. Light transmission aggregometry (LTA) 
 
Light transmission aggregometry (LTA) is a laboratory-based technique allowing the 
evaluation of platelet aggregation in response to agonists
155
. When platelets aggregate, the 
light absorbance (A) is reduced in time. As a result, the light transmittance (T) increases and 
can be calculated from the absorbance (equation below), reflecting the degree of platelet 
aggregation. 
(2 )
10
A
T
                                                                                                                               
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In our setting, the 96-well plate was loaded with different agonists/antagonists and 
platelet rich plasma (prp) before it was placed in the spectrophotometer (FLUOstar OPTIMA) 
for 10 min at 37 °C. Absorbance was measured at 620 nm from the bottom of the plate every 
2 min after a 30 s linear shaking of the plate.  
 
7.1 Th-SNO preparations 
 
In order to test aggregatory capacity, thienopyridine-SNO (Th-SNO) was prepared by 
mixing thienopridine (Th) and nitrite under appropriate conditions (see IV. Results, page 145) 
and the 96-well plate was loaded first with platelet agonist ADP (20 µM) or PBS as a negative 
control. Then various concentrations of Th (10 µM-10 mM), Th-SNO (10 µM-10 mM) or 
nitrite (1-1000 mM) were added. GSNO (0.1-100 µM) was used as a positive control, which 
reflected 100 % RSNO yield. Prp of healthy subjects was isolated from trisodium citrate 
Vacutainer bottles by centrifugation (100 g, 10 min, 25 °C) and added to the plate. The 
increase in transmittance over 10 min was calculated relative to that of ADP-induced 
aggregation. 
 
7.2 Plasma samples 
 
In order to assess the influence of a 600 mg clopidogrel loading dose on platelet 
aggregation in coronary artery disease (CAD) patients, a 96-well plate was first loaded with 
platelet agonists ADP (20 µM) and Thrombin Receptor Activated Peptide (TRAP; 10 µM) or 
PBS as a negative control. Then prp was isolated from CAD patients in the same way as from 
healthy subjects (see above) and added to the plate. The increase in transmittance over 10 min 
was calculated separately relative to that of ADP- and TRAP-induced aggregation. 
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8. Measurement of reduced thiols (RSH) 
 
The content of reduced thiols (RSH) in chemical and biological preparations was 
measured using a ThioStar Fluorescent Thiol Detection Reagent (Bioquote) specific for 
reduced thiols. Fluorescence was recorded by the FLUOstar OPTIMA at the excitation 380 
nm and the emission 510 nm. The corresponding concentrations of free thiols were calculated 
from a standard curve for reduced glutathione (GSH; Figure 2.23). 
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Figure 2.23. Standard curve of GSH used for estimation of RSH in the sample. 
 
8.1 Thienopyridine tablets 
 
Tablets of the commercially available clopidogrel sulphate, prasugrel, ticlopidine and 
ticagrelor were crushed and dissolved in HPLC water to a final concentration 8.35 mM. After 
a 10 min incubation at 37 ºC, pH was adjusted to pH=7-8 and samples were loaded onto a 96-
well plate in triplicate prior to addition of 2.5 µg/ml ThioStar probe. Fluorescence was 
recorded 5-15 min after addition of the probe.  
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8.2 Plasma samples 
 
Platelet poor plasma samples were diluted 1000x in PBS and added in duplicate to a 
96-well plate, followed by addition of 2.5 μg/ml ThioStar Reagent. Fluorescence was 
recorded every 5 min after addition of the probe until fluorescent signals reached plateau 
(Figure 2.24). 
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Figure 2.24. Traces of fluorescence signal of plasma samples loaded with ThioStar Reagent 
changing in time. 
 
 
9. Measurement of total anti-oxidant capacity (TAC) 
 
The principle of the TAC assay, also known as oxygen radical absorbance capacity 
(ORAC) assay has been described in detail elsewhere
32, 33
. Briefly, it is based on the in vitro 
inhibition by anti-oxidants of the free radical damage to a fluorescent probe. This inhibition is 
observed as a preservation of the fluorescent signal over time and is quantified by calculating 
the resultant difference in AUC. It is usually reported in comparison to a standard anti-oxidant 
preparation. 
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Samples were diluted in PBS and added in triplicate to a 96-well plate loaded with 
sodium fluorescein (10 nM). 70 μM 4-hydroxy-TEMPO (tempol; Sigma) was used as a 
standard anti-oxidant on each plate. Then, either water (blank) or 2,2’-azobis-2-methyl-
propanimidamide (AAPH, 240 mM) were added prior to measurement. AAPH starts 
producing peroxyl radicals immediately after being dissolved, which is accelerated by raising 
the temperature.  
Fluorescence measurement was performed on the FLUOstar OPTIMA for 60-90 min 
at 37 °C with 485 nm excitation and 520 nm emission. Fluorescence was measured (from the 
top) every minute after a short orbital shaking of the plate. 
 
9.1 Anti-oxidants 
 
Different concentrations 12.5 – 200 µM of the standard anti-oxidant chemicals 
(tempol; Sigma) and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trolox; 
Sigma), and clopidogrel sulphate (LKT Laboratories, Inc) were prepared in PBS and used in 
the TAC assay to compare anti-oxidant capacity of samples. 
 
9.2 Plasma samples 
 
Although TAC assay is commonly used to assess the anti-oxidant power of various 
compounds, this method is not well described in plasma. Plasma is a good buffering system 
thanks to a rich pool of anti-oxidant proteins, which provide a very condense milieu. Hence, 
in order to measure its anti-oxidant properties, it requires high dilution. After running a series 
of plasma dilutions 10-4000x, we chose 1000x dilution because it showed the most similar 
fluorescence profile to tempol in terms of time of protection against AAPH (Figure 2.25).  
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Figure 2.25. Fluorescence profiles of different plasma dilutions after addition of AAPH. Note that 
dilutions above were added and further diluted 8x on the 96-well plate. 
 
9.3 Method of calculation 
 
Differences between AUC of protected and unprotected loss in fluorescence were 
calculated (equation 1 below) to assess the anti-oxidant protection of tempol, trolox and 
clopidogrel. In case of plasma samples, despite previous adjustment for plasma dilution, the 
baseline fluorescence and the fluorescent profile were different from the standard in water. 
Therefore, plasma samples were assessed differently (equation 2 below) to avoid negative 
numbers (Figure 2.26). 
 
sample sample AAPH AAPH
TAC AUC AUC                                                                                           (1) 
*100%
plasma AAPH
plasma
tempol AAPH
AUC
TAC
AUC


                                                                                        (2) 
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Figure 2.26. Fluorescence profiles of plasma (1000x) and 70 µM tempol before or after addition 
of AAPH. In blue: AUCtempol-AAPH and in yellow: AUCplasma+AAPH.  
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Part 1: Direct influence of clopidogrel on vascular NO homeostasis 
 
Hypothesis: Parental form of clopidogrel primes vascular tissue to exhibit enhanced 
vasodilation. 
 
Specific aims of this chapter were: 
 
    To determine whether the parental form of clopidogrel (pro-clopidogrel) changes the 
responsiveness of vessels to endogenous or exogenous NO. 
    To investigate the potential anti-oxidant and anti-inflammatory effects of pro-
clopidogrel on vascular tissue. 
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1. Introduction 
 
Inhibition of P2Y12 receptors on platelets has other consequences for the whole 
cardiovascular system. Activated platelets release a range of cytokines and chemokines, 
which attract immune cells, including leukocytes to inflammatory sites on vascular 
endothelium and aggravate inflammatory responses. In patients with endothelial dysfunction 
and atherosclerosis the non-resolved inflammation leads to amplification of thrombosis and 
causes further damage to the vasculature. That is why the inhibition of platelet activation and 
aggregation attenuates excessive inflammation, which helps to restore the vascular function.  
Clopidogrel therapy has been associated with numerous anti-inflammatory effects
156-
162
. These studies have demonstrated that: patients undergoing coronary arterial stenting had 
significantly lower levels of P-selectin, IL-1α, IL-2, IL-6, IL-13, TNF-β and TNF-α after 
receiving a maintenance dose of clopidogrel for at least 6 months
156
; plasma levels of hsCRP, 
sCD40L and RANTES and urinary excretion of 8-iso-prostaglandin F2α were decreased in 
CAD patients taking clopidogrel for at least 5 weeks
157
; platelet-leukocyte interactions, 
monocyte activation and plasma levels of RANTES were reduced in patients with type 2 
diabetes mellitus receiving a maintenance dose of clopidogrel for 28 days
160
. Further anti-
inflammatory effects of clopidogrel were also observed in animal models. For instance, tissue 
levels of CD40L and TF were lower in rabbit ischemic coronary artery after infusion of 
clopidogrel
159
 and serum and tissue levels of P-selectin, ICAM-1, VCAM-1 and MCP-1 were 
decreased by clopidogrel treatment in rabbits with early signs of athelosclerosis
158
.  
Since 1997, when clopidogrel was introduced into the market, numerous pleiotropic 
effects of the drug have been reported and some of them have not been fully explained by 
differences in drug metabolism between individuals. In in vitro studies, clopidogrel increased 
intracellular levels of [Ca
2+
]i and nitrite in the immortalized HUVEC cell line ECV304 
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without an influence on viability of cells
163
 implying an influence on NOS activity. 
Furthermore, clopidogrel exhibits anti-platelet actions when pre-incubated with whole blood 
prior to addition of ADP, an effect not seen in platelet-rich plasma
164
. The authors of the latter 
study speculated that blood cells could biotransform clopidogrel into its main active 
metabolite. Others have observed that clopidogrel reduces ectonucleotidase activity of 
HUVECs, impairing the ability of vascular endothelial cells to prevent platelet aggregation by 
inhibition of ADP and AMP hydrolysis
165
. It is important to appreciate that all these in vitro 
effects were observed for the pro-clopidogrel form (without metabolism), which is not 
purported to inhibit P2Y12 receptors directly without conversion to its active metabolite.  
In animal models and humans, clopidogrel has been shown to influence vascular 
tone
166, 167
, improve vascular function and increase release of endothelium-dependent 
relaxants
168
. Namely, clopidogrel (i) normalized increased PE-induced constriction and 
impaired Ach-induced relaxation in small mesenteric arteries from AngII-hypertensive rats
166
, 
(ii) attenuated arterial constriction in rabbit and rat aortic rings
167
, (iii) improved Ach-induced 
forearm blood flow (FBF) in CAD patients
157
, (iv) increased flow-mediated dilation (FMD) in 
CAD patients
169
 and those undergoing PCI
170
 and (v) was associated with increased NO 
bioavailability
157, 159, 171
 and release of prostaglandins
172
. The origin of vasomodulatory 
actions of clopidogrel is poorly understood and is the focus of the work in this chapter.  
P2Y12 receptors have been identified on endothelial and smooth muscle cells of human 
aorta and coronary arteries
173, 174
, and it has been suggested that ADP-stimulated responses via 
P2Y12 receptor activation might not be limited solely to platelets. This is in accord with 
studies on isolated guinea pig heart, where clopidogrel produced an eNOS-dependent increase 
in coronary flow ex vivo
171
 and in CAD patients, where a loading dose of clopidogrel 
increased FMD of the brachial artery without concomitant inhibitory effects on platelet 
aggregation
169
. On the other hand, it was shown in small mesenteric arteries from AngII-
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hypertensive rats that there is rather low expression of P2Y12 receptors and that vascular 
responses to the P2Y12 receptor agonist 2-MeS-ADP were not influenced by clopidogrel. This 
suggests a minor contribution of vascular P2Y12 receptors in clopidogrel-mediated effects on 
vascular function in this model
166
. Additionally, studies using P2Y12 KO mice revealed that 
the platelet P2Y12 receptor, introduced with bone marrow transplantation, influences the 
vessel wall response to arterial injury and thrombosis to a greater extent than vascular P2Y12 
receptors
148
.  
The active metabolite of clopidogrel constitutes only less than 0.01% of the parent 
drug
139
. Despite this, treatment with clopidogrel provides numerous beneficial effects on the 
maintenance of vascular homeostasis and clopidogrel remains the most commonly prescribed 
P2Y12 antagonist worldwide. This disproportion suggests alternative but important 
complementary pathways of clopidogrel action.  
This study was designed to investigate in detail the capacity of the pro-drug 
clopidogrel to influence vascular function in vitro using isolated rabbit vessel preparations. 
Model systems were set up to examine possible differential effects of clopidogrel on the 
vascular responses to endogenous and exogenous sources of NO and their dependence on 
vascular P2Y12 receptor mediated pathways, and the role(s) of documented anti-oxidant and 
anti-inflammatory properties of parental clopidogrel in this process. 
 
 
 
 
 
 
                  
 
IV. RESULTS: Part 1  
-106- 
 
2. Methods 
 
2.1 Pre-incubation of aortic rings with clopidogrel 
 
Prior to any experiments, aortic rings isolated from rabbits or mice were incubated in 
Krebs buffer (for composition see III. General Methods, page 68) with or without purified 
clopidogrel (Axxora Uk Ltd.); the material was relatively soluble and was dissolved directly 
in the buffer. Typically, 40 ml of Krebs buffer was warmed up to 37 °C in the water bath and 
oxygenated with gas (95% O2/5% CO2) before immersion of 2-6 aortic rings. As vessels 
settled at the bottom of the 50 ml tube, narrow gauge tubing supplying the gas was fixed at a 
position approximately half-way through the volume of the buffer to provide sufficient 
aeration but ensuring not to disturb the vascular integrity (Figure 3.1). It was essential that gas 
bubbles were gentle and did not cause vessels to agitate excessively. 
 
 
Figure 3.1. Setup for pre-incubation of aortic rings in Krebs buffer +/- clopidogrel. 
 
 
Aortic rings pre-incubated in Krebs buffer with or without clopidogrel were used 
immediately for the isometric tension or EPR studies. Alternatively, they were snap frozen in 
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liquid nitrogen and stored in -80 °C for the cGMP and cAMP measurements by ELISA, and 
for VCAM-1, TNF- α and IL-6 mRNA relative gene expression by real time qPCR (RT 
qPCR). Samples intended for cAMP and cGMP analysis were incubated for 15 min with 
IBMX (PDE inhibitor; 100 μM) before freezing. A simplified scheme of experimental 
protocol is presented in Figure 3.2; for detailed method description please refer to II Methods. 
 
2.1.1 Denudation. 
 
In experiments with denuded vessels, the endothelium was carefully removed by 
gently rubbing the internal surface of the tissue ring with a wooden applicator before or after 
the pre-incubation stage. Removal of endothelium was confirmed by the absence of a 
vasodilator response to Ach (10 μM) in pre-constricted vessels.  
 
2.1.2 Use of pharmacological inhibitors 
 
Pharmacological inhibitors were used at the following concentrations: L-NMMA 
(eNOS inhibitor; 10 μM; Enzo Life sciences), indomethacin (COX inhibitor; 10 μM), CGS-
15943 (A2 receptor inhibitor; 1 μM) and ODQ (sGC-inhibitor; 10 μM). Concentrations of L-
NMMA, indomethacin and ODQ were chosen on the basis of work of others
42
 (Shawmendra 
Bundhoo MD 2011 and Andrew Pinder PhD 2009) to maximally inhibit their target molecules 
in given conditions. The concentration of CGS-15943 was selected on the basis of published 
data
175
 and additionally checked for efficiency against blocking adenosine receptor agonist 
(NECA); 1 μM CGS-15943 decreased the vascular total relaxation to NECA by 73.85% 
(+CGS-15943 Rmax=18.72±0.25% vs. -CGS-15943 Rmax=71.60±1.75%, n=1).  
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Stock solutions of L-NMMA (in water) , indomethacin (in DMSO) and CGS-15943 
(in DMSO) were diluted in the pre-incubation buffer and were present for the whole pre-
incubation period, whereas ODQ was added to tissue baths for 0.5 h before pre-constricting 
with PE.  
 
 
Figure 3.2. Time scale of experiments in isolated aortic rings. Exercise – a period when aortic rings 
were constricted with PE and relaxed with Ach for three times to achieve the maximal responses. 
 
2.2 Data analysis and statistics 
 
The results are expressed as mean±SD and “n” represent the number of independent 
experiments. In all studies, data was obtained from 2-4 aortic rings of individual animals and 
matched with corresponding controls to give an “n” of 1.  
Concentration-response to agonists were fitted by nonlinear regression curves 
(sigmoidal dose-response) and concentrations producing 50 % response [log10(EC50)] were 
determined. EC50Ratio (EC50R) with a 95 % confidence interval was used to report the change 
of EC50 by clopidogrel in relation to corresponding controls and to compare this change 
between different experimental settings (e.g. in the presence of inhibitors). EC50R was 
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computed using the EC50 Shift function in GraphPad Prism®, according to the formula: 
EC50R= EC50sample/ EC50control (see III. General Methods, pages 69-70).  
EPR spectra were smoothed using polynomial fitting (2nd order) with adjacent 
averaging. The area under curve (AUC) of all component peaks of the EPR spectra was 
analysed individually and log10(AUC) was computed to compare the relative amounts of 
superoxide.  
Differences between groups were analysed using 2-tailed student’s t-test unless stated 
otherwise. Paired analysis was used to compare a single treatment of aortic rings with 
matched controls on the same experimental day while the unpaired analysis was used to 
compare results coming from different experimental days. A normal distribution between 
group differences was assumed on the basis of the interval data type and similar data size. 
All analysis was performed using GraphPad Prism® (version 5) software. 
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3. Results 
 
3.1 Pre-incubation of vessels with clopidogrel enhances vasodilation to NO donors 
 
3.1.1 Model development - rabbit aortic rings 
 
An in vitro model of isolated rabbit aorta was developed in order to study the potential 
direct vascular effects of clopidogrel. Simple addition of clopidogrel to organ baths did not 
induce any immediate changes in contractile or relaxation responses of mounted vessels (as 
previously shown
167
). Therefore, aortic rings were pre-incubated in oxygenated Krebs buffer 
at 37 °C with or without clopidogrel (1000 µM) for 2, 3.5 and 6 h prior to isometric tension 
studies. After 2 h pre-incubation, responses to Ach or the exogenous NO donor GSNO were 
still unaffected by clopidogrel. Pre-incubation for 3.5 h caused an enhanced relaxation to 
GSNO in comparison to controls [log10(EC50)=-7.22±0.21 vs. log10(EC50)=-7.00±0.29, paired 
t-test, n=4, p=0.021] but not to Ach [log10(EC50)=-6.80±0.21 vs. log10(EC50)=-6.91±0.21, 
paired t-test, n=4, p=0.230; Figure 3.3 and 3.4]. This effect was not maintained over time; 
after 6 h pre-incubation, there was a substantial loss of vascular response to Ach compared to 
controls [log10(EC50)=-6.45±0.05 vs. log10(EC50)=-6.73±0.07, n=1] and also the enhanced 
response to GSNO was smaller than at 3.5 h [log10(EC50)=-6.92±0.05 vs. log10(EC50)=-
6.84±0.01, n=1]. 
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Figure 3.3. Concentration response curves to GSNO (A) and Ach (B) after pre-incubation of 
rabbit aortae for 3.5 h with clopidogrel (1000 µM). “Fresh” represents responses of aortic rings 
without the pre-incubation and “control” represent responses of aortic rings pre-incubated in Krebs 
buffer; n=4. 
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Figure 3.4. Influence of clopidogrel (1000 µM) on the GSNO- and Ach-induced relaxation of 
rabbit aortae. Paired 2-tailed student’s t-test, n=4, *p<0.05. 
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The temperature at which vessels were kept during the pre-incubation period was 
crucial. In separate studies, we noticed that by lowering the temperature to 32 °C, we could 
prolong the time of incubation up to 6 h in order to increase the vascular response to GSNO 
even further without inducing significant damage to endothelium (see Shawmendra Bundhoo 
MD 2011). However, in order to provide the most physiological conditions, aortic rings were 
pre-incubated with or without clopidogrel at 37 °C for only 3.5 h for the majority of the 
studies presented in this thesis, since this provided maximal influence on GSNO responses 
without affecting Ach/PE and vessel integrity. 
 
3.1.2 The influence of clopidogrel on constriction to PE 
 
The cummulative concentration response to PE was tested; EC50 was not affected in 
the clopidogrel-treated group compared to controls [log10(EC50)=-6.76±0.02 vs. log10(EC50)=-
6.83±0.02, paired t-test, n=4, p=0.069]. Although a trend towards decreased response to PE in 
clopidogrel-treated vessels was observed, this is unlikely the reason for the observed 
enhancement in vasodilation to GSNO (Figure 3.5). 
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Figure 3.5. PE-induced constriction of rabbit aortae pre-incubated +/- clopidogrel. “Fresh” 
represents responses of aortic rings without the pre-incubation and “control” represent responses of 
aortic rings pre-incubated in Krebs buffer; n=4. A comparison of log(EC50) is presented on page 120. 
                  
 
IV. RESULTS: Part 1  
-113- 
 
3.1.3 Comparison of different NO donors 
 
Clopidogrel enhanced vessel response to GSNO, an NO donor which belongs to the 
group of S-nitrosothiols, relaxing smooth muscle via the SNO moiety. In real terms, it is an 
NO
+
 moiety which is released from nitrosothiols following cleavage of the S-NO bond (such 
as with hv or metal ion). In order to assess whether our observations were specific to GSNO 
or S-nitroso-metabolism by tissue in particular, other NO donors such as NOC9 and ISDN 
were also tested (Figure 3.6). Clopidogrel enhanced NOC9-induced relaxation responses in 
comparison to controls [log10(EC50)=-8.00±0.03 vs. log10(EC50)=-7.90±0.04, paired t-test, 
n=4, p=0.013]. On the other hand, clopidogrel did not influence the relaxation of rabbit aortic 
rings to ISDN [log10(EC50)=-6.67±0.03 vs. log10(EC50)=-6.71±0.03, paired t-test, n=4, 
p=0.426]. 
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Figure 3.6. GSNO-, NOC9-and ISDN-induced relaxation of rabbit aortae +/-clopidogrel. (A) 
concentration response curves to GSNO (graph is reused for comparison); (B) concentration response 
curves to NOC9; (C) concentration response curves to ISDN; (D) Comparison of log(EC50) of GSNO, 
NOC9 and ISDN. “Fresh” represent responses of aortic rings without the pre-incubation and “control” 
represent responses of aortic rings pre-incubated in Krebs buffer. Paired 2-tailed student’s t-test, n=4, 
*p<0.05. 
 
It may be of importance that ISDN exhibited a different relaxation profile compared to 
GSNO and NOC9 (Figure 3.7). ISDN needs to be metabolized in the smooth muscle before it 
begins to take an effect, which influences not only time (approx. 42 min for total 
vasorelaxation to ISDN vs. approx. 27 min in case of GSNO or NOC9) but also the 
effectiveness of relaxation [log10(EC50) ISDN=-6.71±0.03 vs. log10(EC50) GSNO=-7.09±0.24 
vs. log10(EC50) NOC9=-7.90±0.04]. This might explain, in part, the reason why enhanced 
relaxation was not observed in the case of ISDN. 
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Figure 3.7. Relaxation profiles to GSNO, NOC9 and ISDN in rabbit aortae. 
 
3.2 Mechanism of enhanced GSNO-induced vasorelaxation by clopidogrel 
 
3.2.1 Involvement of P2Y12 receptors 
 
Clopidogrel is purported to be a selective P2Y12 receptor antagonist and only the 
active metabolite of clopidogrel formed in the liver can bind to the receptor. In our vascular 
model, the parental form of clopidogrel was used and therefore neither the presence of the 
active drug metabolism, nor activation of P2Y12 receptors in rabbit aortae was expected. 
Nevertheless, in order to test whether the enhanced response of clopidogrel-stimulated tissue 
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to exogenous NO donors depends on the presence of P2Y12 receptor in the vasculature, we 
carried out similar studies in P2Y12
-/-
 mice in comparison to wild type littermates. 
 
3.2.1.1 Model development - mouse aortic rings 
 
Aortic rings isolated from P2Y12
+/+
 (WT) and P2Y12
-/-
 (KO) mice were kept in 
oxygenated Krebs buffer with or without clopidogrel at 37 °C for 3.5 h (akin to the rabbit 
studies described above – see IV. Results, pages 110-112). However, the concentration of 
clopidogrel had to be lowered to 100 µM as the 1000 µM concentration limited vascular 
constriction responses up to 50 % (tested in WT mice). In comparison to controls 100 µM 
clopidogrel did not affect PE response both in WT [log10(EC50)=-7.14±0.02 vs. log10(EC50)=-
7.08±0.03, paired t-test, n=6, p=0.263], and KO P2Y12 mice [log10(EC50)=-7.05±0.02 vs. 
log10(EC50)=-6.97±0.03, paired t-test, n=6, p=0.077; Figure 3.8], respectively. Furthermore, 
the effect of clopidogrel on PE response was not different between phenotypes (P2Y12
+/+
 
EC50R PE vs. P2Y12
-/-
 EC50R PE, unpaired t-test, n=6, p=0.527). Therefore, it was decided to 
pre-incubate mouse aortic rings with 100 µM clopidogrel in further studies. 
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Figure 3.8. PE-induced constriction of aortae from P2Y12 WT and KO mice pre-incubated +/-
clopidogrel. (A) concentration response curves to PE; (B) comparison of log(EC50) of PE. Paired 2-
tailed student’s t-test, n=6, p>0.05. 
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In terms of endothelium-dependent vasodilation, the Ach concentration response in 
mouse aorta was different to that in rabbit tissues; total relaxation to Ach was higher in mouse 
(mouse Rmax=95.4±7.0 % vs. rabbit Rmax=70.6±13.5 %), as well as Ach potency was higher 
[mouse log10(EC50)=-4.40±0.43 vs. rabbit log10(EC50)=-3.89±0.22; Figure 3.9].  
 
 
 
 
 
 
 
 
Figure 3.9. Ach-induced relaxation of mouse and rabbit aortae. (A) concentration response curves 
to Ach, n=4; (B) comparison of log(EC50) of Ach.  
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In comparison to controls 100 µM clopidogrel significantly decreased vessel response 
to Ach both in WT [log10(EC50)=-7.48±0.08 vs. log10(EC50)=-7.37±0.06, paired t-test, n=6, 
p=0.006], and KO P2Y12 mice [log10(EC50)=-7.52±0.08 vs. log10(EC50)=-7.36±0.07, paired t-
test, n=6, p=0.014; Figure 3.10), respectively. The effect of clopidogrel on Ach response was 
not different between phenotypes (P2Y12
+/+
 EC50R Ach vs. P2Y12
-/-
 EC50R Ach, unpaired t-
test, n=6, p=0.532). 
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Figure 3.10. Ach-induced relaxation of aortae from P2Y12 WT and KO mice pre-incubated +/- 
clopidogrel. (A) concentration response curves to Ach; (B) comparison of log(EC50) of Ach. Paired 2-
tailed student’s t-test, n=6, *p<0.05, **p<0.01. 
 
3.2.1.2 Enhanced response to GSNO 
 
The primary question being addressed was whether clopidogrel enhanced 
responsiveness of mouse aortae to GSNO similarly to that observed for rabbit tissue. Studies 
in genetically matched WT strain mice revealed that clopidogrel increased significantly the 
GSNO response in mouse aortae compared to controls [log10(EC50)=-7.19±0.08 vs. 
log10(EC50)=-6.94±0.04, paired t-test, n=6, p=0.015; Figure 3.11]. Having confirmed this, 
parallel studies were carried out in P2Y12
+/+
 and P2Y12
-/-
KO mice to see if the presence of 
P2Y12 receptor made an impact. Clopidogrel improved significantly the GSNO response in 
P2Y12
+/+ P2Y12
-/-
-8.5
-8.0
-7.5
-7.0
-6.5
-6.0
** *
control clopidogrel
lo
g
1
0
(E
C
5
0
) 
A
c
h
[l
o
g
1
0
(M
)]
A B 
                  
 
IV. RESULTS: Part 1  
-119- 
 
KO mice compared to controls [log10(EC50)=-7.34±0.08 vs. log10(EC50)=-7.06±0.05, paired t-
test, n=6, p=0.018] and the extent of improvement was similar to the WT strain (P2Y12
+/+
 
EC50R GSNO vs. P2Y12
-/-
 EC50R GSNO, unpaired t-test, n=0.796), confirming that 
clopidogrel enhances vascular response to GSNO independent of P2Y12 receptor interaction. 
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Figure 3.11. GSNO-induced relaxation of aortae from P2Y12 WT and KO mice pre-incubated +/- 
clopidogrel. (A) concentration response curves to GSNO; (B) comparison of log(EC50) of GSNO. 
Paired 2-tailed student’s t-test, n=6, *p<0.05. 
 
3.2.2 Involvement of endothelium 
 
The site of interaction between clopidogrel and vessels was studied by assessing the 
role of vascular endothelium in our model. Rabbit aortic rings denuded of endothelium were 
incubated with and without clopidogrel and compared with endothelium intact aortic rings. 
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3.2.2.1 Influence of denudation on constriction 
 
Denuded vessels showed no difference in PE-induced vasoconstriction in the 
clopidogrel-treated group in comparison to controls [log10(EC50)=-6.90±0.04 vs. 
log10(EC50)=-6.90±0.05, paired t-test, n=4, p=0.098; Figure 3.12]. The resultant EC50R was 
also not different from vessels with intact endothelium (-EC EC50R PE vs. +EC EC50R PE, 
unpaired t-test, n=4, p=0.118). 
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Figure 3.12. Influence of denudation of vessels on PE-induced constriction of rabbit aortae pre-
incubated +/- clopidogrel. (A) concentration response curves to PE; (B) comparison of log(EC50) of 
PE. Paired 2-tailed student’s t-test, n=4, p>0.05. Concentration response curves to PE in the presence 
of endothelium (+EC) were presented on page 112 as they belonged to a separate experiment. 
 
3.2.2.2 Influence of denudation on relaxation to GSNO 
 
GSNO relaxes smooth muscle directly and is independent of endothelial production of 
NO. In line with this, relaxation of rabbit aorta to GSNO was not mediated by endothelium 
and when vessels were denuded after the pre-incubation with clopidogrel, the enhancement of 
GSNO-induced vasorelaxation remained. However, we were more interested in the role of 
endothelium in the clopidogrel “priming” effect per se, i.e. during the pre-incubation period. 
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Therefore, aortic rings, which were denuded prior to pre-incubation with clopidogrel were 
studied. These vessels showed no enhancement in GSNO-induced vasodilation by clopidogrel 
compared to controls [log10(EC50)=-6.94±0.06 vs. log10(EC50)=-6.93±0.04, paired t-test, n=4, 
p=0.865; Figure 3.13). Moreover, the resultant EC50R was significantly different than in 
vessels with intact endothelium, pointing to a crucial role of endothelium in the clopidogrel 
induced effect (-EC EC50R GSNO vs. +EC EC50R GSNO, unpaired t-test, n=4, p=0.025). 
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Figure 3.13. Influence of denudation of vessels on GSNO-induced relaxation of rabbit aortae 
pre-incubated +/- clopidogrel. (A) concentration response curves to GSNO; (B) comparison of 
log(EC50) of GSNO. Paired 2-tailed student’s t-test, n=4, *p<0.05. Concentration response curves to 
GSNO in the presence of endothelium (+EC) were presented on page 111 as they belonged to a 
separate experiment. Log(EC50) of GSNO (+EC) is reused for comparison. 
 
3.2.3 Involvement of endothelium-dependent relaxants 
 
In order to further characterize the endothelium-dependent mechanism by which 
clopidogrel enhances GSNO-mediated vasodilatation, we assessed the involvement of eNOS 
and COX. The role of vascular adenosine pathways was also tested knowing of adenosine-like 
effects of ticagrelor
147
. Pharmacological blockers of eNOS (L-NMMA), COX (indomethacin) 
and A2 receptors (CGS-15943) were incubated with rabbit aorta with or without clopidogrel.  
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3.2.3.1 Influence of inhibitors on relaxation to GSNO in controls 
 
Since, L-NMMA, indomethacin and CGS-15943 were incubated with rabbit aortic 
rings for 3.5 h, we checked first their influence on the GSNO-induced relaxation in control 
vessels (Figure 3.14). We found that GSNO-induced responses in controls were not changed 
in the presence of L-NMMA (+L-NMMA log10(EC50)=-6.37±0.08 vs. -L-NMMA 
log10(EC50)=-6.27±0.07, paired t-test, n=4, p=0.081), but were affected in the presence of 
CGS-15943 (+CGS-15943 log10(EC50)=-6.98±0.03 vs. –CGS-15943 log10(EC50)=-6.92±0.02, 
paired t-test, n=4, p=0.049) and indomethacin (+indomethacin log10(EC50)=-7.36±0.06 vs. -
indomethacin log10(EC50)=-7.02±0.05, paired t-test, n=4, p=0.007). 
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Figure 3.14. Concentration response curves to GSNO after pre-incubation of rabbit aortae +/- L-
NMMA, +/- CGS-15943 and +/- indomethacin. Paired 2-tailed student’s t-test, n=4, *p<0.05, 
**p<0.01. 
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3.2.3.2 Influence of inhibitors on relaxation to GSNO 
 
We found that the presence of L-NMMA and CGS-15943 did not inhibit the enhanced 
response to GSNO in the clopidogrel-treated group compared to relative controls 
[log10(EC50)=-6.65±0.09 vs. log10(EC50)=-6.37±0.08, paired t-test, n=4, p=0.025; 
log10(EC50)=-7.09±0.04 vs. log10(EC50)=-6.98±0.03, paired t-test, n=4, p=0.054; Figure 3.15], 
pointing to the lack of involvement of eNOS and adenosine pathways. In the case of COX 
inhibition, these results were complicated by the fact that indomethacin had a large direct 
effect on controls (see IV. Results, page 122), and results from this experiment could not be 
interpreted in terms of confirming a real contribution of COX-dependent signalling in the 
GSNO-induced enhanced vasodilation by clopidogrel.  
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Figure 3.15. Concentration response curves to GSNO of rabbit aortae pre-incubated +/- 
clopidogrel and +/- L-NMMA (A),  +/- CGS-15943 (B) and +/- indomethacin (C). Graphs contain 
controls presented before in Figure 3.14. Comparisons of all log10(EC50) were not shown for 
simplicity, n=4.  
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In summary, the enhanced GSNO-induced response by clopidogrel was not different 
with and without inhibitors of eNOS and adenosine receptors (-L-NMMA EC50R GSNO vs. 
+L-NMMA EC50R GSNO, unpaired t-test, n=4, p=0.061; -CGS-15943 EC50R GSNO vs. + 
CGS-15943 EC50R GSNO, unpaired t-test, n=4, p=0.838; Figure 3.16).  
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Figure 3.16. Influence of L-NMMA and CGS-15943 on GSNO-induced relaxation of rabbit 
aortae pre-incubated +/- clopidogrel. Clopidogrel-induced enhancement to GSNO was not different 
with or without these inhibitors. Unpaired 2-tailed student’s t-test, n=4, p>0.05. 
 
3.2.4 Involvement of sGC-cGMP-dependent relaxation 
 
GSNO, like other exogenous NO donors, works mainly via sGC. However, there is 
well documented evidence for cGMP-independent mechanisms of action of NO and NO 
donors
92
. In order to address this issue, we added ODQ, a general blocker of sGC, to organ 
baths with mounted rabbit aortic rings, which were previously pre-incubated with or without 
clopidogrel. 
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ODQ did not prevent the enhanced response to GSNO in the clopidogrel-treated group 
in comparison to controls [log10(EC50)=-7.52±0.17 vs. log10(EC50)=-6.56±0.12, paired t-test, 
n=3, p=0.002; Figure 3.17], suggesting the involvement of NO/sGC-independent pathways. In 
fact, the enhanced response to GSNO by clopidogrel was 2-3-fold higher in the presence of 
ODQ. Noteworthy, the maximal residual relaxation to GSNO (Rmax%) remained unchanged 
by clopidogrel pre-treatment (21.25±3.59 % vs. 21.00±3.95 %, paired t-test, n=3, p=0.882). 
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Figure 3.17. Influence of ODQ on GSNO-induced relaxation of rabbit aortae pre-incubated +/- 
clopidogrel. (A) concentration response curves to GSNO; (B) concentration response curves to GSNO 
in the presence of ODQ (reused and magnified); (C) comparison of log(EC50) of GSNO. Paired 2-
tailed student’s t-test, n=3, *p<0.05, **p<0.005 
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3.2.5 The influence of clopidogrel concentration on relaxation to GSNO 
 
Although all our analysis used rabbit aortic rings pre-incubated with 1000 µM 
clopidogrel, other concentrations of clopidogrel (10 µM and 100 µM) were also tested (Figure 
3.18 and 3.19). This data was analysed using repeated measures ANOVA with a Bonferroni's 
multiple comparison test resulting in significant increases in response of vessels to GSNO in 
all clopidogrel groups when compared to controls [10 µM: log10(EC50)=-6.94±0.27 vs. 
log10(EC50)=-6.68±0.32, n=3, p<0.01; 100 µM: log10(EC50)=-6.87±0.33 vs. log10(EC50)=-
6.68±0.32, n=3, p<0.05 and 1000 µM: log10(EC50)=-7.09±0.24 vs. log10(EC50)=-6.68±0.32, 
n=3, p<0.001]. There were no statistical differences between clopidogrel groups. 
 
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
fresh
10 M clopidogrel
1000 M clopidogrel
control
100 M clopidogrel
log10GSNO
C
u
m
u
la
ti
v
e
 r
e
la
x
a
ti
o
n
 (
%
)
 
Figure 3.18. Concentration response curves to GSNO after pre-incubation of rabbit aortae for 
3.5 h with clopidogrel (10-1000µM). “Fresh” represents responses of aortic rings without the pre-
incubation and “control” represent responses of aortic rings pre-incubated in Krebs buffer, n=3. 
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Figure 3.19. Influence of clopidogrel concentration on the GSNO-induced relaxation of rabbit 
aortae. Repeated measures ANOVA with a Bonferroni's multiple comparison test, n=3, *p<0.05, 
**p<0.01, ***p<0.001. 
 
3.2.6 Involvement of cGMP- and cAMP-dependent pathways 
 
In order to investigate further the effect of clopidogrel on downstream markers of 
vascular NO-signalling, we measured basal tissue levels of cGMP and cAMP with and 
without pre-incubation with clopidogrel (Figure 3.20). Rabbit aortic rings pre-incubated with 
clopidogrel did not show a significant change in intracellular levels of cGMP or cAMP, when 
compared with respective controls (pmol cGMP/mg protein=3.05±0.61 vs. 3.76±2.14, paired 
t-test, n=5, p=0.514; pmol cAMP/mg tissue=0.77±0.32 vs. 0.66±0.31, paired t-test, n=3, 
p=0.958). Taken together with the ODQ results presented above, this suggested that the 
enhanced vasorelaxation of rabbit aortae to GSNO by clopidogrel was not mediated by 
NO/sGC/cGMP-dependent pathways. 
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Figure 3.20. Basal levels of cGMP and cAMP in rabbit aortae pre-incubated +/- clopidogrel. 
“Fresh” represent responses of aortic rings without the pre-incubation and “control” represent 
responses of aortic rings pre-incubated in Krebs buffer. Paired 2-tailed student’s t-test, n=3, p>0.05. 
 
3.3 Anti-oxidant actions of clopidogrel 
 
Clopidogrel therapy in humans has been recently associated with anti-oxidant and 
anti-inflammatory effects. We investigated the influence of the pro-drug clopidogrel on the 
oxidative status of rabbit aortic rings pre-incubated at 37 °C in oxygenated Krebs buffer for 
3.5 h with or without 1000 µM clopidogrel. We used spin trapping techniques in conjunction 
with the DEPMPO probe to specifically capture superoxide released by these vessels to 
surrounding media over a 5 min period (see III. General Methods, pages 71-73). 
 
3.3.1 Direct anti-oxidant properties of clopidogrel 
 
Clopidogrel did not exhibit direct anti-oxidant properties. The amount of superoxide 
generated by a standard preparation of hypoxanthine/xanthine oxidase remained unchanged 
after incubation under similar conditions with 200 µM clopidogrel (Figure 3.21). Higher 
concentration of clopidogrel could not be used due to difficulties in finding the optimal 
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conditions for EPR scanning. The lack of a direct anti-oxidant effect of clopidogrel was 
confirmed by TAC assay (see IV. Results, page 191-193). 
3400 3450 3500
HYP/XO
HYP/XO+
clopidogrel
Gauss (T)
 
Figure 3.21. Representative trace of DEPMPO-superoxide spin adducts of 
hypoxanthine/xanthine oxidase (HYP/XO) +/- clopidogrel. 
 
3.3.2 Influence of clopidogrel on superoxide production by vessels 
 
Fresh vessels did not release detectable levels of superoxide (Figure 3.22), which is in 
agreement with low production of superoxide under physiological conditions. However, the 
3.5 h pre-incubation of vessels triggered an increased extracellular production of superoxide, 
as reflected by the log10(AUC) of the EPR signal, characteristic of the trapped superoxide-
DEPMPO adduct species (7.05±0.19 a.u.). Aortic rings pre-incubated for 3.5 h with 
clopidogrel released, in parallel, significantly lower amounts of superoxide into the 
surrounding buffer compared to controls (6.92±0.17 a.u. vs. 7.05±0.19 a.u., paired t-test, n=4, 
p=0.019), suggesting that clopidogrel provided a partial prevention of reactive oxygen 
intermediate generation in our model. 
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Figure 3.22. Indirect anti-oxidant properties of clopidogrel. (A) Representative traces of 
DEPMPO-superoxide spin adducts; (B) comparison of log10(AUC), representing amount of superoxide 
released by rabbit aortae pre-incubated +/- clopidogrel. Paired 2-tailed student’s t-test, n=4, *p<0.05. 
 
3.4 Anti-inflammatory actions of clopidogrel 
 
In order to determine whether the anti-oxidant actions of clopidogrel observed were 
paralleled by changes in anti-inflammatory status, mRNA coding for VCAM-1, TNF-α, IL-6 
and COX-2 was measured using RT qPCR after pre-incubation of rabbit aortic rings with or 
without 1000 µM clopidogrel. 
Fresh aortic rings expressed low levels of VCAM-1, TNF-α, IL-6 and COX-2 mRNA 
and they were used as a reference for calculation of relative expression in vessels that were 
pre-incubated with or without clopidogrel. The 3.5 h pre-incubation of aortic rings in Krebs 
buffer caused an upregulation of all these genes (Figure 3.23), pointing to an increased 
inflammatory status of tissue. In the presence of clopidogrel during the pre-incubation, vessels 
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expressed significantly lower amount of TNF-α mRNA (5.07±2.53 vs. 7.58±2.96, paired t-
test, n=3, p=0.014), unchanged amount of VCAM-1 mRNA (1.82±1.44 vs. 5.45±3.83, paired 
t-test, n=3, p=0.127), unchanged IL-6 mRNA (7.45±3.83 vs. 4.40±1.92, paired t-test, n=3, 
p=0.234) and significantly higher COX-2 mRNA (33.47±7.46 vs. 14.32±11.10, paired t-test, 
n=3, p=0.017) than corresponding controls. A trend towards lower expression of VCAM-1 
mRNA and higher expression of IL-6 mRNA in the presence of clopidogrel has been 
observed. 
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Figure 3.23. Anti-inflammatory properties of clopidogrel. The comparison of relative expression of 
VCAM-1 (A), TNF-α (B), IL-6 (C) and COX-2 (D) in rabbit aortae pre-incubated +/- clopidogrel, 
Paired 2-tailed student’s t-test, n=3, *p<0.05. 
A B 
C D 
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4. Discussion 
 
This study was designed to investigate the potential direct effects of a parental form of 
clopidogrel (pro-drug clopidogrel) on the vascular response to NO and anti-oxidant/anti-
inflammatory status of vessels. We found that pre-incubation of rabbit aortic segments with 
the pro-drug clopidogrel enhanced the relaxation response to exogenous NO addition, while 
responses to stimulation of endogenous NO remained unaffected. This effect was independent 
of platelet and vascular P2Y12 receptors, mediated by endothelium and limited to 
NO/sGC/cGMP-independent signalling pathways. Pre-incubation of vessels with clopidogrel 
reduced the extracellular release of superoxide by tissue and attenuated tissue TNF-α mRNA 
expression in this model, which may in part explain the enhanced response to exogenous NO 
following clopidogrel. 
Clopidogrel has been associated with attenuated vascular constriction in rabbit and rat 
models
166, 167
. In the present study, cumulative concentration responses to PE were not 
affected.  
Because clopidogrel has been shown to increase eNOS-dependent coronary flow in 
isolated heart of guinea pig
171
 and FBF and FMD in patients
157, 161, 169
, we expected to observe 
the augmented vasorelaxation to endogenous NO in our model. Instead, pre-incubation of 
rabbit aorta with pro-drug clopidogrel enhanced the responsiveness of the vessel only to 
exogenous NO donors (GSNO or NOC9) while response to Ach stimulation was not 
significantly affected. One possible explanation for this difference is the amount of NO 
reaching SMC; Ach-induced release of NO is limited by saturation of Ach receptors at the 
endothelial surface whereas free NO, coming from NO donors can act directly on the smooth 
muscle.  
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An important consideration is that GSNO has specific NO release mechanisms that 
may not be shared with other NO donors, and S-nitrosothiols have unique mechanisms of 
action in addition to the release of NO species involving transnitrosation and S-nitrosylation 
of proteins
66
. However, in the light of our data showing that clopidogrel also enhanced 
vasodilation to another NO donor NOC9, we may conclude that S-nitrosothiol signalling 
induced by GSNO was not critical to this process. In order to relate our finding to the clinical 
use of NO donors, ISDN was chosen because it has been used as a nitrosovasodilator for the 
treatment of angina pectoris
176
 and heart failure
177
. Clopidogrel did not influence the 
relaxation of rabbit aortic rings to ISDN probably due to its slow bioconversion and the 
resulting extremely slow rate of relaxation induced in the isolated vessel model. 
Given that clopidogrel is a P2Y12 antagonist, most of its beneficial effects on the 
vasculature, including the inhibition of platelet aggregation, vasomodulatory actions and the 
anti-inflammatory and anti-oxidative properties, have been considered to be due to blockage 
of primarily platelet P2Y12 and to lesser extent vascular P2Y12 receptors by the active 
metabolite. Our study confirms for the first time that the pro-drug clopidogrel has a direct 
influence on the vascular endothelium beyond platelet and vascular P2Y12 receptor-mediated 
pathways. Which endothelial receptors have been influenced by clopidogrel remains to be 
established. 
Knowing that sGC is the main but not the only vascular receptor for NO, we 
investigated its role in our study using ODQ. We found that the enhanced GSNO-mediated 
vasorelaxation by clopidogrel was sustained and even bigger after blocking sGC with ODQ. It 
suggests that the pre-incubation of rabbit aortae with clopidogrel activated sGC-independent 
pathways and caused the general enhancement of GSNO-induced vasodilation. The possible 
involvement of sGC-independent mechanisms was confirmed by showing that basal cGMP 
levels were unchanged in clopidogrel-treated vessels. Further studies are required to identify 
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how the endothelium influences sGC/cGMP-independent pathways in smooth muscle and 
what sGC/cGMP-independent molecules are affected; the involvement of endogenous NO has 
been excluded. 
Activation of sGC/cGMP-independent mechanisms by clopidogrel might be important 
considering different vascular responses to endogenous and exogenous NO stimuli observed 
in this study. It has been shown that cGMP-independent mechanisms become more prominent 
at higher concentrations of NO (μM-mM) and are generally more common for NO donors92, 
93
. In an attempt to explain this phenomenon, it has been suggested that NO generated within 
the tissue following receptor stimulation has more ready access to sGC, whereas NO 
delivered from outside the cell may more easily access non-sGC sites, such as K
+ 
channels
92
.  
 Although, clopidogrel did not exhibit direct anti-oxidant properties, it attenuated the 
increased extracellular release of superoxide by rabbit aortic tissue. Typically, relatively low 
amounts of superoxide are produced, but under pathological or stress conditions, an 
imbalance between the rate of its generation and removal by cellular anti-oxidant defenses 
occurs. Excessive release of superoxide is involved either directly or via the generation of 
other radicals (H2O2, ONOO
-
) in i) accelerated NO inactivation, (ii) alteration of intracellular 
redox signalling and (iii) oxidative damage of DNA, proteins and lipids, all leading to 
oxidative stress and endothelial dysfunction implicated in the development of various 
cardiovascular diseases
23
. In our model, the incubation of rabbit aorta under optimum 
laboratory conditions was associated with increased extracellular production of superoxide 
over time and paralleled by increased tissue levels of VCAM-1, TNF-α, IL-6 and COX-2 
mRNA. Both excessive superoxide production and upregulated TNF-α gene were attenuated 
by clopidogrel, which is indicative of anti-oxidant and anti-inflammatory effects in this 
model. Similarly, a trend towards decreased VCAM-1 and increased IL-6 mRNA by 
clopidogrel may be interpreted as the initiation of tissue protective mechanisms, since IL-6 
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has been shown to suppress inflammation by inhibition of TNF production
178
. COX-2 is 
known as an inducible enzyme catalyzing the production of various prostanoids, which play a 
variety of biological functions including the regulation of inflammation (see I. General 
Introduction, pages 41-43). Prostanoids exert their effects via activation of GPCR on the 
cellular membranes or peroxisome proliferator-activated receptors (PPARs) in the nucleus. 
Depending on tissue-specific isomerases and the site of release, products of COX-2 activity 
may induce pro-inflammatory or anti-inflammatory responses. It is not known if the 
upregulation of COX-2 mRNA by clopidogrel was pro- or anti-inflammatory and further 
experiments are required for confirmation. However, other results presented might suggest 
anti-inflammatory and anti-oxidant effects on the basis of downregulated TNF-α mRNA and 
reduced formation of O2
•-
 in the same tissues. Further studies using inhibitors of the 
enzymatic sources of superoxide are required to identify the anti-oxidant pathways stimulated 
by clopidogrel. Additionally, results from RT qPCR should be confirmed by protein-based 
techniques to confirm the anti-inflammatory properties of clopidogrel. 
Clearly, less superoxide in the extracellular space translates into more NO available 
from exogenously applied NO donors and consequently, may provide an explanation for the 
enhanced vasodilation to GSNO observed following pre-incubation of vessels with 
clopidogrel (Figure 3.25).  
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Figure 3.25. Summary of pathways involved and not involved in enhanced vascular response to 
GSNO by clopidogrel. The mechanism appears to be via EC-mediated (EC-med.) improvement in 
sGC-independent (sGC-indep.) pathways and/or reducing exogenous release of superoxide. In red, 
main limitations of the study have been outlined: 1) Although the involvement of P2Y12 receptors has 
been eliminated, the actual receptor mediating clopidogrel actions on vascular endothelium has not 
been identified; 2) Knowing the crucial role of endothelium and lack of involvement of NO and PGI2-
dependent signalling, other EC-dependent mediators should be explored; 3) The exact source of  O2
-•
 
is unknown; 4) The role of K
+
 channels, which are involved in sGC-indep. pathways should be 
investigated. 
 
 
The clinical relevance of our in vitro findings is not known. It is acknowledged that 
concentrations of clopidogrel used in experiments were at levels much higher than would be 
found physiologically and observed effects were relatively small. Peak plasma concentrations 
of clopidogrel metabolites 1-2 h after oral loading of clopidogrel (300-600 mg) in CAD 
patients were estimated as follows: (i) the active thiol metabolite 9-19 nM, (ii) the inactive 
carboxyl metabolite 50-140 μM and (iii) unchanged clopidogrel 50-140 nM135. The enhanced 
response of vessels to GSNO was observed when vessels were pre-conditioned with 10-1000 
μM pro-drug clopidogrel and the bioconversion of parental form of clopidogrel to different 
metabolites was not determined.  
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In summary, we consider our findings important to fully understand the influence of 
clopidogrel on vascular homeostasis. Direct vasomodulatory as well as anti-oxidant and anti-
inflammatory effects of clopidogrel observed in this study confirm that the drug has a positive 
impact on the vasculature beyond the inhibition of platelet aggregation. More research is 
required to identify the molecular pathways involved. This also provides impetus for similar 
studies with the newer anti-platelet agents, such as ticagrelor to investigate if these beneficial 
effects on vasculature translate to new generation drugs.  
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Summary: 
 
 Pre-incubation of rabbit aortic segments with pro-drug clopidogrel enhanced the 
relaxation response to exogenous NO addition, while responses to stimulation of 
endogenous NO remained unaffected.  
 
 This effect was independent of the platelet and vascular P2Y12 receptors, mediated by 
endothelium and limited to NO/sGC/cGMP-independent signalling pathways.  
 
 Extracellular release of superoxide and tissue TNF-α mRNA expression was 
attenuated by clopidogrel, which may in part explain the enhanced response to 
exogenous NO following clopidogrel. 
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Part 2: The ability of P2Y12 antagonists to make biologically active 
nitrosothiols 
 
Hypothesis: Thienopyridines can form S-nitrosothiol derivatives under appropriate 
conditions. 
 
Specific aims of this chapter were: 
 
 To investigate whether the thienopyridine and non-thienopyridine anti-platelet 
agents participate in S-nitrosation reactions and the factors that control these 
reactions. 
 To compare S-nitrosation between different forms of the same drug (salts of 
clopidogrel). 
 To examine the biological properties of these SNO derivatives in terms of 
ability to inhibit platelet aggregation, to induce vasorelaxation and participate 
in transnitrosation reactions. 
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1. Introduction 
 
P2Y12 antagonists are a class of very successful agents utilized for the 
inhibition of platelet activation and aggregation by ADP. Their major use is in the 
prevention of thrombotic vascular events and ischaemic complications, often arising 
from percutaneous coronary intervention (PCI), and are recommended for patients 
with acute coronary syndromes (ACS) and/or undergoing coronary stenting as a part 
of a dual anti-platelet therapy
113, 115, 117, 119, 120
. P2Y12 antagonists include 1) 
thienopyridines: ticlopidine, clopidogrel and prasugrel, which bind irreversibly to the 
active site of the ADP receptor, and 2) non-thienopyridines: ticagrelor, cangrelor and 
elinogrel which interact reversibly with the ADP receptor, but without blocking the 
ADP binding site. Thienopyridines (Th) bind covalently to P2Y12 receptors by 
formation of disulfide bridges with the two extracellular Cys residues of the receptor 
(Cys17 and Cys270)
136, 179
. This interaction requires hepatic metabolism of the 
parental drugs to produce the active form which exhibits a critical reduced thiol group 
(Th-SH; Figure 4.1). 
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Figure 4.1. Chemical structures of ticlopidine, clopidogrel and prasugrel and their active 
metabolites. In red circles: critical thiol groups. Adapted from
180
 
 
Reduced thiols (RSH) on proteins are particularly susceptible to oxidation and 
form oxidized thiols (RSSH), which can induce important structural changes for many 
proteins and regulate their function. In the presence of NO
+
 or acidified nitrite (H
+
 
NO2
-
) RSH can be transformed into S-nitrosothiols (RSNO), which are key mediators 
in the NO signalling cascade
68
 (equation 1 below).  
 
RSH NO RSNO H                                                                                           (1) 
2 2Th SH H NO Th SNO H O
                                                                          (2) 
 
RSNO possess many of the biological activities of NO such as vasodilation, 
inhibition of platelet aggregation and regulation of cellular redox, apoptotic and 
inflammatory responses
31, 61-64
. RSNO also provide protection and storage of the NO
+
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group, which can be transferred to proteins such as plasma albumin (transnitrosation) 
and travel in the circulation to sites distal to that of their origin
67
. The in vivo 
mechanism of release of NO from RSNO is still a matter of debate
65
. Recent studies 
have shown that extracellular CysSNO can be uptaken by endothelial and smooth 
muscle cells via L-type amino acid transporters (LAT-1, 2)
181, 182
. Additionally, 
RSNO can also induce post-translational modifications of cysteine residues in 
proteins (S-nitrosation/S-nitrosylation) and therefore, contribute to the regulation of 
their function and signal transduction
66, 68, 69
. Many proteins have been identified to be 
S-nitrosated in pathophysiology of human and other mammals, including those 
affecting NO bioavailability and function (see I. General Introduction, pages 28-30).  
We initially hypothesized that thienopyridine tablets taken orally would form 
nitrosothiol derivatives (Th-SNO) only after conversion to the active form (containing 
free thiol) and in an environment where acidic conditions and nitrite could provide a 
theoretically suitable environment for the formation of RSNO species (equation 2 
above). The formation of Th-SNO would have the potential to participate in all the 
reactions expected of native NO including direct inhibition of platelet aggregation. As 
such, it could also contribute to the observed variation in potency of inhibition of 
platelet aggregation between the active metabolites of different thienopyridines. 
According to the biochemistry of RSNO, the amount of Th-SNO formed would 
depend on the concentration of respective Th-SH, the degree of stomach acidity and 
available nitrite for the reaction.  
Ticagrelor was not expected to form S-nitrosothiol derivatives because it does 
not form metabolites containing a reduced thiol moiety (Figure 4.2).  
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Figure 4.2. Chemical structure of ticagrelor and its active metabolite. Adapted from
183
  
 
It was decided to test our hypothesis in vitro using pharmaceutical grade 
tablets of thienopyridines and ticagrelor under optimum conditions expected for the 
formation of RSNO. –SNO species were measured mainly by ozone-based 
chemiluminescence and Cu
+
/Cys (2Cs) reagent and additionally by spectrophotometry 
and mass spectrometry. Where drug-SNO was formed, it was further examined for 
biological activity in terms of inhibition of platelet aggregation, vasorelaxation and 
transnitrosation. 
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2. Methods 
 
2.1 Drug preparation 
 
Ticlopidine (Ticlopidin-ratiopharm
TM
 Ratiopharm GmbH, Ulm, Germany) 
tablets containing 250 mg ticlopidine hydrochloride, clopidogrel (Plavix
 TM
 Bristol-
Myers Squibb, UK) tablets containing 75 mg clopidogrel hydrogen sulphate, 
prasugrel (Efient
 TM
 Daiichi Sankyo UK) tablets containing 10 mg prasugrel 
hydrochloride and ticagrelor (Brilique
TM
 AstraZeneca, London, UK) tablets 
containing 90 mg ticagrelor were used in these studies. Purified clopidogrel sulphate 
(LKT Laboratories, Inc) was supplied as 98.6 % pure.  
Crushed tablets or purified clopidogrel sulphate were dissolved in 
HPLC/double distilled water to yield a 10 mM suspension unless stated otherwise. 
Drug preparations were kept in dark and additionally double-filtered through a paper 
filter (#42) and a 0.22 µm filter for platelet aggregation studies. The content of 
reduced thiols (drug-SH) was determined using ThioStar™ Fluorescent Thiol 
Detection Reagent (see III. General Methods, page 97). 
 
2.2 Drug-SNO production 
 
Typically, 1 ml drug suspension was acidified with 1 M HCl, mixed with 1ml 
NaNO2 and incubated at 37 °C in the water bath for 10 min. The reaction was carried 
out in a glass brown bottle prior to neutralization with 1 M NaOH and immediate 
analysis by Cu
+
/Cys (2Cs) ozone based chemiluminescence (see III. General 
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Methods, page 88). Some drug-SNO preparations were also analysed by 
spectrophotometry (Jenway 6700) before and/or after addition of 8.9 mM HgCl2. 
 
2.3 Biochemical analysis 
 
Drug-SNO formation was tested in terms of its dependence on 1) pH, 2) NO2
-
 
(nitrite) concentration and 3) time of incubation with nitrite. pH range 2-7 was 
adjusted using appropriate addition of HCl and measured by narrow gauge pH paper 
(Fisherbrand™) confirmed by pH meter, with accuracy to the nearest 0.5/0.1, 
respectively. Initially, high concentrations of nitrite 1-1000 mM were used and then a 
lower, more physiological range (0.01-1 mM) was tested. In order to assess the 
influence of incubation time on the formation of drug-SNO, 10 mM drug suspensions 
were kept with 10.1 mM nitrite for 10-120 min.  
It should be mentioned that mass spectrometry of the purified clopidogrel 
sulphate preparation before and after addition of nitrite was also performed in 
collaboration with Dr Keith Morris in the University of Wales (UWIC) and these data 
are presented in the end of results section (pages 168-169).  
 
2.4 Biological analysis 
 
In order to analyse the biological function of chemically formed clop-SNO and 
pras-SNO, their ability 1) to influence platelet aggregation was investigated using 
light transmission aggregometry (LTA) and 2) to induce vasorelaxation was tested 
using isometric tension studies on isolated rabbit aortae. Furthermore, transnitrosation 
properties of clop-SNO to purified bovine serum albumin (BSA) and plasma protein 
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were analysed by a colleague (Narudeen Hassan) and these results are presented in the 
end of results section for reference (pages 167-168). Each biological assay was 
accompanied with 2 Cs analysis, which allowed the accurate assessment of RSNO 
concentration and its associated biological effect. These studies were conducted in 
collaboration with Dr Shantu Bhundoo (a close colleague within the research group 
conducting his MD) due to the need for immediate measurements conducted in 
parallel. Platelet aggregation measurements (LTA) and isometric tension studies were 
primarily conducted by Dr Bhundoo whereas I took primary responsibility for all 
biochemical analyses.  
Detailed methodology is presented in III. General Methods. Briefly, for the 
LTA assay, platelet rich plasma (prp) was isolated from healthy subjects and added to 
a 96-well plate previously loaded with ADP/PBS and Th/Th-SNO/nitrite/GSNO 
placed for 10 min in the spectrophotometer. The increase in transmittance over time 
was calculated relative to that of ADP-induced aggregation. GSNO reflected 100 % 
RSNO yield.  
In vessel-based studies, rabbit aortic rings were isolated and exercised as 
described before and pre-constricted with 1 µM PE prior to addition of  Th/Th-
SNO/nitrite. The maximal relaxation (Rmax) of Th-SNO was calculated as a 
percentage relative to PE-induced constriction. The relaxation of nitrite was 
determined over the same time and subtracted from Rmax of Th-SNO. In experiments 
with denuded vessels, the endothelium was carefully removed by gently rubbing the 
internal surface of the tissue ring with a wooden applicator before the experiment. 
Removal of endothelium was confirmed by the absence of a vasodilator response to 
Ach (10 μM) in pre-constricted vessels. In experiments, where ODQ (sGC inhibitor) 
was used, 10 μM ODQ was added to tissue baths for 0.5 h before pre-constricting 
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with PE. After thorough washing, aortic rings were pre-constricted again and relaxed 
with cumulative doses of GSNO (1 nM-10 μM) in order to 1) compare Rmax of drug-
SNO with standard nitrosothiol and 2) estimate the intra-assay coefficient of 
variability.  
 
2.5 Statistics and data analysis 
 
The results are expressed as mean±SD and “n” represents the number of 
independent experiments. Concentration-responses to inhibitors of platelet 
aggregation or GSNO were fitted by nonlinear regression curves (sigmoidal dose-
response) and the respective doses producing 50 % platelet inhibition (IC50) or 50 % 
vessel relaxation (EC50) were determined. 
Differences between 2 groups were analysed by 2-tailed student’s t-test 
(paired or unpaired where appropriate). For the comparison of more than two groups, 
one way ANOVA with Bonferroni post hoc test was applied where necessary. A p 
value of <0.05 was considered statistically significant.  
All analysis was performed using GraphPad Prism® (version 5).  
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3. Results 
 
3.1 Optimization of 2Cs method for detection of drug-SNO 
 
Cu
+
/Cys (2Cs) reagent allows for specific detection of RSNO species 
according to the chemistry presented earlier (see III. General Methods, page 88). 
Briefly, cleavage of NO from RSNO is catalysed by Cu
+
, and Cys is used for 
oxidation of Cu
2+
 back to Cu
+
. This reaction requires a neutral pH, therefore pH of 2 
Cs reagent was adjusted to pH=7.2 before use and pH of drug-SNO preparations was 
adjusted to pH>7.2.  
 
3.1.1 Modification of 2Cs reagent 
 
It was noticed that some peaks obtained from drug-SNO preparations had 
irregular shapes (Figure 4.3), different from uniform and defined NAC-SNO peaks 
observed from the standards (see III. General Methods, pages 88-90). It was suspected 
these differences could have been caused by the changing pH of 2Cs reagent in the 
course of study or day, and to solve this another 2Cs reagent was prepared in PBS to 
buffer these changes. 2Cs prepared in PBS provided more consistent signals from 
drug-SNO (Figure 4.4). It was therefore used in all further studies including 
preparation of the standard curves (Figure 4.5). 
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Figure 4.3. Drug-SNO signals detected using 2Cs reagent prepared in water. 
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Figure 4.4. Drug-SNO signals detected using 2Cs reagent prepared in PBS. 
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Figure 4.5. NAC-SNO signals detected using 2Cs reagent prepared in PBS (A) and used 
for preparation of standard curve (B).  
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3.1.2 Interaction of nitrite with 2Cs reagent 
 
The 2Cs reagent is utilized across many fields and is universally accepted as a 
means for specific cleavage of NO from SNO species, however, to the best of our 
knowledge it was never tested with high mM concentrations of nitrite. Such 
excessively high nitrite concentrations were introduced in this study in order to 
improve drug-SNO yield. We found that 2Cs is capable of detecting NO from nitrite 
under these conditions and that the acidic environment and 10 min incubation at 37 
°C utilized for the preparation of drug-SNO had an influence on the signal profile 
obtained (Figure 4.6). Therefore a stringent analysis was performed to ensure accurate 
RSNO reporting. The appropriate nitrite controls were performed on a daily basis and 
the respective AUC was subtracted from the total AUC generated by drug-SNO 
(Figure 4.7).  
 
 
 
 
 
Figure 4.6. Nitrite signals detected using 2Cs reagent. (A) 5 mM nitrite was incubated in 
pH=2.0 or pH=7.0 at 37 °C for 10 min prior to neutralization and measurement on NOA; (B) 
different concentrations of nitrite were incubated in pH=2.0 at 37 °C for 10 min prior to 
neutralization and measurement on NOA. 
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Figure 4.7. Typical signals detected from drug-SNO+nitrite and nitrite control. The 
absolute area of drug-SNO was calculated by subtracting the area generated by nitrite from 
the total area of the signal obtained from drug-SNO and unreacted nitrite.  
 
3.2 Biochemical properties of drug-SNO 
 
3.2.1 Properties of native drug preparations 
 
Knowing that formation of RSNO depends on low pH and amount of free thiol 
available for the reaction with nitrite, we measured pH and the content of reduced 
thiol groups in all of the native drug preparations (Table 11). An important 
observation was that the pH of the aqueous solutions of thienopyridine was acidic, 
even without addition of HCl, with clopidogrel being the most acidic (pH=2.0), 
followed by prasugrel (pH=4.0) and ticlopidine (pH=5.0). The pH of aqueous 
ticagrelor was 7.0. The content of reduced thiol (drug-SH) varied across the different 
drug preparations. Ticagrelor-SH (Ticag-SH) was the lowest exhibiting 33.4± 4.6 
nM/mM of ticagrelor. The respective Th-SH in ticlopidine, clopidogrel and prasugrel 
preparations were 66.7±1.8, 131.0±9.1 and 873.2±50.2 nM/mM of drug. 
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Drug pH of water  
solution 
Free thiol content            
(nM/mM of drug) 
Ticlopidine 5.0 66.7±1.8 
Clopidogrel 2.0 131.0±9.1 
Prasugrel 4.0 873.2±50.2 
Ticagrelor 7.0 33.4± 4.6 
 
Table 11. pH and reduced thiol content of drug preparations. n=3 for ticlopidine, 
clopidogrel and prasugrel and n=1 for ticagrelor. 
 
3.2.2 Detection of drug-SNO using NOA 
 
Firstly, aqueous preparations of native drug (without pH enforcement) were 
mixed with 1 mM nitrite and analysed using OBC and 2Cs reagent (Figure 4.8). 
Prasugrel-SNO (pras-SNO) or clopidogrel-SNO (clop-SNO) formed readily, resulting 
in distinctive NOA signals above that of the nitrite control. Neither ticlopidine nor 
ticagrelor formed the respective drug-SNO derivatives in these conditions.  
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Figure 4.8. Typical NOA signals showing formation of drug-SNO by prasugrel, 
clopidogrel, ticlopidine and ticagrelor in their basal pH. Only prasugrel-SNO and 
clopidogrel-SNO produced clear signals above the background nitrite. Nitrite signals are not 
shown for simplicity. 
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3.2.2.1 Comparison of clopidogrel tablet with purified clopidogrel 
 
Clopidogrel chemical was compared with clopidogrel tablet (Plavix) for 
potential to make clop-SNO. Both preparations generated clop-SNO but in a different 
manner and quantity (Figure 4.9). Clopidogrel chemical produced a sharp, intense 
peak whereas clopidogrel tablet resulted in a wide, low intensity peak. Furthermore, 
although equimolar concentrations of clopidogrel sulphate were used, clopidogrel 
tablet produced ~6 times more clop-SNO than clopidogrel chemical (as AUC were 
compared). None of the excipients of the thienopyridine tablets contained reduced 
thiol groups, which might have accounted for the detected RSNO species (see 
Shawmendra Bundhoo MD 2011). Although the reason for these discrepancies is not 
known, one can speculate that the tablet excipients, which are generally added to 
increase the absorption of the drug could have improved a poor drug solubility in 
water and thus increased the amount of clop-SNO. 
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Figure 4.9. NOA signals generated by a chemical and tablet clopidogrel-SNO. The 
equivalent of 5 mM clopidogrel sulphate and 1 mM nitrite were used.  
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3.2.2.2 Confirmation of clop-SNO formation by spectrophotometry 
 
RSNO exhibit UV and visual absorption maxima in the range 320-360 nm 
with additional peaks at around 545 nm and 510-520 nm
184
. Clopidogrel chemical or 
tablet (10mM) was mixed with 1 mM nitrite, incubated at 37 °C for 10 min and then 
filtered through a 0.22 µm filter. Absorption was determined at the native pH of 
clopidogrel solution in water, i.e. pH=2.0 (Figure 4.10) and after neutralization to 
pH>7.2 (Figure 4.11). Following this, samples at pH>7.2 were pretreated with 
mercuric chloride (8.9 mM HgCl2) to remove the NO
+
 group, thus confirming the 
presence of RSNO.  
At pH=2.0 clop-SNO and nitrite resulted in multiple peaks with no clear and 
distinctive peak in the 320-360 region. Sample neutralization resulted in a smoother 
absorption shoulder with the highest absorbance for tablet clop-SNO, followed by 
chemical clop-SNO and nitrite. However, at pH>7.2 the absorption of particular clop-
SNO preparations was not different from the respective parental clopidogrel solutions 
or after addition of mercuric ions. This suggests that spectrophotometry is not 
sensitive enough for detection of clopidogrel-SNO. 
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Figure 4.10. Spectrophotometric detection of clopidogrel-SNO in its basic pH=2. 
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Figure 4.11. Spectrophotometric detection of clopidogrel-SNO after neutralisation.  
 
 
3.2.3 Influence of pH on the formation of drug-SNO 
 
Drug-SNO formation was dependent on the pH of the native solution. All 
drugs generated SNO in an acidic medium provided that the pH was ≤ 4.0. Although 
ticlopidine and ticagrelor did not generate SNO when in its native solution at a 
respective pH of 5.0 and 7.0, drug-SNO synthesis was observed when the pH was 
forced lower through addition of HCl. Both ticlopidine and prasugrel SNO synthesis 
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was maximal at pH 3.0 whereas clopidogrel and ticagrelor SNO synthesis was 
maximal at pH 2.0 (Figure 4.12).  
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Figure 4.12. Typical pH dependence of drug-SNO formation. 
 
3.2.4 Influence of nitrite concentration on the formation of drug-SNO 
 
3.2.4.1 High nitrite concentration 
 
Clop-SNO and pras-SNO formation increased with increasing nitrite 
concentration 1-100 mM (Figure 4.13). The amount of pras-SNO was greater than 
clop-SNO reaching statistical significance at 50 mM nitrite (856.0±172.2 vs. 
458.5±48.4 µM, unpaired t-test, n=4, p=0.004) and at 100 mM nitrite (1413.0±215.5 
vs. 535.4±57.9 µM, unpaired t-test, n=4, p<0.001). Based on these data, the maximal 
pras-SNO formation was up to 1 % of the parent drug.  
 
 
                  
 
IV. RESULTS: Part 2  
-158- 
 
0 25 50 75 100
500
1000
1500
2000
Clopidogrel
Prasugrel
**
***
Nitrite (mM)
D
ru
g
-S
N
O
 (

M
)
1 2.5 5 10
0
50
100
150
200
Prasugrel
Clopidogrel
Nitrite (mM)
D
ru
g
-S
N
O
 (

M
)
Figure 4.13. Dependence of high nitrite concentration on the clop-SNO and pras-SNO 
formation. (A) 1-100 mM nitrite, contains the insert (graph B); (B) 1-10 mM nitrite. Drugs 
were used at their basal pH. Unpaired t-test, n=4, **p<0.01, ***p<0.001. 
 
In contrast to clop-SNO and pras-SNO, ticagrelor was first acidified to pH=2.0 
in order to generate ticag-SNO and then various nitrite concentrations 0.25-2.5 mM 
were added (Figure 4.14). The formation of ticag-SNO was subsequently higher with 
increasing nitrite concentrations. Additionally, in comparison to clop-SNO formation 
at similar conditions (2.5 mM nitrite, pH=2.0), ticagrelor generated more –SNO 
derivatives (ticag-SNO=127.1±15.4 µM vs. clop-SNO=15.7±10.6 µM, n=2). Based 
on these data, ticag-SNO formation was up to 3 % and clop-SNO was up to 0.5 % of 
parental drugs. 
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Figure 4.14. Dependence of high nitrite concentration on the ticagrelor-SNO formation. 
Ticagrelor was used at forced pH=2.0. n=2. 
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3.2.4.2 Physiological nitrite concentration 
 
Given that the nitrite concentrations in stomach are typically in the order of 
0.6 – 20 µM185, 186, the possibility of drug-SNO synthesis was also studied at 10-1000 
µM nitrite (Figure 4.15). When drug concentrations were adjusted according to the 
expected stomach concentrations after 1-tablet ingestion (ticagrelor 5.7 mM, 
clopidogrel 7.8 mM and prasugrel 0.9 mM) and pH of all drug preparations was fixed 
at pH=2.0, the formation of all drug-SNO derivatives was still apparent at lower 
levels of nitrite. 
 
1000 2000 3000
4
8
16
32
Smoothed data
NOA signal (mV)
10M 100M 1000M
Nitrite concentrations
Time (s)
S
ig
n
a
l 
(m
V
)
 
Figure 4.15. Representative clop-SNO signals generated by 10 mM clopidogrel and 10-
1000 µM nitrite. Because no nitrite signal at a concentration <200 µM could be detected by 
2Cs reagent, these raw traces represent only Th-SNO formation, confirming their synthesis at 
physiological nitrite concentrations. 
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3.2.5 Influence of incubation time on the formation of Th-SNO 
 
Stability of Th-SNO was tested by increasing the incubation time of 10 mM 
clopidogrel and prasugrel with 10.1 mM nitrite (Figure 4.16). Clop-SNO synthesis 
was maximal when mixed with nitrite for 10 min but declined thereafter (t½~66min). 
Pras-SNO formation was sustained over a period of 2 h. The relative proportion of 
Clop-SNO remaining after 2 h was significantly lower when compared to pras-SNO 
(14.0±2.3 % vs. 117.0±21.9 %, unpaired t-test, n=3, p=0.008). All solutions were 
neutralized prior to 2Cs analysis. 
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Figure 4.16. Proportion of formed Th-SNO remaining over time. 10 mM thienopyridine 
was mixed with 10.1 mM nitrite. Unpaired t-test, n=3, **p<0.01. 
 
3.3 Biological properties of Th-SNO 
 
Nitrosothiols have anti-platelet and vasodilatory properties primarily via 
donation of NO
+
 and activation of sGC/cGMP pathways in platelets and smooth 
muscle. These two properties were tested for clop-SNO and pras-SNO. In order to 
relate the amount of Th-SNO made with its biological effect, LTA and isometric 
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tension studies, NOA analysis was run in parallel on the same samples. GSNO was 
used as a standard nitrosothiol and a positive control. Nitrite and basal drug 
suspensions (without SNO) were used as negative controls. 
 
3.3.1 Inhibition of platelet aggregation 
 
Clop-SNO and pras-SNO significantly inhibited the ADP-induced platelet 
aggregation in comparison to their parental forms (Figure 4.17). 20 mM 
thienopyridine preparations mixed with 20 mM nitrite were used to obtain the 
maximal inhibition of platelet aggregation. Clop-SNO inhibited 38.6±19.9 % of 
platelet aggregation in controls (paired t-test, n=8, p<0.0001) while pras-SNO 
inhibited 32.3±15.2 % of platelet aggregation in controls (paired t-test, n=8, p=0.003). 
In turn, 10 µM GSNO resulted in 53.7±16.3 % inhibition.  
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Figure 4.17. ADP-induced platelet aggregation of clop-SNO, pras-SNO and GSNO. 
Paired t-test, n=8, **p<0.01, ***p<0.001. 
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To compare the effective inhibitory concentrations of Th-SNO and GSNO, 
and control for unreacted nitrite in Th-SNO mixture, concentration response curves 
were constructed using different concentrations of inhibitors (Figure 4.18). When 
normalized for the different SNO yields, clop-SNO and pras-SNO inhibited ADP-
induced aggregation equally and similarly to GSNO (pras-SNO IC50=7.9±2.1 µM vs. 
clop-SNO IC50=10.6±2.8 µM vs. GSNO IC50=9.8±4.6 µM, 1-way ANOVA, n=4, 
p=0.270), but were significantly different to that of nitrite alone (IC50=91.7±51.9 mM, 
1-way ANOVA, p=0.002). 
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Figure 4.18. Concentration response curves of ADP-induced platelet inhibition for pras-
SNO, clop-SNO, GSNO and nitrite. 
 
3.3.2 Vasodilation of rabbit aortae 
 
Pras-SNO and clop-SNO induced immediate relaxation of pre-constricted 
rabbit aortic rings and their relaxation profiles were different from the slow relaxation 
observed in the respective nitrite controls (Figure 4.19). The addition of the basal 
prasugrel and clopidogrel preparations followed by nitrite did not change nitrite-
induced relaxation of pre-constricted vessels (not shown), confirming that Th-SNO is 
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made only when the drug preparations are mixed with nitrite prior to addition to the 
tissue bath. 
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Figure 4.19. Relaxation profiles showing the difference between pras-SNO, clop-SNO 
and nitrite-induced responses of pre-constricted rabbit aortic rings.  
 
Pras-SNO and clop-SNO induced greater relaxation when higher nitrite 
concentrations were used for synthesis (Figure 4.20), although this reached statistical 
significance comparing 1 mM and 10 mM nitrite only (clop-SNO Rmax=11.3±5.7 % 
vs. 33.0±13.3 %, unpaired t-test, n=5, p=0.010 and pras-SNO Rmax=14.4±7.8 % vs. 
30.4±13.2 %, unpaired t-test, n=5, p=0.024). Clop-SNO and pras-SNO-induced 
vasodilation was not statistically different at any used concentration of nitrite. 
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Figure 4.20. Maximal relaxation (Rmax) of pre-constricted aortic rings induced by clop-
SNO and pras-SNO where Th-SNO yield was varied by increasing nitrite 
concentrations. Unpaired t-test, n=5, *p<0.05.  
 
To compare the potency of Th-SNO-induced relaxations with a standard 
nitrosothiol GSNO, aortic rings previously used for Th-SNO-induced responses were 
washed, pre-constricted and subjected to different concentrations of GSNO. When 
normalized for the different SNO yields, clop-SNO and pras-SNO-induced relaxation 
was similar and equivalent to ~40 % of GSNO-induced relaxation (Figure 4.21).  
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Figure 4.21. Potency of Th-SNO- and GSNO-induced relaxation of pre-constricted 
aortic rings when related to different RSNO content. 
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In order to understand this result, the extent of unreacted thienopyridine was 
considered. Taken into account that our Th-SNO synthesis resulted in ~1 % of Th-
SNO with respect to the parental drugs, the unreacted thienopyridines (including Th-
SH) had potential to recapture the relaxant NO
+
, leading to only partial relaxation. In 
order to test this hypothesis, a mixture of GSNO/GSH was used in a separate set of 
experiments. As the concentration of GSH was increased, the relaxation induced by 
the same dose of GSNO was proportionally reduced (Figure 4.22). A similar trend 
was observed for Th-SNO/Th, suggesting the competition between reduced thiols 
(RSH) in the buffer and sGC in the smooth muscle for released NO
+
.  
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Figure 4.22. Rmax of pre-constricted aortic rings induced by GSNO (A) and clop-SNO 
and pras-SNO (B) in relation to GSH/GSNO (A) and Th/Th-SNO (B) ratio.  
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In order to find the mechanism of the clop-SNO- and pras-SNO-induced 
vasodilation, the role of endothelium and the involvement of sGC-dependent 
pathways were investigated (Figure 4.23). Denuded vessels produced a similar 
relaxation to both Th-SNO in comparison to normal vessels (clop-SNO –EC 
Rmax=63.1±13.4 % vs. clop-SNO Rmax=52.2±14.8 % and pras-SNO –EC 
Rmax=54.6±4.4 % vs. pras-SNO Rmax=44.4±5.9 %, ANOVA, n=5, ns), suggesting 
primarily that endothelium-independent signalling was involved. In turn, Th-SNO-
induced relaxation in ODQ-treated vessels was significantly lower when compared 
with relative controls (clop-SNO +ODQ Rmax=7.9±13.1 % vs. clop-SNO and pras-
SNO +ODQ Rmax=2.8±1.1 % vs. pras-SNO, ANOVA, n=5, p<0.001), implying a 
crucial role for sGC. 
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Figure 4.23. Involvement of endothelium and sGC-dependent pathways in the relaxation 
induced by clop-SNO and pras-SNO. Relevant nitrite controls were performed. A 
stimulation with clopidogrel and prasugrel alone did not induce any relaxation. ANOVA, n=5, 
***p<0.001. 
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4. Additional data 
 
4.1  Interaction of Th-SNO with human plasma 
 
It was demonstrated by our group
187
 that the SNO moiety from clopidogrel-
SNO can be transferred to bovine serum albumin (BSA) or human plasma protein 
(primarily albumin) (Figure 4.24). This was clearly indicated by the transfer of SNO 
from later fractions of the G50 column (Clopidogrel-SNO) to early fractions 
(BSA/plasma) and confirmed by spectrophotometry and 2 C’s analysis. These results 
suggest that clop-SNO similarly to other RSNO species participate in transnitrosation 
reactions in biological systems.  
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Figure 4.24. Typical experiment showing transfer of SNO from clop-SNO (~fraction 14) 
to plasma albumin (~fraction 7; A) or to BSA (~fraction 7; B). 
 
4.2 Analysis of clopidogrel derivatives before and after addition of nitrite 
 
In order to identify the components present in an aqueous preparation of 
purified clopidogrel sulphate and again following addition of nitrite, MS analysis was 
carried out (Table 12)
110
. Native clopidogrel (identified at m/z 322) was in largest 
abundance, followed by minor contributions (0.01%) at each of m/z 356 (active 
metabolite) and m/z 308 (carboxy metabolite), and 0.05% at m/z 341 (carboxy 
metabolite with open S-H group). Following addition of nitrite, significant peak 
A 
B 
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increases were observed at m/z 192 and m/z 370 amounting to a relative abundance 
each of 0.5% of the native clopidogrel m/z 322 peak. 
Clopidogrel 
species 
Structure m/z Relative 
contribution                  
-nitrite (%) 
Relative 
contribution 
+nitrite (%) 
Native 
clopidogrel 
 
322 99.93 98.99 
Active 
metabolite 
 
356 Trace 0.01 None evident 
Active 
metabolite-
SNO 
 
384/ 
192 
None evident 0.5 
Carboxy 
metabolite 
 
308 Trace 0.01 None evident 
Carboxy 
metabolite 
(open thiol) 
 
341 Trace 0.05 Trace 0.01 
Carboxy 
metabolite-
SNO 
 
370 None evident 0.5 
 
Table 12. Structure, anticipated m/z, and relative abundance of clopidogrel species 
detected prior to and following addition of nitrite. Adapted
110
. 
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4.3 Comparison of different clopidogrel salts 
 
Pharmaceutical companies market clopidogrel tablets made from different 
salts of clopidogrel. This has significant cost implication. Although in this thesis only 
those containing clopidogrel sulphate (clop-S) were studied, our group also 
investigated the nitrosation properties of other clinically relevant preparations, 
containing clopidogrel besylate (clop-B) or clopidogrel hydrochloride (clop-Cl)
110
. 
All clopidogrel salts produced the corresponding SNO derivatives after mixing with 
nitrite but there was a significant variation between drugs in terms of SNO yield and 
the relaxation profile induced in pre-constricted aortic rings (see Shawmendra 
Bundhoo MD 2011). In particular, clop-Cl-SNO seemed to be considerably different 
than other clopidogrel salts. It had the smallest SNO yield (Figure 4.25) and produced 
the most transient relaxation when accounted for the difference in concentration of 
SNO. 
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Figure 4.25. Comparison of typical signals obtained from different clop-SNO salts using 
OBC (left) and their typical relaxation profiles of pre-constricted rabbit aortae (right). 
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5. Discussion 
 
Novel nitrosation properties of thienopyridines and ticagrelor were discovered in this 
study. The formation of in vitro synthesized SNO derivatives of drugs was dependent on the 
extent of free thiol, pH and nitrite concentration and was affected by the resulting stability of 
the SNO produced. Prasugrel exhibited the greatest SNO production, based largely on 
possessing more free thiol and stability of the resulting SNO over 2 h. Clopidogrel also 
readily formed SNO; despite having less free thiol in aqueous solution, the low pH of the 
clopidogrel solution may have favoured increased SNO formation. However, the resulting 
clop-SNO showed reduced stability (t½~66min) when compared to pras-SNO (stable for 240 
min). Ticlopidine and ticagrelor did not readily form SNO when in solution unless the pH was 
artificially reduced further to induce more favourable conditions for SNO synthesis. Increased 
doses of nitrite resulted in proportionate higher concentration of drug-SNO and reached a 
plateau at 10 mM dose probably due to saturation of available thiols. 
The biological effects of synthesized drug-SNO were similar to those expected from 
RSNO biochemistry and included inhibition of ADP-induced platelet aggregation, 
vasodilation of rabbit aortae and transnitrosation to albumin. Pras-SNO, clop-SNO and GSNO 
displayed the same capacity to inhibit platelet aggregation when related to the SNO content. 
Native forms of these thienopyridines were ineffective inhibitors of aggregation, whereas 
nitrite was a relatively poor inhibitor of platelet aggregation in agreement with previous 
studies. Pras-SNO and clop-SNO exhibited direct vasorelaxant properties, although only ~40 
% of the maximal GSNO-induced relaxation. The apparent reduction in effectiveness of NO
+
 
released from Th-SNO could be explained in terms of unreacted thienopyridine in the sample 
‘recapturing’ NO+ before it could reach the smooth muscle. The basal forms of 
thienopyridines did not exhibit any vasomodulatory actions while nitrite induced minor and 
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relatively slow vasodilation, which was deducted from the total Th-SNO-induced responses 
reported in this chapter. The nitrovasorelaxation of clop-SNO and pras-SNO was mediated 
via donation of NO
+
 and activation of classic sGC signal transduction independently of 
endothelium. Importantly, upon the interaction of clop-SNO with human plasma, a transfer of 
NO
+
 from clop-SNO to albumin was observed, confirming its important transnitrosation 
capacity. 
Significant differences were observed between the extent of free thiol detected in the 
thienopyridine/ticagrelor neutral solutions and the extent of drug-SNO formed (at acidic pH). 
For example, the data for ticagrelor shows only ~0.004 % free thiol of the parent drug at 
pH=7, whereas on addition of 2.5 mM nitrite at pH=2 up to ~ 3 % ticagrelor–SNO was 
synthesized. One possible explanation for these differences is an effect of acidic pH on nitrite 
and/or anti-platelet drugs’ molecules, which could govern the availability of drug-SH. The 
potential influence of low pH on the chemical structure of ticagrelor might be particularly 
important not only for the drug-SNO formation but also for the efficiency in the inhibition of 
platelet aggregation.  
The relevance of drug-SNO formation in humans is unknown. Certainly physiological 
conditions were provided in terms of using the relevant amount of commercially available 
tablets (1-10 mM in stomach) and adjusting for the appropriate pH corresponding to the 
stomach pH=1.5-3.5. Additionally, although most studies were conducted using exaggerated 
mM concentrations of nitrite, we were able to detect drug-SNO formation with 10 µM nitrite, 
which is in the range of 0.6-20 µM nitrite found in human stomach (Figure 2.26)185, 186. Direct 
measurement of drug-SNO in patient plasma would be ideal for the in vivo confirmation of 
drugs nitrosation but is unlikely due to possible absorption of SNO species by stomach and 
gastrointestinal tract and complex interactions of RSNO metabolism in the bloodstream. 
Furthermore the metabolism of thienopyridines in the liver might limit a detection of Th-SNO 
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to the enterohepatic circulation. In order to test whether hapatic metabolism has an effect on 
systemic levels of RSNO, SNO derivatives could be given intravenously. 
 
 
Figure 4.26. Simplified scheme of expected clop-SNO, pras-SNO and ticag-SNO formation in 
human stomach after ingestion of 1 tablet of clopidogrel, prasugrel and ticagrelor, respectively. 
The amount of SNO derivatives reaching the bloodstream is unknown and can be limited by tissue 
absorption, hepatic metabolism and transnitrosation reactions. 
 
An interesting consideration, which was not taken into account in this study is the 
influence of disintegration time of tablets in stomach and/or gastrointestinal tract and the 
coating of tablets on the final drug-SNO formation. The tablet coating may partially protect 
P2Y12 antagonists from the influence of stomach acid and subsequent generation of SNO 
derivatives. However, this could potentially be a limiting factor only for ticlopidine- and 
ticagrelor-SNO formation because aqueous clopidogrel and prasugrel readily formed RSNO 
in their normal acidic pH. 
The in vivo formation of RSNO associated with anti-platelet therapy would be 
beneficial for patients suffering from endothelial dysfunction and reduced NO bioavailability. 
Transnitrosation between nitrosothiols and proteins prolongs the biological half life of NO via 
formation of dinitrosothiol iron complexes
188
, which can be transported by circulation and 
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release NO on demand. Released NO may inhibit activation and aggregation of platelets or 
induce local vasodilation where endogenous NO production is impaired. It is important to say 
that because SNO (direct from thienopyridine or other sources) is unlikely to be released 
immediately and other counterregulatory physiological mechanisms can also be activated
65, 66
, 
there is no risk of hypotensive effects. In support, clopidogrel therapy has never been 
associated with changes in systemic blood pressure.  
The effectiveness of P2Y12 antagonists in patients has largely been considered in terms 
of variation in patient metabolism and activation of the drug to its active form, yet the 
potential for direct drug-SNO formation could be important. It has been shown that the co-
administration of some proton pump inhibitors to patients (such as omeprazole) reduce 
thienopyridine efficacy on platelet function
189, 190
, a finding that to date has been attributed to 
competition for CYP450 metabolism
191, 192
 but could clearly influence SNO formation by 
neutralising stomach pH. Remarkably, the extent of active thienopyridine found at peak in 
human plasma following oral loading is ~0.01 % of the inactive drug present at the same 
time
135
, yet this is sufficient to produce irreversible clinically relevant inhibition of platelet 
activation. Based on the data we have shown, ~1 % of the parent drug can potentially be 
nitrosated, which could amount to significant levels systemically. As such, drug-SNO may 
not be detrimental in targeting P2Y12 receptors, but could provide beneficial effects through 
parallel delivery of NO to platelets and blood vessels.  
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Summary: 
 
 Novel nitrosation properties of thienopyridines were discovered without the need for 
prior metabolism to their active form. Unexpectedly, ticagrelor also formed SNO 
derivatives provided pH<4. 
 
 The formation of newly synthesized drug-SNO species was dependent on the extent of 
free thiol, pH and nitrite concentration. 
 
 The biological effects of SNO derivatives of drugs were similar to those expected 
from classical RSNO biochemistry and included inhibition of ADP-induced platelet 
aggregation, vasodilation of rabbit aortae and transnitrosation to albumin. 
 
 Tablets containing different salts of clopidogrel have varying potential to make SNO 
species and have different profiles of drug-SNO-induced vasorelaxation. 
 
 Future work could look at the effect of SNO derivatives on different platelet agonists 
(e.g. thrombin). 
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Part 3: Influence of clopidogrel therapy on NO production, metabolism and 
bioavailability in coronary artery disease (CAD) patients 
 
Hypothesis: Clopidogrel increases NO bioavailability in blood in CAD patients. 
 
Specific aims of this chapter were: 
 
 To determine whether a single loading or maintenance dose of clopidogrel influences 
levels of NO metabolites (nitrite, nitrate and RSNO), cGMP and oxidative and 
nitrosative stress markers in plasma.  
 To investigate the relationship between vascular, oxidative and platelet-derived effects 
of clopidogrel on NO bioavailability in patients. 
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1. Introduction 
 
Dysfunction of the endothelium is an early event in many if not all cardiovascular 
disease (CVD), including coronary artery disease (CAD)
5, 17, 25, 30
. A hallmark feature of 
endothelial dysfunction is deficiency in endothelial production of NO due to augmented 
oxidative stress
25, 193. The reduced ‘NO bioavailability’ promotes abnormal vascular 
reactivity, inflammation and thrombosis leading to progression of disease and increased risk 
of cardiovascular events
30
 (see I. General Introduction, pages 15-18). Clopidogrel treatment in 
CAD patients has been associated with increased FBF/FMD
157, 169, 170
 whether administered 
pre or post percutaneous coronary intervention (PCI). Although, FMD is a technique which 
provides an index of NO-mediated vasodilation and is, therefore commonly used as a clinical 
marker of in vivo NO bioavailability, some evidence suggest it may not solely be related to 
NO
194
. 
The metabolism of NO in the human body is multi-factorial and it depends on 
diffusion rate, redox status and metal complexes within the vascular tissue and different 
compartments of blood (see Andrew Pinder PhD 2009). Different NO derivatives/metabolites 
such as nitrite
195, 196
, S-nitrosothiols and S-nitrosoproteins (RSNO)
67, 197
 and potentially 
nitrate
198
 and nitrated lipids
199
 participate in regulation of NO bioavailability in the 
circulation. The focus of this study was to assess the effect of clopidogrel therapy on the level 
and apportion of these NO metabolites in patients.  
Endothelial nitric oxide synthase (eNOS) is the main source of NO in the 
vasculature
200
 and its activity is considered directly proportional to the concentration of 
plasma nitrite, suggesting nitrite may reflect cardiovascular NO bioavailability
201, 202
. It was 
reported that 70 %  of resting plasma nitrite is derived from eNOS activity in humans and 
other mammals
201
. Additionally plasma nitrite can be affected by diet and oxidative stress 
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limiting the amount of NO (see I. General Introduction, pages 15-18 and 25-27). In contrast, 
plasma nitrate levels are influenced by many eNOS-independent factors such as dietary nitrate 
ingestion and liver and kidney function
203, 204
. Importantly, NO metabolites including nitrite, 
nitrate and RSNO are now considered not only as a direct measure of a physiological activity 
of NO but also as a biologically active NO reservoir. Nitrite can regulate vascular tone and 
provide NO-mediated vascular protection under conditions of low oxygen
196
. Dietary nitrate 
can be reduced to nitrite by bacteria having nitrate reductase enzymes and residing in human 
saliva
56, 198
. Whether basal level of nitrate in human plasma is also bioconverted remains yet 
to be established. Another NO metabolite, RSNOs, possess very unique and versatile 
mechanisms of action. Apart from storage and release of NO on demand, it mediates S-
nitosylation and transnitrosation of proteins, which influence downstream effects of NO 
signalling
68
. RSNO is less stable and occurs in human plasma in much lower quantities than 
nitrite (~10x less) or nitrate (~2000x less), making an accurate measurement of RSNO more 
challenging and often neglected. However, considering the novel nitrosation properties of pro-
drug clopidogrel already identified in vitro (see IV. Results, pages 140-172), the enhanced 
formation of RSNO in patients receiving clopidogrel and the relevance to cardiovascular 
function was an exciting prospect worthy of investigating. 
Platelets also produce NO, although in smaller amounts than endothelial cells
205, 206
. In 
addition, while endothelial-derived NO is known to work in a paracrine manner, i.e. diffuses 
to adjacent cells, platelet-derived NO is thought to exert its major effect within the cell it was 
produced, i.e. in an autocrine manner
205
. NO released by platelets has been recently shown to 
inhibit recruitment of platelets and leukocytes to the growing thrombus, where cells are in 
close proximity to each other
207, 208
. However the role of platelet-derived NO in regulating 
primary platelet aggregation remains controversial. 
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Clopidogrel therapy has been shown to reduce different pro-inflammatory markers in 
patients with stable CAD, ACS and/or undergoing coronary stenting
156, 157, 160-162, 209, 210
. 
Relatively little attention has been given to the influence of drug on oxidative stress, which is 
directly applicable to NO biovailability. Taking into account an inhibitory effect of pro-drug 
clopidogrel on vascular production of superoxide found in rabbit aortae (see IV. Results, 
pages 130-131), it was decided to explore possible anti-oxidant actions of clopidogrel in CAD 
patients.  
Administering a loading dose of 600 mg clopidogrel to patients undergoing coronary 
stenting
128
 is recognised as a standard clinical practice and the maximal inhibition of platelet 
aggregation occurs within 1-2 h after ingestion. A maintenance 75 mg dose of clopidogrel is 
recommended for all ACS patients
211-213
. Most of the recognised beneficial effects of 
clopidogrel have been studied in patients receiving clopidogrel chronically (for 
days/weeks/months). Therefore, aside from recruitment of CAD patients receiving chronic 
treatment with clopidogrel (at least 3 days), it was decided to investigate acute changes 
occurring within hours following a loading dose to clopidogrel naïve patients. 
Previous in vitro studies from the first two results' chapters of this thesis were 
designed to study alternative and unknown effects of pro-drug clopidogrel on NO signalling. 
In order to relate our findings to a physiological/pathophysiological situation in patients, 
where clopidogrel is mainly used as a specific platelet P2Y12 antagonist, the present 
investigation was conducted on CAD patients. The main goal was to investigate the effect of 
clopidogrel therapy on the level of circulating NO metabolites, particularly nitrite, nitrate and 
RSNO in addition to relevant selected markers of oxidative and nitrosative stress. The 
measurement of plasma cGMP was used as an index of vascular NO activity and in attempt to 
distinguish between vascular and platelet related effects, markers of platelet and endothelial 
activity were compared. 
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2. Methods 
 
These patient studies were conducted in collaboration with Dr Shantu Bhundoo, a 
close colleague within the research group conducting his MD. Dr Bhundoo was specifically 
responsible for patient recruitment, consent and blood sampling. Due to the need for 
immediate measurements in parallel and the overall workload, platelet aggregation 
measurements (LTA) were primarily conducted by Dr Bhundoo whereas I took primary 
responsibility for biochemical analyses. The Results presented are those carried out by me 
other than where presented for comparison or background (and clearly stated otherwise). 
 
2.1 Recruitment of patients and collection of blood samples 
 
A prospective, single centre study was undertaken. A total of 58 patients undergoing 
PCI with stent implantation for stable angina or silent ischemia were enrolled after informed 
consent was obtained. The protocol was approved by the local ethics committee, and was in 
accordance with the declaration of Helsinki.  
The first group of patients studied (36 subjects) were clopidogrel naive patients, who 
received 600 mg loading of clopidogrel. Blood samples were collected pre and 2 h post-
loading with clopidogrel, through an intravenous cannula into vacutainers containing 
K3EDTA or 3.2 % trisodium citrate (Vacuette Greiner Bio-One™). The platelet poor plasma 
(ppp) was isolated from K3EDTA bottles by centrifugation immediately after collection (1500 
g, 10 min, 4 °C), then snap frozen in liquid nitrogen and stored at -80 °C. Each sample was 
aliquoted into several tubes to avoid repeated freeze-thaw cycles. The ppp was used for 
measurement of NO metabolites, sP-selectin, cGMP and oxidative markers. The platelet rich 
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plasma (prp) was isolated from trisodium citrate bottles by centrifugation (100 g, 10 min, 25 
°C) and used fresh for light transmission aggregometry (LTA) studies.  
The second group of patients studied (22 subjects) were already on 75 mg clopidogrel 
maintenance dose for ≥3 days. Blood samples were collected and processed as in first group 
of patients. 
It should be mentioned that initially it was calculated 22 people were to be recruited to 
the first and second group on the basis of power calculations (90%) for plasma nitrite levels in 
12 patients pre and 2 h post-loading with clopidogrel (pilot study). However, standard 
deviation was higher in 22 subjects (40-50 %) than in 12 subjects (10-20 %) which influenced 
the power of the study (70 %). Therefore the power calculation was reassesed and an 
additional 14 patients were recruited to the first group.  
Demographics and cardiovascular disease profiles of the CAD patients recruited are 
outlined below in Table 13. Specific recruitment criteria are presented in the results section 
(page 184). 
 
 Clopidogrel Naive         
(N = 36) 
Clopidogrel for ≥3 days            
(N = 22) 
Age 61.8 58.1 
Male (%) 85.7 73.7 
BMI 29.5 27.1 
Hypertension (%) 79.4 57.9 
Treated  
hyperlipidaemia (%) 
91.2 84.2 
Current smoker (%) 14.7 26.3 
Diabetes (%) 20.5 0.0 
Family History (%) 61.8 57.9 
 
Table 13. Demographics and cardiovascular disease profiles of the CAD patients recruited. 
Unpaired t-test was used to compare groups.  
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2.2 Assay techniques 
 
Platelet aggregation was measured using LTA assay before and after loading with 
ADP and TRAP. Platelet activity was assessed on the basis of soluble P-selectin (sP-selectin) 
concentration. NO metabolites were determined using ozone-based chemiluminescence 
(OBC). sP-selectin and cGMP were measured using commercially available ELISA kits. 
Oxidative stress in plasma was assessed by total anti-oxidant capacity (TAC) assay, 3-
Nitrotyrosine (3-NT) measurement by ELISA and reduced thiols measurement using a 
specific fluorescent probe.  
Individual methods are described in more detail in II Methods. 
 
2.3 Statistical analysis 
 
Results are expressed as mean±SD and ‘n’ represents the number of assayed plasma 
samples of individuals. ‘n’ varies between assays within the same group of patients due to 
different amounts of frozen aliquots saved for analysis.  
Differences between samples pre and post clopidogrel loading were analysed using 
paired 2-tailed student’s t-test. Differences between samples pre clopidogrel loading and 
chronic treatment with clopidogrel were analysed by 1-sample t-test where the former was 
used as a hypothesised mean. A normal distribution between group differences was assumed 
on the basis of the interval data type and similar data size. 
The association between variables was determined using Pearson’s correlation 
coefficients. All analysis was performed using GraphPad® (version 5 or 6) software and 
p<0.05 was considered statistically significant. 
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3. Results 
 
3.1 Patient recruitment criteria 
 
Exclusion criteria were a crucial part of this patient study and were applied to all 
subjects (Table 14). Because the aim was to investigate both the short (“acute”) and long-term 
(“chronic”) effects of clopidogrel, patients attending for PCI and scheduled to receive a 
loading dose or currently receiving the maintenance dose of clopidogrel were engaged, 
respectively. Knowing, though, from previous biochemical analysis that different clopidogrel 
salts have varying potential to make RSNO (see IV. Results, pages 170-171), only those 
taking clopidogrel hydrogen sulphate (Plavix™) were included.  
Major exclusion criteria were factors known to influence the amount of circulating NO 
metabolites, e.g. diet and organic nitrate therapy. Since we planned to measure the effect of 
clopidogrel on plasma levels of nitrite and nitrate, subjects were fasted for at least 6 h before 
the blood was taken and they were not taking any organic nitrates (e.g. GTN). Additionally, 
because drugs changing the stomach pH were anticipated to influence the potential in vivo 
production of RSNO, people receiving proton pump inhibitors or anti-histamines were 
excluded.  
Another relevant issue was co-administration of drugs, which inhibit the activity and 
aggregation of platelets apart from clopidogrel. Thus, all patients on alternative anti-coagulant 
or anti-thrombin therapy were excluded. This involved patients receiving non-steroidal anti-
inflammatory drugs (NSAIDs) in previous 7 days, as these have also been shown to affect 
platelet function
214
.  
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Care was also taken to exclude people with ACS who have higher basal platelet 
activation than patients with stable disease
215
, which could, in turn, interfere with the 
measurement of platelet inhibition by clopidogrel.   
Finally, an important inclusion criterion was angiographically confirmed obstructive 
CAD. It is well documented that subjects with CAD suffer from endothelial dysfunction and 
reduced NO bioavailability. Thus, a positive impact of clopidogrel on vascular NO production 
and oxidative stress could be of considerable potential benefit. 
All recruited patients were receiving a standard dose of aspirin (75 mg daily) as part of 
routine primary treatment for cardiovascular diseases. 
 
Condition  Inclusion  Cause  
Receiving or about to receive clopidogrel 
hydrogen sulphate  (Plavix™)  
Yes  
Other clopidogrel salts have different 
nitrosation properties  
Fasted for ≥6h  Yes  
Influence of diet on levels of NO 
metabolites  
Receiving organic nitrates  No  Influence on levels of NO metabolites  
Receiving proton pump inhibitiors  No  
Increase in stomach pH and influence 
on levels of RSNO  
Receiving anti-histamines  No  
Increase in stomach pH and influence 
on levels of RSNO  
Receiving anti-coagulants  No  Influence on platelet inhibition  
Receiving anti-thrombin therapy  No  Influence on platelet inhibition  
Receiving non steroidal anti inflammatory drugs 
(NSAIDs)  in previous 7 days  
No  Influence on platelet inhibition  
Acute coronary syndromes (ACS)  No  High basal platelet activity  
Obstructive coronary artery disease (CAD)  Yes  Endothelial dysfunction  
Receiving aspirin (75 mg/day)  Yes  Standard treatment  
 
Table 14. Patient recruitment criteria on the basis of published data and previous results. 
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3.2 Confirmation of pharmacological actions of clopidogrel 
 
In order to investigate the influence of clopidogrel therapy on NO bioavailability in 
CAD patients, we wanted to confirm in parallel its principal pharmacological target and 
effectiveness on platelets. Thus, we initially determined the effect of clopidogrel on ADP-
induced aggregation in prp and the content of sP-selectin in ppp. 
 
3.2.1 Inhibition of platelet aggregation  
 
After 2 h-intake of a loading dose of clopidogrel, the ADP-induced aggregation was 
significantly inhibited by 49.6±31.9 % (pre-clopidogrel ΔTransmittance = 6.8±1.5 vs. post-
clopidogrel ΔTransmittance = 3.4±2.3, paired t-test, n=8, p=0.006; Figure 5.1). Clopidogrel 
also inhibited significantly the thrombin-induced aggregation by 59.0+/-32.8 % (pre-
clopidogrel ΔTransmittance = 6.9±3.3 vs. post-clopidogrel ΔTransmittance = 3.0±2.6, paired 
t-test, n=8, p=0.010), suggesting an influence of P2Y12 blockage on thrombin-mediated 
aggregation. The platelet aggregation study was carried out on a randomised sample n=8 from 
the total cohort of 36 patients. 
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Figure 5.1. Inhibition of ADP- and TRAP-induced platelet aggregation by a loading dose of 
clopidogrel. (A, B) ΔTransmittance assessed by LTA; (C) % change (0-2h) of platelet inhibition.  
Paired student’s t-test, n=8, **p<0.01. 
 
3.2.2 Influence on the level of soluble P-selectin in plasma 
 
Clopidogrel administered acutely reduced significantly levels of sP-selectin in ppp 
from 29.6±10.0 ng/ml to 26.7±8.2 ng/ml after 2 h of a single loading dose of clopidogrel 
(paired t-test, n=19, p=0.031; Figure 5.2). Levels of sP-selectin were not changed following at 
least 3 days of treatment (28.6±8.8 ng/ml (one sample t-test, n=14, p=0.688)). 
 
A B 
C 
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Figure 5.2. Plasma levels of sP-selectin in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=19, *p<0.05; (B) one sample t-test, n=14 (≥3 days), p>0.05. 
 
 
3.3 Influence of clopidogrel on NO metabolites 
 
In order to determine the influence of acute and chronic therapy with clopidogrel on 
the vascular production of NO, the primary NO metabolites (namely nitrite, nitrate and 
RSNO) were measured in ppp. 
 
3.3.1 Plasma nitrite 
 
Clopidogrel significantly upregulated levels of nitrite (Figure 5.3). After 2 h treatment, 
plasma nitrite increased from 160.0±78.9 nM to 202.6±84.7 nM (paired t-test, n=36, 
p=0.015). In ≥3 days of treatement, nitrite levels were 254.3±139.4 nM (one sample t-test, 
n=22, p=0.005). Elevated amounts of plasma nitrite in ppp suggests the augmented 
endothelial production of NO or NO from another source in these patients. 
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Figure 5.3. Plasma levels of nitrite in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=36, *p<0.05; (B) one sample t-test, n=22 (≥3 days), **p<0.01. 
 
3.3.2 Plasma nitrate  
 
The increase in nitrite following initiation of clopidogrel treatment was not associated 
with increased levels of nitrate (Figure 5.4). In the acute setting, plasma nitrate declined 
significantly from 30.2±11.5 µM to 28.6±11.0 µM (paired t-test, n=36, p=0.025). After at 
least 3 days of treatment nitrate was 29.9±13.5 µM and unchanged from controls (one sample 
t-test, n=22, p=0.938).  
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Figure 5.4. Plasma levels of nitrate in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=36, *p<0.05; (B) one sample t-test, n=22 (≥3 days), p>0.05. 
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3.3.3 Plasma RSNO 
 
On the basis of our previous results showing the potential for clopidogrel to make 
biologically active clopidogrel-SNO in vitro (see IV. Results, pages 140-172), we 
hypothesized that circulating levels of RSNO would increase following clopidogrel intake. 
However, RSNO levels remained unchanged after 2 h treatment with clopidogrel, (15.5±8.7 
nM versus 14.1±5.4 nM (paired t-test, n=36, p=0.401)) and after at least 3-day treatment 
(14.2±9.2 nM (one sample t-test, n=22, p=0.504; Figure 5.5)). 
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Figure 5.5. Plasma levels of RSNO in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=36, p>0.05; one sample t-test, n=22 (≥3 days), p>0.05. 
 
3.4 Plasma cGMP  
 
Having shown the increase in plasma nitrite following clopidogrel, cGMP was also 
measured, as a marker of vascular NO activity. The level of cGMP in ppp was significantly 
upregulated (Figure 5.6). After 2 h treatment with clopidogrel, plasma cGMP increased from 
215.2±127.0 pmol/ml to 234.6±109.0 pmol/ml (paired t-test, n=24, p=0.039) and was 
281.7±70.8 pmol/ml after at least 3-day treatment (one sample t-test, n=19, p<0.001). 
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Figure 5.6. Plasma levels of cGMP in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of maintenance therapy (≥3 days). (A) 
Paired t-test, n=24, *p<0.05; (B) one sample t-test, n=19 (≥3 days), ***p<0.001. 
 
3.5 Anti-oxidant actions of clopidogrel 
 
Following on from our vascular experiments using rabbit aortae where we established 
an inhibitory effect of clopidogrel on vascular superoxide production (see IV. Results, pages 
130-131), we also investigated whether a similar effect might be borne out in clopidogrel-
treated CAD patients. 
 
3.5.1 Direct anti-oxidant properties of clopidogrel 
 
TAC assay did not reveal direct anti-oxidant properties of clopidogrel (Figure 5.7-8). 
While AAPH-induced loss in fluorescence was inhibited by common direct anti-oxidants such 
as trolox and tempol in a dose-dependent manner, clopidogrel did not provide similar 
protection.  
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Figure 5.7. Fluorescent decay curves of fluorescein induced by AAPH in the presence of trolox, 
tempol and clopidogrel at different concentrations.  
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Figure 5.8. Linear plot of the net AUC vs. concentration of trolox, tempol and clopidogrel. 
 
3.5.2 Influence of clopidogrel on the anti-oxidant status of plasma 
 
Total anti-oxidant capacity (TAC) of ppp increased significantly from 60.7±11.5 
%Tempol to 64.2±10.6 %Tempol after a single loading dose (paired t-test, n=25, p=0.037; 
Figure 5.9) and was not changed after a maintenance dose of clopidogrel: 62.1±4.2 %Tempol 
(one sample t-test, n=20, p=0.148). Results from TAC assay suggest that although clopidogrel 
is not an anti-oxidant itself, it was associated with an acute upregulation of the anti-oxidant 
defense mechanisms in plasma. 
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Figure 5.9. TAC of plasma from CAD patients (A) before (0h) and after (2h) receiving a loading 
dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) Paired t-
test, n=25, *p<0.05; (B) one sample t-test, n=20 (≥3 days), p>0.05. 
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3.5.3 Influence of clopidogrel on nitrosative stress 
 
Taking into account that clopidogrel therapy was associated with higher amount of 
circulating nitrite and increased anti-oxidant capacity, the effect on nitrosative stress was also 
investigated. 3-NT was measured in ppp as a marker of nitrosative stress (Figure 5.10). 3-NT 
was not significantly changed after a single loading dose (from 249.0±380.7 nM to 
331.1±564.6 nM, paired t-test, n=12, p=0.278) or after a maintenence dose of clopidogrel 
(465.4±628.6 nM, one sample t-test, n=12, p=0.363). It is acknowledged however, this result 
was not confirmatory; there was high variation (0-1842 nM) between levels detected and 
some of them (n=8) could not be measured (see III. General Methods, page 94).  
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Figure 5.10. Plasma levels of 3-NT in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=12, p>0.05; (B) one sample t-test, n=12 (≥3 days), p>0.05. 
 
3.5.4 Influence of clopidogrel on the level of reduced thiols 
 
The dynamic relationship between reduced (RSH) and oxidised (RSSR) redox state of 
proteins is regulated by reactive oxygen/nitrogen species (ROS/RNS) and correlates with the 
extent of various measures of oxidative stress
216, 217
. Hence, the amount of reduced thiols 
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present in plasma should reflect, in the most part, the global level of oxidative stress. In the 
short-term, levels of RSH did not change in comparison to control (364.6±34.2 µM vs. 
355.2±29.5 µM; paired t-test, n=20, p=0.138) and in ≥3 days of treatment they reached 
significantly higher concentration: 389.7±25.1 µM (one sample t-test, n=14, p<0.001; Figure 
5.11). 
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Figure 5.11. Plasma levels of RSH in CAD patients (A) before (0h) and after (2h) receiving a 
loading dose of clopidogrel and (B) after at least 3 days of a maintenance therapy (≥3 days). (A) 
Paired t-test, n=20, p>0.05; one sample t-test, n=14 (≥3 days), ***p<0.001. 
 
3.6 Inter-relation between the various parameters measured 
 
In an attempt to investigate potential relationships between vascular, oxidative and 
platelet-derived effects of clopidogrel on NO bioavailability, correlation analysis was 
performed for all measured parameters in plasma. 
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3.6.1 Relationship between different parameters in all groups of patients 
 
Raw readings of all parameters from all patients (before, 2 h after receiving a loading 
dose of clopidogrel, as well as those on the maintenance dose) were compared (Table 15). 
This analysis was to provide the overall relationship between different parameters regardless 
the presence of clopidogrel. 
 
 
sP-
selectin 
nitrite nitrate RSNO cGMP TAC RSH 
sP-
selectin  
       
nitrite  
r=0.07  
n=48 
p=0.620 
      
nitrate  
r=0.41  
n=48 
p=0.004 
r=-0.04  
n=67 
p=0.765 
     
RSNO  
r=0.08  
n=48 
p=0.590 
r=-0.13  
n=67 
p=0.297 
r=0.03  
n=67 
p=0.836 
    
cGMP  
r=0.05  
n=48 
p=0.753 
r=0.35  
n=67 
p=0.004 
r=-0.11  
n=67 
p=0.361 
r=0.08  
n=67 
p=0.533 
   
TAC  
r=0.08  
n=48 
p=0.609 
r=-0.27  
n=67 
p=0.028 
r=0.22  
n=67 
p=0.078 
r=-0.07  
n=67 
p=0.565 
r=-0.53  
n=67 
p<0.0001 
  
RSH  
r=0.03  
n=50 
p=0.820 
r=0.37  
n=48 
p=0.011 
r=0.04  
n=48 
p=0.778 
r=-0.07  
n=48 
p=0.640 
r=0.43  
n=48 
p=0.002 
r=-0.24  
n=48 
p=0.098 
  
 
Table 15. Summary of the results of Pearson’s correlations between parameters in all groups of 
patients. The Pearson’s correlation coefficient (r), number of correlated samples (n) and the 
significance of  correlation (p) have been reported. In red: significant correlations (p<0.05). 
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Nitrite and cGMP correlated with each other but did not correlate with sP-selectin 
(Figure 5.12). On the other hand, nitrite and cGMP correlated positively with RSH and 
negatively with TAC (Figure 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Pearson’s correlations between nitrite, cGMP and sP-selectin in all groups of 
patients.
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Figure 5.13. Pearson’s correlations between nitrite, cGMP and RSH and TAC in all groups of 
patients.
 
 
3.6.2 Relationship between changes in different parameters following a single 
loading dose of clopidogrel 
 
In order to relate changes in one parameter to another caused by the administration of 
clopidogrel, differences between clopidogrel naïve and the respective 2 h-post clopidogrel 
levels were compared (Table 16). This analysis was only performed within the group of 
patients receiving a loading dose of clopidogrel on the day of the study. 
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 ΔsP-selectin Δnitrite Δnitrate ΔRSNO ΔcGMP ΔTAC ΔRSH 
ΔsP-
selectin  
       
Δnitrite  
r=-0.50  
n=18 
p=0.034  
      
Δnitrate  
r=-0.53 
n=18 
p=0.022 
r=0.32  
n=24 
p=0.134 
     
ΔRSNO  
r=-0.46 
n=18  
p=0.054 
r=0.15 
n=24 
p=0.478 
r=0.42 
n=24 
p=0.042 
    
ΔcGMP  
r=-0.01  
n=18 
p=0.965 
r=0.33  
n=24 
p=0.115 
r=0.20  
n=24 
p=0.361 
r=-0.04  
n=24 
p=0.841 
   
ΔTAC  
r=0.12 
n=18 
p=0.650 
r=-0.62 
n=24 
p=0.001 
r=-0.32  
n=24 
p=0.123 
r=0.07  
n=24 
p=0.730 
r=-0.16 
n=24 
p=0.448 
  
ΔRSH  
r=0.27  
n=18 
p=0.276 
r=0.06  
n=18 
p=0.807 
r=0.16 
n=18 
p=0.534 
r=-0.08  
n=18 
p=0.756 
r=-0.13 
n=18 
p=0.593 
r=-0.16 
n=18 
p=0.523 
  
 
Table 16. Summary of the results of Pearson’s correlations between changes in parameters (Δ) 
after a loading dose of clopidogrel. The Pearson’s correlation coefficient (r), number of correlated 
samples (n) and the significance of correlation (p) have been reported. In red: significant correlations 
(p<0.05). 
 
The influence of clopidogrel on sP-selectin correlated significantly with changes in 
nitrite, nitrate and RSNO. Two extreme values of sP-selectin were identified (indicated by # 
on Figure 5.14) but were not significant outliers according to Grubbs' test, also called the 
(extreme studentized deviate) ESD method (p>0.05). 
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Figure 5.14. Pearson’s correlations of changes in sP-selectin with nitrite, nitrate and RSNO after 
a loading dose of clopidogrel. # extereme values but not significant outliers (see text). 
 
Interestingly, increased levels of nitrite after a loading dose of clopidogrel correlated 
inversely with increased levels of TAC in the same samples (Figure 5.15). It implies that the 
greater the increase in nitrite concentration following clopidogrel loading, the less TAC was 
upregulated. 
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Figure 5.15. Pearson’s correlation of changes in nitrite and TAC after a loading dose of 
clopidogrel.
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4. Discussion 
 
This observational study was designed to assess the potential influence of 
clopidogrel therapy on NO production, metabolism and bioavailability in CAD 
patients and to verify some of our previous findings in vitro. Patients receiving short- 
or long-term clopidogrel exhibit an increase in NO metabolites and effective 
vasodilation, as reflected by higher levels of nitrite and cGMP. The increased total 
anti-oxidant capacity of plasma in acute treatment group and augmented production of 
reduced thiols in the chronic treatment group also suggest a parallel positive influence 
on the anti-oxidant status of plasma.  
A variety of methods have previously been utilized to assess platelet function 
and its inhibition during anti-platelet therapy. Among the available methods 
measuring aggregation of platelets, LTA has been the most widely used by 
researchers, whereas more recently VerifyNow
TM
 has been developed for more 
convenient clinical use
218
. My colleagues and I have found that a clopidogrel loading 
dose resulted in 49.6±31.9 % inhibition of ADP-mediated platelet aggregation 
assessed by LTA, and this was in close agreement with values reported by 
VerifyNow
TM
 assay (48.6±9.2 %  - see Shawmendra Bundhoo MD 2011). These 
findings are also in line with published data, where 600 mg clopidogrel inhibited ~50 
% of ADP-induced platelet aggregation
135
, although it is acknowledged that the 
degree of inhibition by clopidogrel varies considerably between patients. The 
magnitude of platelet activation can also be measured using soluble markers of 
platelet activity such as sP-selectin
219, 220
. sP-selectin can be produced by both 
platelets and endothelial cells, although evidence suggest that the majority of 
circulating sP-selectin arises from activated platelets
221, 222
. Loading dose of 
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clopidogrel downregulated levels of sP-selectin after 2 h intake, which together with 
results from LTA and VerifyNow
TM
 assays imply that clopidogrel met its 
pharmacological purpose.  
It is worth mentioning that 59.0+/-32.8 % TRAP-induced aggregation was also 
inhibited by clopidogrel. Inhibitory effect of P2Y12 antagonists on PAR1 and PAR4-
mediated thrombin signalling has been observed by others
223, 224
 and led to 
reformulation of the reference channel in VerifyNow
TM225
. 
An important consideration in the interpretation of results of this chapter is 
that there were two distinct clopidogrel-treated groups of CAD patients studied here. 
The first group involved individuals who received a loading 600 mg dose of 
clopidogrel for the first time, followed by evaluation of acute changes after 2 h 
ingestion. These people received the drug prior to PCI to protect them from peri-
procedural complications. The second group involved those who were maintained on 
a daily 75 mg dose of clopidogrel for a minimum of 3 days. In this setting clopidogrel 
was used mainly to prevent vessel restenosis. 
One of the main and novel findings of this work is the positive effect of 
clopidogrel on production of NO accompanied with augmented accumulation of 
cGMP in plasma (Table 17). Plasma nitrite, a marker of endothelial NO production 
and cGMP, a major secondary messenger of vascular relaxation were both 
significantly increased in the acute and chronic setting. It is very interesting 
considering that most of the beneficial effects of clopidogrel including reduced 
inflammatory markers and enhanced FMD were reported after prolonged anti-platelet 
therapy with clopidogrel. What is more, they have primarily been attributed to the 
inhibition of platelet activation and adhesion to the vascular wall leading to an 
improvement of vascular function over time, rather than the possibility of a platelet-
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independent effect. However, in the light of our data, clopidogrel appears to be 
responsible for an improvement in production of NO and cGMP as early as 2 h after a 
loading dose, which points to an alternative route of action, possibly via direct 
interaction with vascular endothelium. 
An increase in plasma nitrite and cGMP by clopidogrel is likely to be 
favorable for CAD patients with dysfunctional endothelium, where the classical L-
arginine-eNOS-NO-sGC-cGMP pathway is dysregulated due to increased oxidative 
stress
5, 17, 25, 30
. Plasma nitrite levels reflect endothelial eNOS activity and is a marker 
of NO bioavailability
200, 201
. NO released by endothelium inhibits both platelet 
aggregation and adhesion as well as leukocyte recruitment and adhesion to sites of 
vascular injury, which could add to the anti-platelet and anti-inflammatory effects of 
clopidogrel mediated by direct blockage of P2Y12 receptors. In addition, increased 
levels of plasma cGMP might be a consequence of enhancement of endothelium-
dependent vasorelaxation mediated by NO
226
. 
In addition, under conditions where the endothelium is damaged or 
dysfunctional, circulating nitrite can serve protective roles, especially where lower pH 
or oxygen promote reduction of nitrite to NO by several mechanisms, including 
enzymatic reduction by deoxygenated hemoglobin or myoglobin, components of the 
mitochondrial respiratory chain, XO, eNOS, and cytochrome P450, as well as 
nonenzymatically by acidic disproportionation
198
. These mechanisms have been 
implicated in a variety of animal and human models of vascular injury. However, in 
our study the concentration of plasma nitrite is mainly taken to reflect the increased 
NO bioavailability and the potential advantageous effect of nitrite augmentation itself 
would be an interesting subject for further investigation. 
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Groups  Effects 
Pre  Post  Chronic  Post vs. pre  Chronic vs. pre 
Mean SD N  Mean SD N  Mean SD N  
Mean of 
differences 
p-value  
Difference 
between 
means 
p-value 
sP-selectin 
[ng/ml] 
29.6 10.0 19  26.7 8.2 19  28.6 8.8 14  -2.9 p < 0.05  -0.7 p > 0.05 
Nitrite 
[nM] 
160.0 78.9 36  202.6 84.7 36  254.3 139.4 22  42.6 p < 0.05  94.3 p < 0.01 
Nitrate 
[µM] 
30.2 11.5 36  28.6 11.0 36  29.9 13.5 22  -1.6 p < 0.05  -0.2 p > 0.05 
RSNO [nM] 15.5 8.7 36  14.1 5.4 36  14.2 9.2 22  -1.4 p > 0.05  -1.3 p > 0.05 
cGMP 
[pmol/ml] 
215.2 127 24  234.6 109.0 24  281.7 70.8 19  19.4 p < 0.05  67.5 p < 0.05 
TAC [% 
Tempol] 
60.7 11.5 25  64.2 10.6 25  62.1 4.2 20  3.5 p < 0.05  1.4 p > 0.05 
RSH [µM] 355.2 29.5 20  364.6 34.2 20  389.7 25.1 14  9.4 p > 0.05  34.5 p < 0.01 
3-NT [nM] 249.0 380.7 12  331.1 564.6 12  465.4 628.6 12  82.1 p > 0.05  193.8 p > 0.05 
 
Table 17. Summary of effects of acute and chronic treatment with clopidogrel in CAD patients. In red: significant results. 
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 Despite demonstrating nitrosation properties of clopidogrel in vitro, the level of RSNO 
in plasma was not increased in CAD patients receiving clopidogrel. Certainly all necessary 
conditions considered optimal for formation of RSNO were fulfilled. Briefly, clopidogrel 
acted as a donor of –SH moiety delivered in a form of active (0.01%) and inactive (1%) 
metabolites. The stomach and acidic clopidogrel provided an acidic pH environment (pH=2-
3) and there was a potential source of nitrite ions in stomach (0.6-20 μM)185, 186 or 
gastrointestinal tract. It is difficult to pin-point why the in vitro results were not translated to 
the patient setting. The lack of influence of an oral dose of clopidogrel on plasma level of 
RSNO might be explained by: 
 
i) the labile nature of RSNO species, in terms of their sensitivity to temperature, light, 
and breakdown by transition metals
65
, which would result in higer NO2
-
 as an end 
product (as observed), 
ii) generally low concentrations of RSNO in comparison to other NO metabolites in 
blood, which influence the detectability
34
,  
iii) tissue absorption and hepatic metabolism of clopidogrel as well as common 
transnitrosation reactions of RSNO, which could influence detectability 
110, 187
  
iv) the relatively low level of physiological nitrite185, 186. 
 
We found that a loading dose of clopidogrel increased the hydrophilic anti-oxidant 
activity of plasma against peroxyl radicals, whereas a maintenance dose resulted in a bigger 
plasma pool of reduced thiols. The mechanism for these observed changes is not known and 
requires further study. However, it was established using TAC assay that clopidogrel did not 
itself act as a direct scavenger of peroxyl radicals, but rather via regulation of enzymatic anti-
oxidants. A positive correlation between cGMP, nitrite and reduced thiols also pointed to a 
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close relationship between these parameters. In turn, a negative correlation between nitrite, 
cGMP and TAC suggests the resolving mechanism is not straightforward. 
The regulation of platelet-vascular wall interactions is shared between vascular 
endothelium and platelets, which makes a strict distinction between vascular- and platelet-
originated effects a real challenge. Clopidogrel is an anti-platelet drug and yet there is 
substantial evidence in the literature and in this thesis (IV. Results Part 1 and 2) of additional 
effects on vasculature which are clearly platelet and/or P2Y12 receptor independent. However, 
these additional effects are easier studied in vitro or in animal models than in humans. In 
patients, markers of platelet activation and aggregation are usually compared with markers of 
endothelial function in order to establish a relationship. It is commonly accepted that plasma 
nitrite reflects endothelial production of NO and plasma sP-selectin is mainly released by 
activated platelets. In our study the influence of clopidogrel on sP-selectin correlated 
significantly with changes in nitrite in acute setting suggesting that enhanced endothelial NO 
production by clopidogrel was related to the altered activation of platelets. However this 
relationship has not been confirmed in the chronic setting, where levels of sP-selectin were 
not changed and levels of nitrite were even higher than in former comparison. 
The main limitations of this study is the relatively small number of recruited CAD 
patients receiving chronic treatment with clopidogrel and the fact that the study was not 
longitudinal, in that the same patients were not measured in all three groups. N=22 
demonstrated a significant increase in nitrite, cGMP and reduced thiols but measurement of 
other markers (e.g. sP-selectin) could have been underpowered. In retrospect, the aggregation 
of platelets assessed by LTA should have been measured in all samples, which would have 
provided a more sensitive marker of platelet activation/aggregation as a functional test, rather 
than a biochemical assessment of sP-selectin.  
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Summary: 
 
 Acute and chronic treatment of CAD patients with clopidogrel caused an increased 
endothelial production and vasoactivity of NO (as reflected by levels of plasma nitrite 
and cGMP, respectively). 
 
 The level of NO3
-
 in plasma was lower only in acute setting while RSNO was not 
changed in any CAD patients receiving clopidogrel. 
 
 Clopidogrel therapy was associated with direct effects on plasma anti-oxidant and 
reduced thiol status, but more work is required to identify the precise signalling 
pathways involved. 
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V. GENERAL DISCUSSION AND CLINICAL RELEVANCE 
 
My work focused on the influence of anti-platelet agents, in particular P2Y12 
antagonists on vascular NO metabolism and signalling. The rationale for addressing this is the 
equal importance of platelet activity and formation of endothelium-derived NO in the 
maintenance of vascular homeostasis. Platelets play a central role in the pathophysiology of 
atherothrombosis, which is a common consequence of many cardiovascular diseases. 
Endothelial derived NO is a key regulator of platelet aggregation, vascular relaxation and 
inflammation. Reduced endothelial NO production and bioavailability is the main determinant 
of endothelial dysfunction, which leads to the development of cardiovascular diseases and 
subsequent activation and aggregation of platelets. P2Y12 antagonists target the ADP-induced 
activation and aggregation of platelets, which has been particularly efficient in treatment of 
patients with ACS and those undergoing coronary stenting as a secondary prevention strategy. 
However, therapies with different P2Y12 blockers are often limited by drug metabolism, 
increased risk of bleeding or other side effects. Importantly, other beneficial effects of anti-
platelet agents secondary to the main target have been noted, but these have been considered a 
result of the effects on platelets. Consequently, not much is known about their direct influence 
on vascular NO signalling, which might be a critical component for further improving patient 
outcomes and adjusting future treatment modalities. 
In the first results chapter of this thesis the enhanced response to NO donors following 
incubation of rabbit aortic rings with pro-drug clopidogrel was observed. This effect was 
independent of inhibition of P2Y12 receptors by clopidogrel in platelets or the vasculature. In 
the clinical setting, this might imply that patients receiving concomitant therapy with organic 
nitrates and clopidogrel could have an enhanced dilatory response than patients receiving 
organic nitrates alone. Clopidogrel loading has been recently associated with an enhancement 
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of brachial artery diameter when GTN was subsequently administered
161, 170
. This could be 
particularly important for patients requiring coronary stenting, where an accurate adjustment 
of coronary stents to the vessel diameter is crucial for clinical outcomes
227
. There is also 
longer term benefit for patients with existing endothelial dysfunction (reduced NO production 
or effectiveness) as a given amount of NO will have greater effect.   
Results reported in the first results chapter also revealed anti-oxidant and anti-
inflammatory effects of pro-drug clopidogrel when incubated with rabbit vessels for 3.5 h. 
The time necessary to observe these effects might have been the result of several factors 
including i) methods’ sensitivity, ii) time required for genetic transcription and translation 
and/or iii) basal inflammation. With regards to the last point, it is possible that an induction of 
oxidative and inflammatory responses in the vascular tissue was needed in order to observe 
anti-oxidant and anti-inflammatory effects of clopidogrel – the model system we utilised 
(rabbit aortae) was essentially harvesting healthy tissue that may subsequently experience a 
degree of insult as a function of being kept under laboratory conditions, whereas future 
studies may show greater benefit comparing tissue from normal versus diseases animal 
models. In agreement with this, it has been noticed that clinical evidence of inflammation not 
only predicts major cardiovascular events in patients undergoing PCI but also defines the 
patients who will benefit from clopidogrel therapy
228
. For example, the post hoc analysis of 
CREDO trial revealed that treatment with clopidogrel was beneficial only in patients with 
high levels of inflammation markers i.e. high-sensitivity C-reactive protein (hs-CRP) and 
pregnancy associated plasma protein-A (PAPP-A)
209
. Furthermore, 1-year but not the 28-day 
treatment was sufficient to detect a significant reduction in the composite end point 
confirming the importance of time scale to the observed changes. The authors of this study 
questioned whether these anti-inflammatory effects of clopidogrel were the result of its anti-
platelet effects alone. In our model, the anti-oxidant and anti-inflammatory effects of 
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clopidogrel could not be attributed to platelets pointing to the direct action of clopidogrel on 
vessels. It is relevant therefore that other invasive treatment strategies in CAD patients (e.g. 
revascularization, PCI)  were more efficient among those who had evidence of inflammation 
on the basis of elevated Il-6 levels
229
. Likewise, the benefit of aspirin therapy for the primary 
prevention of MI was greatest in men with evidence of baseline inflammation
230
.  
The second results chapter of this thesis presented a discovery of novel nitrosation 
properties of thienopyridines and non-thienopyridines in an environment of nitrite ions and 
acidic pH (pH<4). All tested drugs were capable of the formation of drug-SNO derivatives 
but their amount was dependent on many factors such as chemical properties of 
pharmaceutical grade tablets, nitrite concentration available for the reaction and the stability 
of formed SNO complexes. At first, it was surprising to see that the pH of water solutions of 
P2Y12 antagonist varied (from pH=2 of clopidogrel to pH=7 of ticagrelor) and that 
thienopyridine solutions contained reduced thiol groups even without prior metabolism. 
Despite this, we found that the low levels of reduced thiol in thienopyridine solutions detected 
was not sufficient to have biological action (in terms of inhibiting the ADP-induced 
aggregation or effects on vessel vasorelaxation). This is in complete agreement with the 
known pharmacology of these agents, which require hepatic metabolism to produce much 
higher amounts of active metabolites sufficient to exhibit biological effects. Importantly, we 
showed that the corresponding levels of SNO derivatives that could be formed under 
physiological conditions could certainly exert such activity. 
In the presence of nitrite ions clopidogrel-SNO and prasugrel-SNO were formed 
readily in their basal pH and participated in all the reactions expected of RSNO species such 
as inhibition of platelet aggregation, vasodilation and transnitrosation. According to our 
expectations ticagrelor did not form SNO derivatives in its basal solution due to the very 
small detectable amount of reduced thiol group and a neutral pH. However, when pH was 
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lowered to pH=2-3, the formation of ticagrelor-SNO was also apparent. This unforeseen result 
might be important in terms of blocking platelet P2Y12 receptors by ticagrelor. Whereas the 
exposure of the reduced thiol group in thienopyridines is desirable and increases their 
pharmacological activity, in ticagrelor this would alter its structure and could be detrimental 
to its specific interaction with P2Y12 receptors. Certainly more studies are necessary to 
confirm the influence of acidity on the pharmacological efficiency of ticagrelor. One can 
speculate that the in vivo effect of stomach acid on ticagrelor would rather be small since the 
chemical is protected by tablet coating. 
Although the drug-SNO formation was not confirmed in vivo, this might be due to 
overall low concentration and labile nature of RSNO species in comparison to other NO 
metabolites, especially in blood. Hypothetically, the oral intake of P2Y12 antagonists could 
lead to the production of drug-SNO in the stomach or GI tract and increase the total pool of 
RSNO metabolites in blood, which would be beneficial for patients with reduced NO 
bioavailability. RSNO comprises an important part of NO signalling via protection of the NO 
moiety, which can then be released when required, but these effects are paralleled by the 
importance of RSNO in regulating S-nitrosylation and regulation of various proteins 
downstream from NO production.  
In the third results chapter the positive influence of clopidogrel therapy on NO 
production and bioavailability in CAD patients was investigated. Plasma biomarkers 
reflecting endothelial release of NO and its main effector molecule cGMP were increased 
already after a 2 h loading dose and following a maintenance dose. This would imply that 
clopidogrel enhanced NO bioavailability and recovered, at least partially, endothelial function 
improving cardiovascular health and well-being in these patients. Although an early effect of 
clopidogrel on plasma nitrite and cGMP levels suggests the lack of platelet influence, the 
possible role of platelets remains to be confirmed. These findings could be important for 
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understanding the “rebound” phenomenon after withdrawal of clopidogrel, which has been 
reported in several studies
231-233. The “rebound” effect occurs as a result of clopidogrel 
cessation when one or more parameters of either platelet activity or vascular inflammation is 
increased even further compared to before clopidogrel therapy was initiated. This effect has 
been observed in ACS patients undergoing PCI and/or coronary stenting in diabetic and non-
diabetic populations and was associated with a clustering of adverse clinical events such as 
death and MI
231-234
. There is no clear indication whether “rebound” phenomenon is due to 
increased platelet activation resulting in pro-thrombotic and pro-inflammatory responses or 
due to independent augmentation of inflammation, which could be pro-thrombotic. In respect 
to our results, a premature cessation of clopidogrel could potentially deprive patients of a 
beneficial effect on endothelial NO, which in turn inhibits platelet activation and aggregation 
as well as having anti-inflammatory properties. 
The increases in plasma nitrite measured as a result of clopidogrel treatment are 
particularly relevant to recent studies employing administration of nitrite, either i.v. or via 
dietary intake of nitrate, to alter vascular function and/or homeostasis. Nitrite itself is a 
relatively weak dilator, but it has been shown in animal and human models that in 
ischemic/hypoxic conditions it can be reduced to NO providing vasodilation, inhibition of 
platelet aggregation and cytoprotection
42-45, 198
. Additionally, novel anti-inflammatory 
pathways of nitrite have been revealed recently
235, 236
. In our laboratory a low dose sodium 
nitrite infusion (1.5 µM/min) for 20 min in patients with stable CAD increased plasma NO2
-
 
concentration from ~160 nM up to ~350 nM, which reduced inducible myocardial ischaemia 
without influencing normoxic vasculature
46
. Because a similar level of plasma NO2
-
 
concentration was observed in clopidogrel-treated CAD patients (254±140 nM), it is 
reasonable to assume that anti-platelet therapy with clopidogrel may protect patients from 
ischaemic events also by endogenous stimulation of NO production from the enhanced nitrite. 
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Although the advantage of clopidogrel pre-loading and treatment long-term has been 
demonstrated, the optimal duration and dosage of maintenance therapy is still a matter of 
debate
232
. Currently, 1-12 months of clopidogrel 75 mg is recommended for all ACS patients, 
depending on the indication, after which the clopidogrel is stopped. We have shown that 
plasma nitrite and cGMP levels were increased (accumulated) during clopidogrel treatment 
i.e. within minimum 3 days after intake. In order to establish the overall and the most optimal 
effect of clopidogrel on vascular NO signalling, further longitudinal studies using more 
specific time points throughout the entire treatment regimen and possibly after cessation of 
the drug preferably in the same people would need to be undertaken. 
In summary, our studies using biochemical and biological in vitro and in vivo models 
show an influence of clopidogrel on vascular response to NO as well as NO production, 
metabolism and bioavailability. Some of these effects extended beyond the inhibition of 
platelet P2Y12 receptors by clopidogrel increasing uncertainty about the precise mechanism 
by which clopidogrel achieves its anti-platelet effects. More research is required to identify 
the molecular pathways involved in the observed “side effects” not only to improve the 
understanding of the interpersonal variability in response to clopidogrel but also to develop 
better anti-thrombotic therapies for different individuals. Newer more potent anti-platelet 
agents such as prasugrel and ticagrelor already offer better inhibition of platelet aggregation 
but their influence on vascular health in long-term is not known and worth investigating. 
Furthermore because too efficient blockage of platelet aggregation is associated with life-
threatening bleeding, the ultimate goal of new therapies should be an improvement of 
vascular function with adequate inhibition of platelet activity. Currently, because platelet 
activation is the only convenient clinical indication of risk, the drive is for more efficient 
platelet inhibition and the non-classical benefits of existing anti-platelet therapies are not 
being actively pursued. 
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